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Perspectives in organ preservation





Maintaining organ viability after donation until transplantation is critically important 
for optimal graft function and survival. To date, static cold storage is the most widely 
used form of preservation in every day clinical practice. Although simple and 
effective, it is questionable whether this method is able to prevent deterioration of 
organ quality in the present era with increasing numbers of organs retrieved from 
older, marginal and donation after cardiac death donors. This chapter describes 
principles involved in effective preservation and focuses on the basic components and 
methods of abdominal organ preservation in clinical and experimental transplantation. 
Concepts and developments to reduce ischemia related injury are discussed including 
hypothermic machine perfusion. Despite the fact that hypothermic machine perfusion 
might be superior to static cold storage preservation, organs are still exposed to 
hypothermia induced damage. Therefore, recently some groups have pointed at the 





Despite better insights in surgical technique, immunosuppressive agents and treatment 
of postoperative complications, five and ten year results in organ transplantation have 
only moderately improved in the past decades (1).  One explanation for this slightly 
disappointing fact is that more experience has led to an increased acceptance of 
older and more complex recipient candidates. Another reason is the fact that due to 
the persistent shortage, criteria for inclusion of deceased donors have been extended. 
Organs are nowadays more often retrieved from older, more marginal and sometimes 
donation after cardiac death (DCD) donors than ten years ago. Between 1988 and 
1995, the United Network of Organ Sharing (UNOS) registered a 170% increase in 
the number of deceased donors over 50 years of age (2;3). The use of older donor 
kidneys, livers and pancreata has resulted in a decrease in graft function and survival 
compared to grafts retrieved from young donors (4-7). Marginal and DCD donor 
organs suffer from additional warm ischemic injury. As a result these organs have 
higher primary non function (PNF) and delayed graft function (DGF) rates  compared 
to heart-beating deceased donors (8-11). 
Maintaining organ viability during preservation is an important prerequisite for 
successful outcome after transplantation. With the current practice to accept older 
and more injured donor organs, improvement of preservation techniques has now 
become a must. To date, most centers use static cold storage (CS) to preserve organs. 
This preservation method, however, was developed in an era with younger donors 
with good quality organs (12). With the introduction of extended donor criteria the 
limitations of CS have probably been reached. 
This chapter aims to describe a number of principles and pathophysiological 
mechanisms as well as current techniques in abdominal organ preservation. 
Organ preservation by static cold storage
Currently, CS is the preferred organ preservation method in most centers. Simple cold 
storage starts with a rapid vascular washout to allow cooling of the organ, removal of 
blood components and equilibrate the CS solution with the tissue (13;14).
Hypothermia
The principle of CS preservation is based on suppression of metabolism and catabolic 
enzymes by hypothermia (0-4°C). Metabolic rate is halved with each 10°C drop in 
temperature resulting in a remaining 10-12% metabolism at 4°C (15). Already in the 
early 1960s, it was shown that cooling by itself was able to improve preservation 
of small bowel, kidney and liver: The so called temperature effect (16-18). To further 
extend cold ischemic time (CIT) and counteract the detrimental side-effects of the 
required hypothermia, special preservation solutions are necessary: The solution 


















HES, g/l - - - 50 - - -
PEG-35, g/l - - - - - - 1
Impermeants (mM)
Citrate - 80 - - - - -
Glucose 195 - - - - - -
Histidine - - - - 198 30 -
Lactobionate - - - 100 - 80 100
Mannitol - 185 - - 38 60 -
Raffinose - - - 30 - - 30
Sucrose - - 140 - - - -
Buffers (mM)
Citrate - 80 - - - - -










 43 - - 25 - - 25
NaHCO
3










- - 56 - - - -
Electrolytes (mM)
Calcium - - - - 0.0015 0.25 0.5
Chloride 15 - - 20 32 42 -
Magnesium - - - - 4 13 -
Magnesium sulphate - 40 - 5 - - 5
Potassium 115 79 - 120 9 15 25
Sodium 10 84 125 25 15 100 120
ROS Scavengers (mM)
Allopurinol - - - 1 - - 1
Glutathione - - - 3 - 3 3
Mannitol - 185 - - 38 60 -
Tryptophan - - - - 2 - -
Additives (mM)
Adenosine - - - 5 - - 5
Glutamic acid - - - - - 20 -
Ketoglutarate - - - - 1 - -
Table 1. Composition of organ preservation solutions*
* Numbers between brackets represent references to relevant literature
EC: EuroCollins; HOC: Hypertonic Citrate / Marshall’s solution; PBS: Phosphate-Buffered-Sucrose; UW: 
University of Wisconsin Cold Storage Solution; CEL: Celsior; HTK: Histidine-Tryptophan-Ketoglutarate; 
IGL-1: Institut Georges Lopez; HES: hydroxyethyl starch, PEG-35: polyethylene glycol with an average 
MW of 35 kDa, ROS: reactive-oxygen species.
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(ROS) upon reperfusion are important side effects of hypothermia. To reduce these 
undesirable effects CS solutions include a number of specific compounds (20;21). 
The composition of several preservation solutions is illustrated in Table 1.
Cell swelling
A very prominent alteration in the cellular structure during hypothermia is the formation 
of edema (22). The responsible mechanism is an impaired activity of Na+/K+ ATPase. 
As a result, sodium is no longer extruded but passively enters the cell. This creates a 
hyperosmolar intracellular environment and subsequently an influx of water. To prevent 
cell swelling, impermeants and colloids are added to preservation solutions.
Effective impermeants are saccharides and non-saccharide anions. Molecular 
weight (MW) determines the effectiveness of saccharides to prevent cell swelling, 
with larger saccharides being more effective (23-25). 
Glucose (MW 180) is a monosaccharide and was used in early CS solutions, e.g. 
EuroCollins solution. When it became evident that glucose passes the cell membrane 
and becomes a source of lactate in an anaerobic environment, it was no longer 
considered as an effective impermeant (26). The slightly larger monosaccharide 
mannitol (MW 182) is not a source of lactate since it is not metabolisable and will not 
enter the cell through facilitated transport. In addition, mannitol has a beneficial effect 
as a scavenger of reactive oxygen species, and was therefore added in Marshall’s 
(hypertonic citrate; HOC), Bretschneider’s Histidine-Tryptophan-Ketoglutarate (HTK) 
and Celsior (CEL) solution. Sucrose (MW 342) is a disaccharide and is used in 
the renal preservation solution Phosphate-Buffered-Sucrose (PBS) (27;28). Raffinose 
(MW 504) is the largest one and a trisaccharide. It was added as an impermeant 
in the University of Wisconsin CS solution (UW-CSS) developed by Belzer and 
Southard.
Non-saccharide impermeants such as negatively charged gluconate, citrate 
and lactobionate limit cell swelling by electrochemical forces. Effectiveness of these 
anions is determined by molecular weight as well as charge.  While HOC contains 
citrate, both UW-CSS and Celsior use the anion lactobionate. 
As impermeants are predominantly effective at the level of cell membranes and 
the interstitial compartment, colloids are used for the intravascular compartment. 
These macromolecules are retained in the vascular spaces and act by imparting 
colloid osmotic pressure. Colloids were originally added to hypothermic machine 
preservation solutions (MPS) to prevent tissue edema due to hydrostatic pressure. 
Belzer and his group first used cryoprecipitated plasma, than albumin and finally 
diafiltrated hydroxyethyl starch (HES) as they aimed at developing one solution 
suitable for both CS and hypothermic machine perfusion (HMP). The feasibility of 
HES as a colloid in UW-CSS has been extensively debated. HES prevents interstitial 
edema but also increases viscosity (29). For short preservation times addition of a 
colloid has been doubted, although some organs such as the pancreas appeared 
to be more susceptible to edema when HES is omitted (30). Analyzing the effect 
of HES on red blood cells (RBC), several authors have shown an increased RBC 
aggregability in both human and rat whole blood when large molecular sized HES 
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is present (31;32). This effect could partially explain the frequently slower washout 
of blood and initially patchy reperfusion of organs when UW-CSS is used in clinical 
practice (33).  
The HES controversy initiated a search for other colloids, e.g. dextran and 
polyethylene-glycol (PEG) (34-36). In this respect, UW-PEG preserved rat livers have 
shown lower transaminase levels, higher bile flow and higher urea synthesis rate after 
transplantation (37). Several experimental studies have now confirmed the efficacy of 
PEG for liver as well as for kidney, pancreas and small bowel preservation (38-40).  
In contrast to UW-CSS, both HTK and Celsior do not contain a colloid. In a 
prospective study with short CIT, both solutions showed equal efficacy compared to 
UW-CSS for the preservation of kidney and liver grafts (41;42). With prolongation 
of preservation times beyond 24 h, the presence of a colloid does appear to be 
important to maintain organ viability (43). 
Energy and acidosis
At a temperature of 0-4°C cold storage results in a rapid depletion of cellular ATP. 
Within four hours nearly 95% of ATP has disappeared with a shift to AMP as the 
predominant nucleotide. During CS, anaerobic metabolisation of one mol glucose, 
however, only yields two mol ATP versus a maximum of 38 mol in aerobic glycolysis. 
Moreover, two lactic acid molecules are formed leading to acidosis (44;45). 
The contribution of acidosis to ischemic injury is pH dependent. Severe acidosis 
activates phospholipases and proteases causing lysosomal damage and eventually 
cell death (46). Mild acidosis (pH 6.9-7.0), however, has been suggested to have a 
protective effect by inhibiting phosphofructokinase as the rate-limiting step in glycolysis 
(46;47). Adequate control of pH is therefore an important function of preservation 
solutions. UW-CSS and PBS use phosphate as a buffer, while Celsior and HTK use 
histidine. Of those two solutions, HTK has the highest buffering capacity due to a high 
concentration of histidine (21). 
Reactive Oxygen Species (ROS)
ROS are widely recognized as important mediators of post-reperfusion induced organ 
injury (48). CS per se, however, has also been shown to promote ROS production, 
probably due to mitochondrial damage (49;50). An extensively studied generator 
of ROS is xanthine oxidase, which simultaneously produces hydrogen peroxide 
(H2O2) and the superoxide anion (O2
.-) (51;52). The subsequent reduction of H2O2, 
catalyzed by iron, leads to hydroxyl radical formation (
.
OH). Free or chelatable iron 
is not only a catalyst of ROS formation but also contributes directly to hypothermia 
induced injury by mediating mitochondrial damage and induction of apoptosis (53-
55). ROS react rapidly with other molecules which will result in severe damage to 
lipids, nucleic acids and proteins (56;57). The subsequent cell death mechanism 
appears to be ATP dependent. ATP is required for the execution of the apoptotic cell 
death program whereas complete ATP depletion will lead to necrosis (58;59). As free 
radical mediated injury during preservation is strongly correlated with the absence 
of immediate and reduced long-term kidney function (57), preservation solutions aim 
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to counteract ROS mediated injury during preservation and especially at time of 
reperfusion. 
In UW-CSS, the compounds allopurinol and glutathione (GSH) were included 
to prevent formation of ROS. Allopurinol inhibits xanthine oxidase, which improved 
kidney preservation, while liver or pancreas preservation remain almost unaffected 
(60). 
GSH is a tri-peptide which is oxidized to glutathione disulphide together with 
converting peroxides. Experimental studies have shown the importance of GSH 
in an isolated perfused rabbit liver model. In the absence of GSH, more lactate 
dehydrogenase (LDH) was released into the perfusate (61) which was confirmed 
in the canine kidney transplant model. Subsequent studies have shown that GSH is 
especially important in long term liver preservation (62). 
GSH is also used in Celsior solution, while in HTK tryptophan might protect the 
organs against ROS mediated damage. The anti-oxidative effects of tryptophan are, 
however, controversial. Tryptophan can act as an anti-oxidant through its oxidative 
metabolites in the kynurerine pathway, such as 5-hydroxy-tryptophan (63). On the 
other hand, tryptophan can be pro-oxidant as well by presenting low molecular 
weight iron in a redox cycling event (64;65). In a cultured rat hepatocyte experiment, 
the amount of thiobarbituric acid reactive substances (TBARS), as a marker for ROS 
mediated injury, was measured. After 24 h preservation, TBARS were significantly 
higher in HTK preserved hepatocytes compared to UW-CSS suggesting a superior 
anti-oxidant capacity of UW-CSS (66). 
Electrolyte composition
During the pioneering years in organ preservation a high potassium/low sodium ratio 
of the solution (intracellular type) was assumed necessary to prevent cell swelling. It 
was hypothesized that due to the inactivity of Na+/K+ ATPase during hypothermia 
an intracellular sodium/potassium ratio in the extracellular fluid compartment would 
prevent sodium and chloride to enter the cell (67). Balancing extracellular sodium 
ions and intracellular protein anions creates the so called  Donnan-equilibrium that 
prevents edema formation (24). Intracellular type solutions like UW-CSS were long 
considered to be pivotal for preservation of cell viability (68). Recent work, however, 
has suggested equal or improved results of extracellular type solutions with a low 
potassium/high sodium ratio, e.g. Celsior and HTK (69-74). This clearly demonstrates 
that sodium/potassium ratios as such do not play a central role in preservation. 
However, a low potassium content will probably facilitate the washout of blood during 
organ procurement as the potassium induced vasospasm is absent (71;75). 
In summary: essential components of effective preservation solutions are impermeants 
or colloids, an adequate buffering capacity and anti-oxidants. In the next paragraph 




Current cold storage solutions
The first static CS preservation solution was developed by G.M. Collins in 1969 
(76), which was modified by the Eurotransplant Foundation in 1976 by  eliminating 
magnesium (Table 1) (77). EuroCollins (EC) solution was a simple and cheap 
intracellular type preservation solution. Phosphate was used for pH buffering and 
glucose served as the osmotic agent. In the late seventies, an Australian group 
developed a hypertonic citrate (HOC) solution which is also known as Marshall’s 
solution. This solution was effective for 72 h canine kidney preservation and is still 
in clinical use (78). Another simple solution is Phosphate-Buffered-Sucrose (PBS) 
developed by Coffey and Andrews in the early eighties. PBS was shown to be 
effective in kidney preservation confirming the hypothesis that high concentrations of 
impermeant saccharides suppress hypothermic cell swelling (27;79). When UW-CSS 
became available, a randomized clinical trial comparing EuroCollins with UW-CSS 
in kidney preservation showed that DGF was significantly lower in the UW-CSS group 
(23% vs. 33%). Also, one year graft survival was found to be significantly higher in the 
UW-CSS group (29). As a result of this study EC was no longer the preferred solution 
for clinical abdominal organ preservation in Europe (Fig. 1A).
University of Wisconsin Solution
Continuous and systematic research by Belzer and Southard led to the development 
of the University of Wisconsin Solution in 1987. Metabolic inert substrates such as 
lactobionate and raffinose served as osmotic agents. HES was used as a colloid. 
Scavengers (glutathione, allopurinol) and an ATP precursor (adenosine) were added 
to the solution. Today, UW-CSS is still considered the gold standard preservation 
solution for kidney, liver, pancreas and small bowel (Fig. 1). (29;80-86).
Histidine-Tryptophan-Ketoglutarate solution
Histidine-Tryptophan-Ketoglutarate solution (HTK) was initially introduced as a 
cardioplegic solution in open heart surgery by Bretschneider in the 1970s but was 
also tested in kidney, liver and pancreas transplantation (87). The basic design 
of the solution consists of histidine, a very potent buffer, combined with two (pre)
amino acids. Tryptophan serves as membrane stabilizer while ketoglutarate acts as 
substrate for anaerobic metabolism during preservation. HTK has a low viscosity 
and to achieve complete tissue equilibration, high volumes (~15 l) have to be 
rinsed through the organs at low flow rates. A multicenter randomized clinical trial 
comparing UW-CSS versus HTK in kidney preservation showed equal results in 
terms of incidence of DGF (33% vs. 33%) (80). For prolonged cold storage times (> 
24 h) little data is available. One single center study reported a two fold increase 
in incidence of DGF after HTK kidney preservation compared to UW-CSS when 
CIT was longer than 24 h (88). The opposite was shown in another study with a 
DGF rate of 16% after HTK preservation versus 56% after UW-CSS (89). Direct 
comparison of these conflicting findings, however, is impossible due to a different 
definition of DGF in both studies.
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In liver preservation, it has been suggested that HTK could be advantageous due 
to its low potassium concentration. Therefore, the need to flush out the potassium-rich 
UW-CSS from the organ prior to reperfusion would be limited. Although patient numbers 
were relatively small and cold ischemic times short, two studies using HTK in liver 
preservation showed equality of HTK and UW-CSS for short term preservation (82;90). 
Despite the lack of a proper randomized and controlled trial, HTK is currently used 
by many centers as a preservation solution for all abdominal organs retrieved for 




























































































Figure 1.  A. Use of cold storage solutions in Eurotransplant region in deceased donors from 1985- 
 2005 (based on Eurotransplant data of October 2006).
  B. Use of cold storage solution in the US in deceased donors from 1995-2005 (based on  




Celsior is an extracellular type preservation solution developed in 1994 for CS 
preservation of cardiac grafts (91). This solution, however, proved to be effective in 
preserving abdominal organs as well (41;84;85). It combines the inert osmotic agent 
philosophy of UW-CSS with the strong buffering capacity of HTK. Reduced glutathione 
is added as a free radical scavenger. Currently, it has been successfully used in clinical 
heart, lung, liver, pancreas, kidney and small bowel preservation (92;93). 
New solutions 
The increasing awareness that ischemia/reperfusion injury does determine a significant 
part of post-transplant outcome has stimulated research in the field of preservation injury 
and the development of new preservation solutions. A relatively new preservation 
solution developed at the University of Amsterdam is Polysol. Its composition is based 
on the fact that metabolism is still present at 4°C.  Polysol has been tested both as an 
experimental CS solution and as HMP solution (94;95). It is a classic preservation 
solution enriched with amino acids, vitamins and anti-oxidants (96). Many components 
in Polysol, however, have not yet been evaluated separately. In experimental liver 
preservation studies, superiority over HTK was seen in CS preservation of steatotic 
livers showing improved functional parameters, e.g. oxygen consumption, bile 
production and damage markers (94). Transplantation data in experimental and clinical 
preservation are now required to demonstrate the efficacy of Polysol. Based on its 
‘metabolic support’ design, however, beneficial effects of Polysol can be expected. 
Another new and now clinically available preservation solution is IGL-1 (Institut 
Georges Lopez), developed by the Lyon group in France. IGL-1 builds on the heritage 
of both UW-CSS and Celsior (35;94;97). It combines the extracellular composition 
of Celsior with the colloidal support of UW-CSS using polyethylene glycol (PEG) 
instead of HES. In a porcine kidney autotransplantation model with IGL-1, PEG was 
found to limit influx of macrophages by approximately 50% (98). Polymers, such 
as PEG, spontaneously bind to cell and tissues surfaces and sterically stabilize the 
underlying surface from interactions with other components. The main advantage of this 
‘immunocamouflage’, is that it directly modifies inherent immunogenicity of donor tissue 
(99;100).  PEG does not exert any aggregating effects on RBCs and in combination 
with the extracellular composition of IGL-1, washout of blood during the donor operation 
should be superior to UW-CSS (31;101). 
Both rat and porcine transplantation studies of liver and kidney have shown 
encouraging results in terms of organ function after transplantation following preservation 
with IGL-1 (42;70;102). The first preliminary clinical results in renal transplantation 
with IGL-1 demonstrated a reduction in DGF compared to kidneys preserved with UW-
CSS (5.7% vs. 13.8%, respectively). Furthermore, less apoptosis was seen in IGL-1 
preserved kidneys (103). Until now, however, patient numbers have been too small to 
draw clinically relevant conclusions and a randomized controlled multicenter study will 
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have to confirm the initial results. Given its extracellular composition and the beneficial 
effects of PEG, IGL-1 could be considered a promising successor to UW-CSS.
Despite the fact that CS preservation methods have facilitated many transplant 
programs all over the world, it appears that the increasing challenge to maintain 
viability in extended-criteria donor organs is touching the limits of CS preservation. 
Even with beneficial additives and enriched compositions, static CS, at best, slows 
down ischemic damage. Furthermore, pre-transplant viability testing is limited and 
preservation time is still counted in hours rather than in days. To further improve organ 
viability, a more dynamic preservation method is needed to better fulfil the metabolic 
demands of damaged organs. Therefore, many groups have recently switched gears 
and are revisiting the possibilities of hypothermic machine perfusion (HMP) (104-106). 
Preservation by hypothermic machine 
perfusion
In the early 1970s, hypothermic machine perfusion (HMP) was used by many centers 
in the United States and Europe to preserve kidneys, allowing transportation to a 
transplant center (107-110). Although modern HMP systems are smaller, lighter and 
more sophisticated than the original machine used by Belzer and co-workers, the 
principles of HMP have not changed. 
Machine perfusion generates a controlled continuous or pulsatile recirculating 
flow of preservation solution at 0-4°C. This continuous flow allows complete 
































































Figure 2. Relative amount of renal hypothermic machine preservation (HMP) and cold storage   
 preservation (CS) in the US from 1988-2005. (based on OPTN data of October 2006).
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equilibration with the preservation solution. Beneficial effects claimed on behalf of 
machine perfusion are a low incidence of DGF, the possibility of real-time viability 
assessment, the ability to provide metabolic support during perfusion and the potential 
to add pharmacologic agents to the perfusate. 
In kidney preservation, both in animal experiments and in historical controlled 
retrospective clinical studies, HMP has been demonstrated to provide better early 
graft function compared to CS (111;112). In addition, when kidneys retrieved from 
expanded-criteria, marginal or DCD donors were analyzed, HMP was found to be 
superior to CS (113-117). Unfortunately, in most studies no prospective randomization 
was performed and patient numbers were not large enough to allow extrapolation of 
the results. Recently, Wight and colleagues reported an excellent meta-analysis based 
on aggregated results of the current literature concerning HMP versus CS, clearly 
demonstrating a 20% reduction in DGF with HMP (118). DGF reflects a compilation 
of accumulated risk factors and depends on the presence or absence of independent 
donor, preservation and recipient characteristics (29). Possibly, some of the detrimental 
effects caused by these risk factors can be reduced with HMP. The occurrence of DGF 
requires continuation of dialysis and is associated with an increased incidence of 
acute rejection and inferior long-term outcome (119;120). While individual studies 
suggest potential benefits of HMP such as reduced DGF-rates, less acute rejection, 
and an improved better short and long-term function, no comparative study of these 
modalities has been performed under strict conditions (121;122). 
Most experience with HMP concerns the kidney (Fig. 2). Only scarce experimental 
data exist in experimental liver transplantation by the groups of Belzer, Slapak and 
Brettschneider (123-125). Several strategies regarding perfusion of portal vein and/
or hepatic artery have been applied. In 1986, D’Alessandro, and later Pienaar, from 
the Madison group, managed to successfully transplant canine livers after 72 h HMP 
(126;127). Clinical application of HMP in liver transplantation, however, has been 
limited to recent pioneering work of Guarrera and colleagues (104). 
Overall, both experimental and clinical data suggest that HMP improves kidney 
and liver preservation. Modern, portable and stand-alone HMP systems for kidney 
preservation are now available, allowing user-friendly transportation within an 
international organ sharing system. Therefore, a broader clinical application of HMP 
should be considered to reduce the impressively high DGF rate of 60-85% in DCD 
kidneys and possibly reduce the Achilles heel in liver transplantation: Ischemic type 
biliary lesions (128-131). 
New approaches in organ preservation
Apart from HMP, several other concepts have been developed to allow expansion 
of the donor pool. During the past decades, not only age but also the type of organ 
donors has changed. The cause of death has shifted from a relative healthy donor 
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with cerebral trauma to older patients suffering from cerebral hemorrhage. As a result, 
average donor organ quality has decreased and the task to at least maintain the 
quality of the graft before transplantation has become much more important. 
A rather unusual but attractive technique to resuscitate damaged kidneys and 
livers is the perfusion of gas through the vasculature. This concept was initially 
described by Bunzl in 1954 and named “persufflation” by Isselhard in 1972. It 
consists of retrograde venous application of humidified pure oxygen (O2) at 13-18 
mmHg during CS (132;133). Renal persufflation preservation has been applied 
clinically in a small pilot study including ten paired kidneys. Although numbers were 
small, persufflated kidneys did show improved initial function compared to CS (134). 
Its application in liver preservation was extensively studied by the group of Minor. In 
several experiments they showed that gaseous oxygenation during CS was highly 
effective in improving liver graft viability (135-137). Using this method, survival after 
45 min of warm ischemia in a DCD liver transplant model was 100%, compared to 
0% in the CS group (137). 
Another, more static way to deliver O2 to CS grafts is the dual layer perfluorocarbon 
technique. Perfluorocarbons (PFC) are hydrocarbons in which most of the hydrogen 
atoms have been replaced with fluorine. The attractive property of PFC is a very high 
capacity for dissolving O2. PFC liquids can store 20-25 times greater amounts of O2 
than water or blood. In addition, the very low O2 binding constant of PFC allows a 
more effective release of O2 in tissue than haemoglobin does. These properties make 
PFC-based solutions interesting for organ preservation (138). 
PFC was first used in organ preservation as a component of the two-layer method 
(TLM) (139). The TLM is comprised of UW-CSS and oxygenated PFC for pancreas 
preservation. During preservation by TLM, canine pancreas grafts continuously 
generated ATP up to 96 h (140). In animal models, TLM appeared to be useful 
not only for pancreas but also for small bowel preservation (141). In the clinical 
setting, however, TLM remains controversial since it did not improve whole pancreas 
transplantation (142). Furthermore, there is debate about its effects on islet isolation. 
Although some small clinical trials have reported beneficial effects, the largest and 
most recent survey did not demonstrate superiority over UW-CSS in the field of human 
islet isolation (143-145). 
The alternative approaches mentioned above, all have in common that they take 
advantage of the beneficial effect of O2 during hypothermic preservation. Improving 
the energy status of organs during preservation leads to earlier recovery, especially 
in ischemically damaged organs. Whereas O2 supports metabolism, various other 
gaseous compounds that act on signal transduction have also proven their efficacy 
to improve graft viability in the experimental setting. Donor pre-treatment with carbon 
monoxide (CO) at low concentrations in a rat small intestine transplant model reduced 
pro-inflammatory interleukins and improved survival to 100% compared to 58% in 
air-treated controls (146). Similarly, in rat liver transplants, exposure of the recipient to 
CO suppressed induction of TNF-α, iNOS and ICAM-1. Liver grafts showed improved 
liver function and less neutrophil infiltration after CO exposure (147).  Nitric oxide 
(NO), the radical produced from L-arginine by the enzyme NO synthase (NOS), is 
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a potent vasodilatator that inhibits platelet and neutrophil aggregation and adhesion 
(148;149). This effect is potentially beneficial for preservation. Vasodilatation will 
improve organ washout during procurement, whereas the immunological effects of 
NO may limit reperfusion damage. Adding NO during cold ischemia improved small 
bowel viability in both rat and pig autotransplantation models (150). In addition, 
topical exposure of rat kidneys with NO significantly reduced the effects of 60 min 
warm ischemia (151).
These experiments suggest that exposure of the graft to CO and/or NO during 
preservation might induce a protective effect before reperfusion. HMP devices could 
enable administration of these compounds, either via an oxygenator as a gas or by 
pharmacological donors in the solution.
Outlook
As often before in transplant history, major improvements in preservation will probably 
be derived from new philosophies instead of adaptations of current strategies. 
Ideally, good preservation should facilitate the use of marginal and older organs and 
provide real-time viability assessment before transplantation. Normothermic (37°C) 
or sub-normothermic (25-32°C) machine perfusion (NMP) is becoming popular as a 
preservation alternative that may indeed achieve these goals (152). In canine kidney 
transplantation after 120 min warm ischemia, 18 h normothermic perfusion allowed 
eventual recovery of normal renal function, whereas primary non-function occurred in 
all kidneys preserved for 18 h with static CS (153). Raising the temperature during 
preservation provides more adequate ways to test and optimize graft viability and 
allows elimination of hypothermia induced injury (45;154). 
Normothermic perfusion of the abdominal organs using a cardiopulmonary bypass 
system followed by CS has already been applied in human kidney transplantation. 
This so called normothermic recirculation protocol showed significant improvements in 
a group of 44 DCD kidneys. PNF and DGF rates were 0% and 12.5%, respectively, 
compared to 22.5% and 55% for conventional preservation techniques. Despite the 
fact that this study was retrospective and included patients over a 12 year period, 
it suggests a potential benefit for clinical application of normothermic techniques 
(155). 
In liver preservation, normothermic perfusion of porcine livers subjected to 60 min 
of warm ischemia resulted in functioning liver grafts, whereas the animals transplanted 
with CS livers all died. Normothermic perfused livers demonstrated stable metabolic 
function with adequate production of coagulation factors, hyaluronic acid clearance, 
glucose metabolism and significantly lower transaminases compared to CS grafts 
(152;156;157). 
The voluminous perfusion set-up, necessity of continuous monitoring during 
perfusion and technical complexity, however, have limited clinical application of 
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NMP so far (154;158). To introduce NMP as a feasible option in clinical practice 
a combination of techniques has to be used. After an initial period of conventional 
hypothermic preservation, allowing transportation to a specialized facility, NMP can 
be started. In kidney preservation it has been shown that HMP with intermittent NMP 
improves graft survival of canine kidneys after 30 min warm ischemia (159). The liver, 
however, is more vulnerable. Recently, initial NMP for 24 h was compared to 4 h CS 
followed by 20 h NMP in a porcine DCD model with 60 min of warm ischemia. The 
latter combination, however, was ineffective as the benefits of NMP were lost due to 
the short CS period (160). 
Overall, NMP offers several advantages over conventional preservation 
techniques. Therefore, the development of a portable and easy-to-handle stand-alone 
device is crucial for the introduction of NMP into day-to-day practice for kidney and 
liver preservation.
Conclusion
Organ preservation has always been crucial for transplant outcome, but will become 
even more important in the present era with increasing numbers of older, more 
marginal and DCD donors. Although CS has proven its efficacy in the past, it seems 
that the limitations of this technique have been reached. To maintain organ viability, 
more efforts are necessary to reduce ischemia/reperfusion injury and initiate repair. 
Awaiting the results of several clinical trials, hypothermic machine perfusion or even 
normothermic machine perfusion may be (re)introduced in clinical preservation in 
general or for special categories of donor organs. 
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Chapter II




Static cold storage (CS) using the University of Wisconsin solution (UW-CSS), which 
was developed in the 1980s, is currently the most widely method for kidney and 
liver preservation. The success of kidney transplantation, however, is compromised 
by delayed graft function (DGF) rates as high as 20-30%, resulting in decreased 
graft survival and subsequent re-transplantation. In liver transplantation a primary 
non function (PNF) rate of 5-10% and an initial poor function (IPF) rate of 20-25% 
reduce transplantation effectiveness. When looking at donor demographics, the 
average deceased donor today is older, has suffered from a CVA rather than head 
trauma, and has more concomitant morbidity which negatively influences graft 
quality compared to donors in the 1980s. Furthermore, usage of organs derived 
from donation after cardiac death (DCD) is increasing and it is well known that these 
organs, which suffered from additional warm ischemia, have even higher DGF rates. 
Improved organ preservation might be able to reduce the high DGF, PNF and IPF 
rates and allow a successful expansion of the donor pool. The use of an improved 
organ preservation solution or a different preservation modality like hypothermic or 
normothermic machine preservation (HMP / NMP) may help to reach these goals. In 
Chapter I an overview is given on the main principles in organ preservation and the 
wide variety of preservation solutions and methods.
The recognition that organ preservation is an important factor in transplantation 
outcome has led to the development of new static cold storage preservation solutions. 
An example of such a new cold storage preservation solution is IGL-1, which was 
developed by the Edouard Herriot Hospital in Lyon, France. In contrast to UW-CSS, IGL-
1 does not contain hydroxyethyl starch (HES), but instead polyethylene glycol (PEG) is 
used for colloidal support. HES induces red blood cell aggregation as was previously 
demonstrated in our laboratory (1). PEG does not cause aggregation of red blood 
cells (2). Another important advantage of PEG is its ability to sterically limit immune 
activation after reperfusion. Finally, IGL-1 has a low potassium content, preventing 
a potassium induced vasospasm and thereby improving wash-out efficacy. Based 
on these compositional differences the evaluation of this new preservation solution 
was started in the isolated perfused kidney (IPK) model. This model offers unique 
possibilities to study selected effects of ischemia/reperfusion injury under controlled 
conditions. In Chapter III the IPK model was used to focus on renal vasomotor function 
as a functional marker for vascular viability after wash-out and cold storage using 
either IGL-1 or UW-CSS. 
The IPK model proved to be adequate for studying vasomotor functions but has 
some important limitations. Both the short period of approximately 90 minutes, in 
which adequate organ function is maintained and the use of an a-cellular perfusate 
limit proper assessment of post-preservation organ viability. Therefore in Chapter IV a 
rat kidney transplantation model was used to compare renal function and ischemia/




Although static cold storage is simple and effective it might not be sufficient 
anymore in the current era with an increasing portion of older, more marginal and 
DCD donors. This recognition has led to a renaissance of HMP. Although clinical 
kidney preservation in the 1960s started with HMP, this technique was subsequently 
abandoned on financial and practical grounds when CS was developed in 1969. 
For a successful re-introduction of HMP into an international organ sharing system 
like Eurotransplant, the system has to be portable, easy to use and stand-alone. 
Therefore, a new HMP system that fits these criteria was recently developed in our 
group (3). The Groningen Machine Perfusion (GMP) system was initially designed 
for liver preservation and makes use of blood compatible cardiopulmonary bypass 
machine components including an oxygenator. In Chapter V the results of a functional 
evaluation of the GMP system in a porcine liver preservation model are reported. 
To be able to effectively study and compare organ viability after HMP using the 
GMP a large animal transplantation model is mandatory. Liver transplantation in the 
pig, however, is a very demanding, complex and expensive experimental model. By 
switching to a kidney transplantation model a proof of principle experiment using the 
GMP system could be performed. In Chapter VI the re-design of the GMP system for 
kidney preservation is presented including its evaluation in a porcine autotransplant 
model. In this study kidney preservation with HMP using the GMP system at a pressure 
of 30/20 mmHg or 60/40 mmHg was compared to CS using UW-CSS. Focussing 
on graft function, renal injury and endothelial damage the most optimal perfusion 
regimen for hypothermic machine perfusion of porcine kidneys was defined. 
Athough static cold storage has been the preferred method of organ preservation 
for most transplant centers in the world, retrospective studies have suggested that 
HMP may result in improved short-term outcome, with lower DGF rates after kidney 
transplantation from all types of deceased donors (4;5). No data from sufficiently 
powered randomized controlled trials on the effect of HMP versus CS in clinical 
kidney transplantation are available at this point. Based on our experience with HMP 
in experimental kidney transplantation we started a prospective European multicenter 
study in co-operation with the Eurotransplant organization to determine the efficacy of 
HMP in clinical kidney transplantation. A commercially HMP device was used for this 
trial since the GMP system was not certified for clinical application. In Chapter VII the 
results of the first prospectively randomized controlled clinical trial on HMP versus CS 
in kidney transplantation are reported.
While HMP might be able to improve organ preservation, it is still based on the 
concept of hypothermia. Well known side effects of hypothermia include acidosis, 
cell swelling, and formation of radical oxygen species. Therefore, several research 
groups are currently exploring the possibilities of preserving organs at normothermic 
temperature (37°C) to avoid hypothermia induced damage (6-10). Since the 
metabolic rate of organs is significantly higher at these temperatures, traditional organ 
preservation solutions cannot be used. The extra demand for nutrients, oxygen and 
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buffer capacity cannot be fulfilled by solutions designed for traditional cold storage. 
The perfusion solution most frequently used in experimental normothermic preservation 
is diluted blood derived from the donor. In preparation of normothermic preservation 
using the GMP system and considering the sensitivity of endothelial cells in Chapter 
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Chapter III
Deterioration of endothelial and 
smooth muscle cell function in DCD 
kidneys after static cold storage in 
IGL-1 or UW-CSS
MHJ Maathuis, M de Groot, RJ Ploeg and HGD Leuvenink




Background: Kidneys obtained from donors after cardiac death are damaged by 
the combination of warm and cold ischemia. Although the parenchymal damage of 
these kidneys is well studied, little is known about the functional effects of warm and cold 
ischemia on the renal vascular bed. Kidney preservation using the new extracellular-type 
cold storage (CS) solution from Institut Georges Lopez (IGL-1) was compared with the 
University of Wisconsin solution (UW-CSS) with a special focus on vasomotor functions. 
Methods: The influence of warm and cold ischemia on vasomotor functions was 
studied in an isolated perfused kidney (IPK) model. Six groups of DCD rat donor 
kidneys were studied with warm ischemia of 0, 15 and 30 minutes followed by 0 or 
24 h cold storage (CS) preservation in IGL-1 or UW at 4°C. Endothelial dependent 
vasodilation was studied using acetylcholine, smooth muscle cell (SMC) constriction 
was assessed using phenylephrine (PE) and finally endothelial independent relaxation 
was tested using papaverine-sulphate. 
Results: Smooth muscle cells were significantly affected by cold ischemia showing 
a 50% reduction of PE mediated constriction after preservation. Additional warm 
ischemia did not affect SMCs. After UW-CSS preservation endothelial dependent 
vasodilation was only significantly reduced when the combination of warm and cold 
ischemia was present. IGL-1 preserved kidneys showed a reduction in endothelial 
dependent vasodilation after isolated warm ischemia. Both preservation solutions 
rendered equal results after 24 h preservation.
Conclusion: Vasomotor functions are negatively influenced by the combination of 
warm and cold ischemia. Both IGL-1 and UW-CSS performed equally in preserving 
vasomotor functions. The interesting finding of the rapid decline of smooth muscle 
cell function might point at the first step towards intimal hyperplasia as seen in late 
transplant dysfunction. 
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Introduction
The main principle of static cold storage preservation is lowering of metabolism by 
cooling the organ (1). Although hypothermia is pivotal to organ preservation at this 
moment, it has negative side effects and induces extra injury to the organ. Both the 
vasculature and parenchyma of retrieved donor organs are affected by hypothermic 
preservation. In liver preservation ballooning of hepatocytes can be found after 
prolonged cold storage. In kidney preservation, the tubules are most affected by 
hypothermia (2;3). Focussing on the vasculature, two structurally and functionally 
different important components of the (arterial) vessel wall are the endothelium and 
the smooth muscle cells (SMCs). Endothelial cells are known to be very susceptible to 
ischemia/reperfusion injury (IRI) (4;5). Little is known, however, about the susceptibility 
of SMCs to IRI. Adequate preservation of organs with attention for the endothelium as 
well as for the SMCs is relevant for both short-term and long-term outcome of organ 
preservation. Rademacher et al. demonstrated the clinical relevance of vascular viability 
using Doppler ultrasonography in over 600 renal transplant patients. His group could 
show a significant correlation between the arterial resistance index measured after 3 
months post transplant and long term graft function and graft survival (6). Focussing 
on long term failure, transplant arteriosclerosis (TA) is the primary cause of allograft 
loss after the first year post transplant. A common histomorphological feauture of TA 
is a concentric proliferation of SMCs, endothelial swelling and myocyte necrosis. The 
etiology of TA is multifactorial but donor related risk factors are thought to be important 
in the development of TA (7). Especially organs donated after cardiac death (DCD), 
where a combination of warm and cold ischemia is present, are expected to suffer 
extra damage in comparison to heart beating donation (8). Most studies addressing 
the problem of vascular damage after preservation, focus on structural alterations or 
use isolated aortic artery ring segments which are mounted in a myograph to study 
endothelial cell vasomotor function (5;9;10). There is, however, evidence that aortic 
endothelial cells are different from renal artery endothelial cells in terms of functional 
and morphological changes after transplantation (11). In an allogeneic rat model both 
kidney and aorta were transplanted. In the aorta allograft vasoconstriction was absent 
within two weeks after transplantation, whereas in the main renal artery this response 
was fully maintained up until 33 weeks posttransplant. This experiment elegantly 
demonstrates that the renal artery appears to be more resistant to transplantation 
in comparison to an aorta allograft. In kidney transplantation, however, not only 
the renal artery but the entire renal vascular bed is transplanted. Therefore, to 
study the effects of IRI on vascular functioning it is necessary to use a method that 
enables the assesment of the entire vacular bed, instead of merely the renal artery. 
The isolated perfused kidney model (IPK) with continuous pressure monitoring is an 
adequate model to assess endothelial and SMC reactions to various stimuli before 
and after preservation (12). In this study the effects of warm and cold ischemia on 
renal vasomotor function were investigated using two different preservation solutions. 
The first preservation solution is the University of Wisconsin solution (UW-CSS), 
which is currently the most widely used kidney preservation solution (1). The second 
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preservation solution is Institut Georges Lopez-1 (IGL-1), which was developed by 
the Lyon Group in 1997 (13-18). With regards to the present study a few aspects 
of these preservation solutions are important. The sodium and potassium content of 
UW-CSS is based on the intracellular sodium/potassium ratio in human cells with a 
relative high potassium content. In contrast to UW-CSS, IGL-1 has an extracellular 
composition and contains polyethylene glycol (PEG) instead of hydroxyethyl starch 
(HES, Table 1). PEG is a non-toxic synthetic colloid that reduces lipid peroxidation 
and has immune-modulating properties and, unlike HES, PEG does not cause red 
blood cell (RBC) aggregation (14;16;19-22). Based on these properties IGL-1 might 
be better capable of preserving vasomotor function.
The goal of this study is twofold. The first goal is to study the extent of vascular 
injury, with a focus on smooth muscle and endothelial cell vasomotor function. The 
second objective is to assess whether IGL-1 is capable of ameliorating the effects of 
warm and cold ischemia. This study is performed in a DCD animal model with various 
warm ischemic periods followed by 24 h CS with either UW-CSS or IGL-1. 
Animals, materials and methods
Animals 
Male inbred Fisher rats (F344), weighing 250-300 gram, were used as organ donors 
(Harlan, Horst, The Netherlands). All experimental procedures were approved by 
the Animal Experiments Committee of the University of Groningen. The principles of 
laboratory animal care (NIH publication no. 85-23, revised 1985) were followed. 









25 mM 25 mM
MgSO
4
5 mM 25 mM
Raffinose 30 mM 30 mM
Allopurinol 1 mM 1 Mm
Gluthathione 3 mM 3 mM
Adenosine 5 mM 5 mM
Hydroxy-ethyl starch 0.25 mM 0
Macrogol (PEG) 35 0 0.03 mM
Na+ 25 mM 120 mM
K+ 120 mM 25 mM
pH 7.4 7.4
Osmolality 320 mOsm/L 320 mOsm/L
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Experimental groups
To study the effects of warm and cold ischemia on vasomotor function six groups (n=6) 
with increasing periods of warm ischemia time (WIT), with and without static cold 
storage (CS), were studied. 
Group 1: 0 min WIT, 0 or 24 h CS using UW-CSS (control group for UW-CSS);•	
Group 2: 0 min WIT, 0 or 24 h CS using IGL-1 (control group for IGL-1);•	
Group 3: 15 min WIT, 0 or 24 h CS using UW-CSS;•	
Group 4: 15 min WIT, 0 or 24 h CS using IGL-1;•	
Group 5: 30 min WIT, 0 or 24 h CS using UW-CSS;•	
Group 6: 30 min WIT, 0 or 24 h CS using IGL-1.•	
Experimental design
After a WIT of 0, 15 or 30 minutes (min) one kidney was randomized to direct 
assessment of vasomotor function in the isolated perfused kidney model (IPK, Fig.1). 
Both endothelial dependent vasodilation using acetylcholine (ACH) and endothelial 
independent vasoconstriction using phenylephrine (PE) were assessed (Fig. 2). These 
measurements provided baseline data on the influence of WIT on vasomotor function. 
The other kidney was preserved using 24 h CS with UW-CSS or IGL-1. Following 
preservation, the combined effect of WIT and cold storage on vasomotor function was 
subsequently investigated in the IPK. 




After induction of isoflurane anaesthesia, donors were heparinized with 250 IU 
heparin through the penile vein. Both kidneys and renal vessels were isolated via 
a midline incision. After opening the thoracic cage, cardiac arrest was induced by 
manual cardiac tamponade for 5 minutes (23). Following cardiac arrest a warm 
ischemic period of 0, 15 or 30 minutes was applied. This period resembles the 
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Figure 2.  A. Typical example of recorded intra renal pressure changes during the course of  
one experiment. Pressure readings were used in calculation of renal vascular resistance 
changes (Fig. 2B). *Phenylephrine (PE) infusion resulting in an increase of pressure. # bolus 
injections of acetylcholine (ACH) using increasing doses (10-5, 10-4, 10-3, 10-2 and 10-1 mol.l-1) 
resulting in a dose dependent decrease in pressure. † Bolus injection of papaverine-sulphate 
resulting in a decrease in pressure.
 B. Schematic representation of changes of renal vascular resistance (RVR) during one dose/
response cycle.  After equilibration of RVR, phenylephrine (PE ) infusion was started to 
obtain submaximum contraction. When RVR had stabilized, the first dose of acetylcholine 
(ACH) was given. After maximum ACH response and subsequent return to baseline RVR the 
next ACH dose was given.
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the renal arteries to prevent flushing of liver and intestine. The kidneys were routinely 
flushed with 5 ml of 0.9% NaCl at 37°C immediately followed by 5 ml IGL-1 or UW-
CSS solution at 4°C. The composition of these solutions is described in Table 1.
Preservation 
During CS, kidneys were submerged in 25 ml of preservation solution at 0-4°C 
during 24 h in a 50 ml falcon tube (Greiner, Bio-One B.V., Alphen aan den Rijn, The 
Netherlands). 
Reperfusion model and endothelial function
In the isolated perfused kidney (IPK) model (Fig. 1), the kidney was continuously 
perfused via the renal artery with 700 ml warmed (37°C) and oxygenated (95% O2 
and 5% CO2 gas mixture) Krebs-Henseleit-Bicarbonate (KHB) solution at a pH of 7.4 
± 0.05 and a pO2 > 100 kPa, by using a roller pump (Ismatec mv-ca/04, Ismatec, 
Glattbrugg, Switzerland) delivering a constant flow (8 ml/min) throughout the experi-
ment (24). The composition of the KHB was as follows (mmol.l-1). NaCl: 118; KCL: 
4.7; CaCl2: 2.5; KH2PO4: 1.2; MgSO4: 1.2; NaHCO3: 25; glucose: 10. After 
connecting the kidney, the flow was gradually increased to 8 ml/min and the first 
50 ml of perfusate were discarded to avoid contamination with preservation solution. 
Drugs were either constantly perfused or given as bolus injections into an injection 
port 2 cm from the renal artery. Vascular responses were monitored by an electrome-
chanical pressure transducer (Cobe, Arvada, USA) connected to a computer program 
(LabVIEW, National Instruments, Austin, USA). Changes in renal vascular resistances 
were subsequently calculated and adjusted for kidney weight. After an equilibration 
period of 25-30 min, when renal vascular resistance (RVR) had stabilized, perfusion 
with PE at a concentration that causes submaximum constriction (7.1 x 10-7 mol.l-1, 
Sigma-Aldrich, Steinbach, Germany) was initiated and continued until the end of the 
experiment. After the PE-induced vasoconstriction had reached a plateau, subsequent 
doses (1.10–5 mol.l-1 to 1.10–1 mol.l-1) of 0.1 ml acetylcholine (ACH, Sigma-Aldrich) 
were given single pass by bolus injection (Figs. 2A and 2B). The next dose of ACH 
was not given until RVR had returned to baseline. Time between doses varied between 
1.5-2.5 min. ACH causes endothelial dependent vasodilation and was used to inves-
tigate the functional effects of warm ischemia and CS on endothelial cells. Vascular 
responses to every ACH-dose were quantified by the maximum decrease in RVR. After 
the last ACH dose of 1.10-1 mol.l-1, 0.1 ml of 0.5% papaverine-sulphate (Centrafarm, 
Ettenleur, The Netherlands) was given to induce endothelial independent SMC relaxa-
tion and demonstrate SMC viability.
Statistics
Data are expressed as mean ± standard error of mean (SEM). Statistical significance 
of differences between groups was assessed by the Mann-Whitney U test. A p-value 




Baseline renal vascular resistance (RVR) in control kidneys was 7.8 ± 0.6 mmHg· 
ml-1·min-1·g-1. No differences between the two tested solutions were observed. Similar 
values (data not shown) were obtained in groups with 15 and 30 minutes warm 
ischemic kidneys. Preservation during 24 h using either solution did not result in a 
significant increase of RVR.
Smooth muscle cells
The addition of PE caused constriction of the SMCs as illustrated by a rapid 
increase of the RVR varying from 6.1 to 8.8 mmHg·ml-1·min-1.g-1, in control kidneys 
and kidneys that were subjected to warm ischemia only. The response to PE, however, 
was signficantly reduced with 50-68% in kidneys that were preserved for 24 h in 
either solution. This suggests a hypothermia induced loss of SMC vasoconstriction 
function (Fig. 3).
When studying endothelial independent vasodilation, the capacity of SMCs to 
relax using papaverine-sulphate showed a reduction of RVR of 5.1 ±   0.8 mmHg· 
ml-1·min-1·g-1 in control kidneys. Similar values (data not shown) were obtained in warm 
ischemic and preserved kidneys. No differences were observed between IGL-1 and UW-
CSS. This data proofs that SMCs are capable of endothelial independent vasodilation after 
warm and cold ischemia. 
Endothelial cells
To study endothelial cell dependent vasodilation bolus injections of ACH were 
given and dose response curves could be made, showing the relation between ACH 
dose and reduction in RVR (Fig. 4).  In kidneys not subjected to warm ischemia, CS 
did not affect ACH induced vasodilation, showing similar reductions in RVR before 
and after 24 h CS preservation in either solution. In UW-CSS, the combination of 
warm ischemia and CS caused a significant decrease in the effectiveness of ACH to 
induce vasodilation, suggesting a loss of endothelial cell function.  In IGL-1 a reduction 
in ACH induced vasodilation was already present after isolated warm ischemia was 
present. In contrast to IGL-1, UW-CSS solution was able to preserve endothelial 
vasomotor function after 15 and 30 min of warm ischemia without additional cold 
ischemia. Following 24 h CS, however, there was no difference between the two 
solutions in terms of endothelial cell function. 
Discussion
Successful organ preservation should result in adequate recovery of all components 
of the transplanted organ including the vasculature. In this study we compared the cold 
storage preservation solution IGL-1 to UW-CSS and focused on vasomotor functions. 
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Figure 3.  Phenylephrine responses in IGL-1 groups (left) and UW-CSS groups (right) before and after 
24 h preservation following 0, 15, or 30 min of warm ischemia (WIT). Irrespective of warm 
ischemia the phenylephrine response was reduced after 24 h preservation. No differences 
between solutions were observed. * p<0.05 vs. direct.
Figure 4.  Acetylcholine dose response curves on rat renal vascular beds after 0, 15, or 30 min warm 
ischemia (WIT) before and after 24 h preservation using IGL-1 (left) or UW-CSS (right). 
After 24 h preservation, no differences between solutions were observed. 
 a: p<0.05 vs. direct, b: p<0.05 vs. control, c: p<0.05 vs. other solution.
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Chapter III
Using the isolated perfused kidney model (IPK) we could investigate the effects 
of warm ischemia and cold storage on vasomotor functions of the entire renal vacular 
bed. By using different vasoactive substances we could study endothelial cell and 
SMC function.
The endothelium is a key player in mediating normal vascular phsyiology. Exposure 
to hypothermia during static cold storage alters the phsyiological and biochemical 
characteristics dynamics of endothelial cells (25). Morphologic studies of cold-stored 
blood vessels show cytoplasma vacuolisation and cell swelling of endothelial cells after 
prolonged storage times (10). Several in-vitro studies on coronary and aortic segments 
have shown a negative effect of cold storage on vasomotor functions (5;26;27). Less 
is known, however, about whole organ endothelial function (12). 
Our results show that the combination of warm and cold ischemia results in a 
reduction of endothelial dependent vasodilation. We suggest that this is caused by a 
reduction in NO production and NO transport due to a loss of aquaporins (AQPs) in 
endothelial cells.
Acetylcholine induced endothelial cell relaxation was not affected by cold storage 
in the absence of warm ischemia. Both IGL-1 and UW-CSS were equally capable 
of preserving endothelial dependent vasodilation after 24 h CS if no warm ischemia 
was present. Vasodilation in reaction to acetylcholine was, however, significantly 
reduced in kidneys subjected to both warm ischemia and static cold storage. In 
contrast to this reduced responsiveness to acetylcholine, the reaction to papaverine-
sulphate, was not affected. The positive reaction to this NO independent and 
endothelial independent vasodilator proves that the SMC apparatus was capable of 
vasodilation. This suggests that combined warm and cold ischemia, found clinically 
in the DCD setting, affect either NO production by endothelial cells or the reaction 
to NO by SMCs. Recently, it has been shown that aquaporin-1 (AQP-1) is a very 
important NO transporter, transporting NO out of endothelial cells and into vascular 
SMCs. AQP-1 is a transmembrane protein that is present in water transporting cells 
such as the proximal tubule cell but also in endothelial cells and SMCs, in which water 
transport is not a key function. In AQP-1 -/- knockout mice NO-dependent relaxation 
of thoracic aortas was found to be impaired (28). Another study showed that AQPs 
are sensitive to warm ischemia, resulting in decreased expression and functioning of 
AQPs following a warm ischemic insult (29). A possible explanation of our findings in 
the present study is that warm ischemia might have reduced the expression of AQPs 
and thereby impaired NO transport from the endothelial cell to the SMC. More 
research is needed to study this hypothesis. 
Looking at the difference in potassium content of IGL-1 and UW-CSS the 
present experiment shows that potassium concentration is not an important factor in 
renal endothelial cell preservation. Concerns have been raised regarding potential 
endothelial injury from the high potassium concentration in UW-CSS. Several studies 
in the field of  cardiac preservation have stated that high potassium concentrations 
damage the endothelium dependent vasodilatory response (30;31). In contrast, one 
study reported superiority of high potassium containing solutions like UW-CSS and 
EuroCollins over a low potassium solution like HTK in endothelial preservation (32). In 
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the present study both IGL-1, with a low potassium content, and UW-CSS, with a high 
potassium content, resulted in equal 24 h preservation of renal vascular endothelial 
response to acetylcholine, showing that potassium is not pivotal in renal endothelial 
cell preservation. Furthermore, the direct reaction to ACH in warm ischemic kidneys 
was better when kidneys were flushed-out using UW-CSS. Although this UW-CSS 
benefit does not easiliy translate to the clinical situation, where a (short) period of CS 
is always present, it shows that flush-out using high potassium content solutions does 
not harm renal endothelial function.
A novel finding of this study is that smooth mucle cells are more susceptible to 
cold storage than endothelial cells.  In contrast to endothelial cell vasomotor function, 
both IGL-1 and UW-CSS could not prevent a reduction in SMC constriction after PE 
stimulation following cold storage. SMCs, the effectors of vasomotor responses, are 
generally considered to be sufficiently well resistant to hypothermia (33). The present 
study demonstrates, however, that SMCs are injured by 24 h CS with and without 
warm ischemia. A marked reduction of approximately 50% in contractile response 
to phenylephrine was seen after 24 h CS, which was, in contrast to endothelial 
cells, not further affected by additional warm ischemia. Presumably, cold ischemia is 
detrimental for SMC function in contrast to warm ischemia. These data show that rat 
renal vascular SMCs are less tolerant to hypothermia than previously thought. Looking 
at transplant arteriosclerosis, which is a late cause of graft failure characterized by a 
concentric proliferation of SMCs, we hypothesize that damage to the SMCs during 
cold storage contributes to this late event. This ‘early hit’ hypothesis is supported by 
experimental kidney transplant models which show a correlation between prolonged 
preservation time and the development of transplant arteriosclerosis (7;34;35). 
In conclusion, we compared IGL-1 and UW-CSS in their efficacy to preserve renal 
vascular motor functions after warm and cold ischemia. The combination of warm and 
cold ischemia negatively affects endothelial dependent vasodilation. SMCs seem to 
be more tolerant than endothelial cells when it comes to warm ischemia but more 
suspectible for hypothermia induced damage. Both solutions were equally capable of 
preserving vasomotor functions after 24 h preservation and subsequent assessment in 
the isolated perfused kidney model.  
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Static cold storage preservation of 
ischemically damaged kidneys. 
A comparison between IGL-1 
and UW-CSS
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Background: Nowadays kidneys derived from donation after cardiac death (DCD) 
are used in many centers to reduce donor shortage. Especially in these damaged 
organs, adequate organ preservation is critically important to maintain graft viability. 
IGL-1 is a new preservation solution, with an extracellular sodium/potassium ratio and 
polyethylene glycol (PEG) as a colloid. 
Methods: The influence of warm and cold ischemia on renal damage and graft 
function was evaluated in a Lewis-Lewis rat transplant model with a follow up of 14 
days. Eight groups of donor kidneys were studied with warm ischemia of 0 and 15 
minutes followed by 0 or 24 h cold storage preservation in IGL-1 or UW-CSS. Blood 
was collected daily during the first week and at day 14. Recipients were placed in 
metabolic cages at days 4 and 14 after transplantation allowing urine collection and 
adequate measurement of glomerular filtration rate. 
Results: Focussing on inflammation, reactive oxygen species production, proximal 
tubule damage, proteinuria, histology, and renal function after transplantation we 
could not show any relevant difference between IGL-1 and UW-CSS. Furthermore, the 
combination of 15 minutes warm ischemia and 24 h cold ischemia did not result in 
life sustaining kidney function after transplantation, irrespective of the used solution. 
Conclusion: In the present experiment, static cold storage preservation of 
ischemically damaged rat kidneys in either IGL-1 or UW-CSS led to equal results after 
transplantation. 
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Introduction
To date, static cold storage (CS) using University of Wisconsin solution (UW-CSS) is 
the most frequently used kidney preservation method. It consists of a rapid vascular 
wash-out allowing cooling of the organ, removal of blood and equilibration between 
CS solution and tissue (1). The increasing awareness, however, that ischemia/
reperfusion injury does significantly affect outcome after transplantation has stimulated 
research of preservation damage and the development of new preservation solutions 
(2). A new and now clinically available preservation solution is Institut Georges 
Lopez-1 (IGL-1), developed by the Lyon group in 1997 (3-8). In contrast to UW-
CSS, IGL-1 has an extracellular composition and contains polyethylene glycol (PEG) 
instead of hydroxyethyl starch (HES). PEG is a synthetic colloid that reduces lipid 
peroxidation, has immune-modulating properties and does not cause red blood cell 
(RBC) aggregation (4;6;9-12). Recommended wash-out volumes are comparable 
with UW-CSS while the pricing of IGL-1 is approximately 50% of UW-CSS. Both, the 
extracellular composition and the use of PEG in IGL-1 could be an important advantage 
over UW-CSS, especially in the donation after cardiac death (DCD) setting (13). 
The aim of these transplant experiments was to compare the efficacy of IGL-1 in 
preserving ischemically damaged rat kidneys to UW-CSS. In a DCD rat transplant 
model, kidneys were explanted after 0 or 15 minutes warm ischemia followed by 
0 or 24 h static cold storage preservation in IGl-1 or UW-CSS. After preservation, 
kidneys were transplanted in an isogeneic recipient directly followed by a bilateral 
native nephrectomy.
Animals, materials and methods
Animals
Inbred male Lewis rats, weighing 250-300 g, obtained from Harlan (Zeist, The 
Netherlands), where used as kidney donors and recipients. All experimental procedures 
were approved by the Animal Experiments Committee of the University of Groningen. 
All animals showed normal renal function before the start of the study. The principles of 
laboratory animal care (NIH publication no. 85-23, revised 1985) were followed.
Experimental design
The animal model used was a modification of an established rat kidney transplantation 
model including bilateral native nephrectomy (14). Warm ischemia times (WIT) of 0 
min and 15 min were studied. Cold ischemia times (CIT) were either 0 h, i.e. only 
wash-out, or 24 h. Donor kidneys (n=7 per group) were recovered immediately or 
after 15 min following cardiac arrest and subsequently preserved for 24 h using either 
IGL-1 or UW-CSS.  Eight experimental groups were studied:
Group 1: 0 min WIT and 0 h CS with IGL-1;•	
Group 2: 0 min WIT and 0 h CS with UW-CSS;•	
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Group 3: 15 min WIT and 0 h CS with IGL-1;•	
Group 4: 15 min WIT and 0 h CS with UW-CSS;•	
Group 5: 0 min WIT and 24 h CS with IGL-1;•	
Group 6: 0 min WIT and 24 h CS with UW-CSS;•	
Group 7: 15 min WIT and 24 h CS with IGL-1;•	
Group 8: 15 min WIT and 24 h CS with UW-CSS.•	
DCD donor procedure
After induction of isoflurane anaesthesia, donors were heparinized with 250 IU 
heparin through the penile vein. The left kidney, renal vessels and ureter were isolated 
via a midline incision. After opening the thoracic cage, cardiac arrest was induced 
by manual cardiac tamponade for 5 min (15). A ligature was placed superior to the 
left renal artery to prevent flushing of the right kidney, liver and intestine. The explanted 
left kidney was routinely flushed with 2.5 ml of 0.9% NaCl at 37°C immediately 
followed by 2.5 ml IGL-1 or UW-CSS solution at 4°C by means of a 20 G needle 
inserted at the aortic bifurcation. The left kidney was removed including  patches of 
aorta and caval vein. 
Preservation 
Kidneys in groups 5-8 were submerged in 25 ml of preservation solution at 0-4°C 
during 24 h in a falcon tube (Greiner, Bio-One B.V., Alphen aan den Rijn, The 
Netherlands). Kidneys in groups 1-4 were immediately transplanted with a cold 
ischemic time ranging from 23-28 min.
Recipient procedure
To allow stress-free and undisturbed blood sampling, recipient animals received a 
permanent jugular vein cannula with subcutaneous tunnelling of the cannula to a head 
attachment device one week prior to transplantation (16). After complete recovery, 
demonstrated by a return to pre-cannulation bodyweight, animals were eligible for 
transplantation. Time between jugular vein cannulation and transplantation did not 
exceed seven days. The microsurgical transplantation technique used in this study 
was a modification of the technique described by Lee (17). Prior to reperfusion, the 
graft was flushed with 1 ml of 0.9% NaCl at 4°C to wash out preservation solution. 
The renal vessels were anastomosed end-to-side to the recipient’s aorta and caval vein 
using 9-0 prolene suture (Johnson & Johnson, Brussels, Belgium) and the ureter was 
anastomosed end-to-end to the recipient’s ureter using 10-0 prolene sutures (Johnson & 
Johnson, Brussels, Belgium). The vascular clamps were released immediately after the 
vascular anastomosis was completed, with a mean warm ischemia time ranging from 
20 to 25 min. At this point both native kidneys were removed. 
Blood collection
Blood samples (0.4 ml) were taken daily until day 7 and on day 14 after transplantation. 
Fluid replacement was obtained using 0.4 ml 0.9% NaCl. Subsequently, 0.08 ml 
65% poly vinyl pyrrolidone solution with 5000 IE heparin/ml was inserted in the 
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catheter’s lumen to prevent clotting. After centrifugation, the plasma was collected and 
stored at -80°C until further analysis.
Urine collection
On days 4 and 14 after transplantation rats were housed for 24 h in individual 
metabolic cages, with access to drinking water. Urine volume was determined 
gravimetrically and samples were subsequently stored at -80°C until further analysis.
Tissue preparation and biochemical analysis
Sacrifice
At day 14 rats were anesthetized with isoflurane followed by cannulation of 
the aorta and a 5 ml blood sample was subsequently taken. The kidney graft was 
perfused in situ with 10 ml 0.9% NaCl at 4°C to obtain optimal tissue morphology. 
After removal of the kidney, it was divided in three pieces. Both upper and lower 
poles were snap frozen in liquid nitrogen. The middle pole was halved and stored 
in 4% formalin or embedded (Tissue-Tek, Zoeterwoude, The Netherlands) and snap 
frozen in liquid nitrogen. 
Microscopic techniques
Tissue was collected, fixated in 4% formalin, subsequently paraffin embedded and 
cut into 3 μm thick sections. Light microscopy (20x magnification) of haematoxylin and 
eosin (HE) and periodic acid-Schiff (PAS) stained sections were used to demonstrate 
changes in morphology.
Immunohistochemistry
To assess the extent of tubular and interstitial injury in the different groups, 
immunostaining for α-smooth muscle cell actin (pre-fibrotic changes; α-SMA, clone 
1A4, Sigma St. Louis, MO, USA), osteopontin (marker of tubular injury; OPN, clone 
MPIIIB10, Developmental Hybridoma Studies, Iowa City, IA, USA) and macrophages 
(ED-1, Serotec, Oxford, UK) was performed. As previously described, deparaffinized 
sections (3 μm) were subjected to heat-induced antigen retrieval by overnight incubation 
in 0.1 M Tris.HCl buffer (pH 9.0) at 80°C (18). Endogenous peroxidase was blocked 
for 30 min with 0.3% H2O2 in PBS. Primary antibodies (Table 1), diluted in 1% 
BSA/PBS, were incubated for 60 min at room temperature. Binding was detected 
using sequential incubations (30 min, Table 1) with appropriate peroxidase-labeled 
secondary antibodies (DakoCytomation) diluted in PBS with 1% BSA and 1% normal rat 
serum. Peroxidase activity was determined using 3,3’-diaminobenzidine tetrachloride 
(DAB) for 10 min. Relevant sections were counterstained with haematoxylin. 
Measurements in blood and urine
Plasma creatinine levels were determined using a routine clinical laboratory 
test (CREA plus, Roche) which has been validated for measurements of rat serum 
creatinine concentrations (19). Urinary creatine levels were determined by the Jaffé 
method (Sigma-Aldrich Chemie b.v., Zwijndrecht, The Netherlands). ThioBarbituric 
60
Chapter IV
acid reactive substances (TBARS) in urine were analyzed as an indication of increase 
in lipid peroxidation by reactive oxygen species (ROS) after reperfusion (20). 
Malondialdehyde binds to thiobarbituric acid and the subsequently formed TBARS 
were extracted in a butanol layer, measured with a fluorescence spectrophotometer at 
485/590 nm (Beun de Ronde FL 600, Abcoude, The Netherlands). Urinary protein 
content was assayed via the method of Lowry and colleagues (21). Activity of brush 
border enzymes alanine aminopeptidase (AAP) and lysosomal enzyme N-acetyl-β-
D-glucosaminidase (NAG) in urine were measured using colorimetric assays (22). 
NAG was measured using a modified enzyme assay according to Findlay (23) at pH 
4.25 using p-nitrophenyl-n-acetyl-β-D-glucosaminide as a substrate. AAP was detected 
with the modified enzymatic assay of Pfleiderer (24) using alanine-p-nitroanilide as a 
substrate. 
Table 1. Antibodies used for immunohistochemistry and primers for RT-PCR
Specificity Primary  
Antibody
Supplier Dilution  
Primary 
Antibody
Secondary / Tertiary 
Antibodies
α-SMA Monoclonal mouse 
anti-SMA clone 1A4
Sigma St. Louis, USA 1:10000 Rampo/Garpo 1:100









Serotec, Oxford, UK 1:750 Rampo/Garpo 1:100
Primer Forward Reverse Amplicon 
(bp)
IL-18 5’-CAACCGCAGTAATACGGAGCATA-3’ 5’-CAGGCGGGTTTCTTTTGTCA-3 62
ß-actine 5’-GGAAATCGTGCGTGACATTAAA-3’ 5’-GCGGCAGTGGCCATCTC-3’ 75
α-SMA 5’-GAGAAAATGACCCAGATTATGTTTGA-3’ 5’-GGACAGCACAGCCTGAATAGC-3’ 74
GAPDH 5’-GTATGACTCTACCCACGGCAAGTT-3’ 5’-GATGGGTTTCCCGTTGATGA-3’ 79
E-Selectin 5’-GTCTGCGATGCTGCCTACTTG-3’ 5’-CTGCCACAGAAAGTGCCACTAC-3’ 73
Collagen III 5’-AGTTCTAGAGGATGGCTGCACTAAAC-3’ 5’-TCTCATGGCCTTGCGTGTT-3’ 81
ICAM-1 5’-CCAGACCCTGGAGATGGAGAA-3’ 5’-AAGCGTCGTTTGTGATCCTCC-3’ 251
TNF- α 5’-AGGCTGTCGCTACATCACTGAA-3’ 5’-TGACCCGTAGGGCGATTACA-3’ 67
Rampo, peroxidase-conjugated rabbit anti-mouse antibody; Garpo, peroxidase-conjugated goat anti-
rabbit antibody.
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Measurement of renal damage
Focal glomerular sclerosis (FGS) was semiquantitively scored (scale 0-400) in 
PAS-stained sections and expressed as the mean score of 50 glomeruli/kidney. FGS 
was scored positive when mesangial matrix expansion and adhesion of the visceral 
epithelium to Bowman’s capsule were simultaneously present. A score of 1 was given 
when 25% of the glomerulus was involved, 2 for 50%, 3 for 75% and 4 for 100% 
(25). Interstitial fibrosis (IF) was scored similarly in 30 interstitial fields. A score of 0 was 
given when no interstitial fibrosis was present in a field, 1 for 0-25%, 2 for 25-50%, 3 
for 50-75% and 4 for 75-100% of the field showing IF. IF was defined as expansion 
of the interstitial space, with or without the presence of atrophied and dilated tubules 
and thickened tubular basement membranes (26). Computerized morphometry was 
used to quantify immunohistochemical data (18). 
RNA isolation and quantitative PCR for inflammation, injury and fibrosis.
Real-Time quantitative RT-PCR analysis of interleukin-18 (IL-18), Tumor Necrosis 
Factor-alfa (TNFα), E-selectin, Intracellular Adhesion Molecule-1 (ICAM-1), Collagen-
type III and α-SMA gene expression was performed to detect inflammation, endothelial 
damage, tubular injury or fibrosis 14 days after transplantation. Amplification primers 
(Table 1) were designed with Primer Express software (Applied Biosystems) and 
validated in a 6-step 2-fold dilution series. RNA was extracted from snap frozen tissue 
using TRIzol (Invitrogen, Breda, The Netherlands). Total RNA was treated with DNase 
I, Amp Grade (Invitrogen, Breda, The Netherlands). cDNA synthesis was performed 
from 1 µg total RNA using T11VN oligo’s and M-MLV Reverse Transcriptase, according 
to supplier’s protocol  (Invitrogen). Amplification and detection were performed with 
the ABI Prism 7900-HT Sequence Detection System (Applied Biosystems, Foster City, 
USA) using emission from SYBR green (SYBR Green master mix, Applied biosystems). 
All assays were performed in triplicate. After an initial activation step at 50°C for 
2 min and a hot start at 95°C for 10 min, PCR cycles consisted of 40 cycles of 
95°C  for 15 sec and 60°C for 60 sec. Gene expression was normalized with the 
mean of β-actin mRNA content and calculated relative to controls. Results were finally 
expressed as 2–ΔCT (CT threshold cycle). 
Statistics
Data are expressed as mean ± standard error of mean (SEM). Area under the 
creatinine curve was determined using SigmaPlot software (Systat Software, Point 
Richmond, U.S.A.). Statistical significance of differences between groups was 
assessed by Kruskall-Wallis followed by the Mann-Whitney U test. For all analyses, a 
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Results
One microsurgeon performed all experimental procedures. No significant differences 
in anastomosis times were observed between groups (Table 2). 
Survival
After a challenge of 15 min WIT in combination with 24 h CIT (15-24 groups), 
independent of the used solution all animals died within three days post-transplant. 
Death was caused by renal failure demonstrated by increasing serum creatinine levels 
(Fig. 1). Therefore, on animal welfare grounds, no further attempts were made to 
complete this group and inclusion was stopped after n=4 for both UW-CSS and IGL-1 
groups. Survival in all other groups was 100%.
Renal function
Post-transplant renal function data are presented in Figure 1 and Table 2. Kidneys 
subjected to both 15 min WIT and 24 h CIT (15-24 groups) were severely damaged 
resulting in an irreversible rise of serum creatinine for both IGL-1 and UW-CSS kidneys. 
Serum creatinine levels at day 1 and day 2 and area under the creatinine curve 
were significantly higher (p<0.05) in kidneys subjected to 24 h CIT (0-24 groups) 
compared to control kidneys (0-0 groups). Renal dysfunction in this group was further 
demonstrated by significant (p<0.05) higher urine volumes at day 4 and 14 post 
transplantation compared to controls (Table 2). There was no difference between 
IGL-1 and UW-CSS. Serum creatinine levels of kidneys subjected to 15 min WIT 
(15-0 groups) were numerically higher compared to control kidneys but this did not 
reach statistical significance. 
Glomerular filtration rate (GFR) was calculated using 24 h urine volume and 
urinary and serum creatinine levels (Table 2). On day 4 there was no significant 
difference between the GFR although a trend was seen towards a lower GFR in 
the 0-24 groups. After 14 days GFR was higher compared to day 4 for all groups 
but only statistically significant for the 0-24 group. No difference between the two 
solutions in renal function was observed. 
Proximal tubule damage
Detection of NAG and AAP activity in urine allowed an assessment of injury 
to the proximal tubule at 4 and 14 days after transplantation (Table 2). Urinary 
concentrations of AAP were significantly higher in IGL-1 preserved kidneys at day 4 
compared to UW-CSS. NAG levels measured at day 4 were significantly increased 
in 15-0 and 0-24 groups, compared to controls. No difference in NAG levels could 
be demonstrated between IGL-1 and UW-CSS.
ROS formation
Measurement of TBARS in urine at day 4 allowed detection of ROS production 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.  Representative section of kidney specimens after two weeks immunostained for ED-1 in 
0-0 IGL (A), 0-0 UW-CSS (B),  0-24 IGL (C) and 0-24 UW-CSS (D) preserved grafts. 
Significant more ED-1 staining was observed in both 0-24 groups compared to both 0-0 
groups (p<0.05). No difference between IGL-1 and UW-CSS could be detected.
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Proteinuria
Urinary protein content was measured on day 4 and 14 after transplantation. 
On day 4, there was no difference between 15-0 groups and controls. 0-24 
groups showed, however, a two fold significant (p<0.05) increase in urinary protein 
concentrations compared to controls (Table 2). At day 14, proteinuria was more 
profound in all groups compared to day 4 measurements. Again, 0-24 groups 
demonstrated the most severe proteinuria. No difference in proteinuria between IGL-1 



























































Figure 3.  ED-1 positive cells in interstitium (A) and glomeruli (B) 14 days after transplantation using 
IGL-1or UW-CSS.  * p<0.05.
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Immunohistochemical assessment of infiltrating cells
To detect any differences in immunoprotection of both solutions infiltrating ED-1-
positive macrophages were identified by immunohistochemical analysis 14 days after 
transplantation (Fig. 2). A distinction was made between interstitial and glomerular 
infiltration. Interstitial analysis showed significant differences between groups in the 
number of ED-1-positive cells with more infiltration in 15-0 and 0-24 groups compared 
to controls (Fig. 3A). Glomerular infiltration was similar in all groups (Fig. 3B). In 
both glomerular and interstitial infiltration of macrophages no difference could be 
















































Figure 4.  Focal gomerulosclerosis (A) and interstitial fibrosis (B) given in arbitrary units 14 days after 
transplantation using IGL-1or UW-CSS. * p<0.05 vs. other groups.
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Renal damage
There was a significant increase in FGS and IF in both 0-24 groups compared to 
controls. Both IGL-1 and UW-CSS preservation resulted in the same amounts of FGS 
and IF (Fig. 4A and Fig. 4B)
Real-Time quantitative Taqman RT-PCR analysis of IL-18, TNFα, E-selectin, 
ICAM-1 and α-SMA gene expression did not differ between groups. Computerized 
morphometry showed the same pattern. 
Discussion
In the present study, a Lewis-Lewis rat kidney transplant model with and without warm 
and cold ischemia was used to compare the efficacy of IGL-1 and UW-CSS in terms 
of functional recovery from ischemia/reperfusion injury. As recipient animals were 
bilaterally nephrectomized at time of transplantation, this model is able to selectively 
study preservation effects of IGL-1 and UW-CSS. The present study shows equivalence 
of the new IGL-1 solution compared to UW-CSS in rat kidney transplantation.
Several ex-vivo experiments that have focused on static cold storage preservation 
of rat kidneys with (protoypes of) IGL-1 reported increased viability versus UW-CSS 
using an isolated perfused kidney (IPK) model for functional assessment (3;27). In the 
present study, however, we were not able to demonstrate any significant advantage 
of IGL-1 over UW-CSS.  Although the IPK model offers an opportunity to control 
and manipulate renal function and has been well established in transplantation 
and pharmacology research, it has important shortcomings. Most relevant in the 
context of preservation experiments is the absence of whole blood reperfusion. In 
a transplant model blood reperfusion aggrevates the hypothermic induced structural 
damage (2;28). We therefore speculate that the extra damage in this transplantation 
experiment nullified the potential beneficial effects of IGL-1 as demonstrated previously 
in IPK models. 
This experiment demonstrated that kidney function is negatively affected by 15 
min WIT or 24 h CIT. A combination of both 15 minutes WIT and 24 h CIT did not 
result in life sustaining post-transplant kidney function. After four consecutive failures, 
inclusion in these groups was stopped. In the literature only a few studies combine 
both WIT and 24 h CIT in a rat model with direct bilateral nephrectomy. A study 
from Yin and colleagues, however, combining both 20 min WIT and 24 h static 
cold storage using UW-CSS confirms our results with 0% survival in a Lewis rat model 
(29). For the remaining groups the first GFR measurements was performed three days 
after transplantation allowing full postoperative recovery before putting the animals in 
metabolic cages. Although the area under the creatinine curve was significantly larger 
in the 0-24 groups compared to controls, GFR measurements at day 4 did not show 
a significant difference. Judging from the serum creatinine values, however, kidney 
function had already recovered by that time. Overall we were not able to demonstrate 
any functional differences between IGL-1 and UW-CSS. 
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Both warm and cold ischemia have drastic and duration-dependent effects on 
proximal renal tubule cells. Maintaining their integrity is crucial for early graft function 
as proximal tubule cells play a critical role in electrolyte, water and solute reabsorption 
from the glomerular filtrate. Therefore, the preservation efficacy of both IGL-1 and UW-
CSS was compared with a special focus on the proximal tubule (30-32). Measuring 
both urinary AAP and NAG levels as proximal tubule specific damage markers we 
could demonstrate that both 15 minutes WIT and 24 h CIT result in significant proximal 
tubule injury compared to controls. Although AAP levels were significantly higher in 
IGL-1 compared to UW-CSS preserved kidneys after 15 minutes WIT, this was not 
the case with NAG levels. AAP reflects damage to the brushborder of the proximal 
tubule while urinary NAG is pointing towards intracellular, lysosomal damage. We 
therefore speculate that temporal differences in reconstitution of the brushborder rather 
than structural differences have caused this marked difference between IGL-1 and 
UW-CSS.  The extent of proteinuria at day 4 and 14 after transplantation was most 
severe in 0-24 groups irrespective of the preservation solution. Proteinuria progressed 
in all groups over the course of the experiment. 
Based on compositional differences some specific advantages of IGL-1 over UW-
CSS could be expected. The extracellular composition of IGL-1, with a low potassium 
content, is believed to favour wash-out efficacy resulting in better tissue penetration 
of the preservation solution. In this study we choose to pre-flush the donor kidney 
with 0.9% NaCl before flushing it with either IGL-1 or UW-CSS to study preservation 
capacity without a possible blunting effect of differences in wash-out. We could not 
demonstate any advantage of the extracellular IGL-1 over the intracellular UW-CSS.
Furthermore, IGL-1 differs from UW-CSS with regards to the used colloid. The 
feasibility of HES as a colloid in UW-CSS has been extensively debated. HES 
prevents interstitial edema but also increases viscosity. Analyzing the effect of HES on 
red blood cells (RBCs), several authors have shown an increased RBC aggregability 
in both human and rat whole blood when large molecular sized HES is present 
(9;11). PEG in IGL-1 does not have aggregating effects on RBCs and has immune-
modulating properties. In contrast to Hauet and colleagues, who found a marked 
reduction of inflammatory injury when using a PEG based solution compared to UW-
CSS we could not detect any differences in macrophage infiltration (6). There are 
three possible explanations for the different results. First, we have used an isogenic rat 
transplant model versus the pig autotransplantation model of Hauet and colleagues. 
Second, our data on infiltration in the present study was obtained 14 days after 
transplantation, whereas Hauet and colleagues used biopsies taken after seven days. 
Therefore, it is possible that we have missed a transient macrophage infiltration. At 
an earlier timepoint, 4 days post-transplant, we did measure urinary TBARS levels as 
indicator for increased lipid peroxidation by ROS. Apart from ischemia/reperfusion 
injury, leukocyte infiltration is an important generator of ROS production (33). We 
could, however, not detect any differences between IGL-1 and UW-CSS when 
studying downstream post-infiltration effects such as urinary TBARS levels at day 4. 
Furthermore, focal glomerular sclerosis and interstitial fibrosis at day 14 post-transplant 
did not differ between the two solutions. Third and probably most important, the 
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molecular weight of PEG in IGL-1 is 35 kDa whereas Hauet and colleagues used a 
20 kDa PEG in their preservation solution. Therefore, the size of high-molecular weight 
PEG could be critically important to sterically avoid T-cell activation via immunological 
synapses (34). We speculate that PEG 35 kDa is too large to interfere in these 
synapses and limit T-cell activation. When comparing PEG 35 kDa to PEG 20 kDa in 
a porcine proximal tubular epithelial cell preservation experiment PEG 35 kDa was 
more potent than PEG 20 kDa in preserving ATP content, reducing LDH release and 
limiting oxidative stress (34). To have the best of both worlds, the combination of PEG 
20 kDa and PEG 35 kDa should be examined in future preservation solutions. 
This study has some limitations. We could not study the combination of 15 min 
of WIT and 24 h CIT in more detail because all animals died of renal failure shortly 
after transplantation. Therefore we are developing a rat kidney transplantation model 
with isolated cannulation of the ureter. This will allow selective functional assessment of 
the transplanted kidney, while a native kidney can remain in situ to sustain adequate 
dialysis. Since, in our model, serum creatinine levels revealed that adequate kidney 
function restored within one week after transplantation, future studies need evaluation 
at earlier timepoints.  After two weeks most of the ischemia/reperfusion injury has 
already been repaired, making it difficult to pinpoint differences between groups.
Overall, there was no significant difference between the used solutions in terms 
of kidney damage or graft function. Although IGL-1 was expected to have some 
advantages over UW-CSS based on compositional differences, we were not able to 
demonstrate any differences between IGL-1 and UW-CSS in this rat transplantation 
model. 
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Chapter V
The Groningen Machine Perfusion 
system: Functional evaluation of a new 
machine perfusion device
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Background: To improve preservation of donor livers, a portable hypothermic 
machine perfusion (HMP) system was developed as an alternative for static cold 
storage. A prototype of the system was built and evaluated on functionality. Evaluation 
criteria included 24 h of adequate pressure controlled perfusion, sufficient oxygenation, 
a maintained 0-4°C temperature and sterile conditions. 
Methods: Porcine livers were perfused with pump pressures that were set at 4 
mmHg (continuous flow, portal vein) and 30/20 mmHg at 60 BPM (pulsatile flow, 
hepatic artery). Control livers were preserved using the clinical gold standard: static 
cold storage. In the HMP group, pressure, flow and temperature were continuously 
monitored for 24 h. At time-points 0, 2, 4, 8, 12 and 24 h samples of UW-MPS were 
taken for measurement of partial oxygen pressure (pO2) and lactate-dehydrogenase 
(LDH). Biopsies in every lobe were taken for histology and electron microscopy; 
samples of ice, preservation solution, liver surface and bile were taken and cultured 
to determine sterility. 
Results: Temperature was maintained at 0-4°C; perfusion pressure was maintained 
at 4 mmHg and 30/20 mmHg for portal vein and hepatic artery, respectively. Flow 
was approximately 350 ml/min and 80 ml/min, respectively, but decreased in 
the portal vein, probably due to edema formation. Arterial pO2 was kept at 100 
kPa. Histology showed complete perfusion of the liver with no major damage to 
hepatocytes, bile ducts and non-parenchymal cells compared to control livers. 
Conclusion: The machine perfusion system complied with our design criteria and 
will have to demonstrate the superiority of machine perfusion over cold storage in 
transplant experiments.
Evaluation of the Groningen Machine Perfusion system
75
Introduction
Liver transplantation is nowadays an effective therapy for patients with end-stage 
liver disease. Preservation of the liver is routinely realised by static cold storage (CS), 
allowing transport of the donor liver to the receiving patient. However, in the pioneering 
years of organ preservation hypothermic (0-4˚C) machine perfusion (HMP) was used 
instead of CS. With the first generation perfusion machines it became possible to 
preserve kidneys for more than 72 h. Soon after this pioneering work in kidney 
preservation, liver machine preservation became feasible as well (1;2). Following the 
discovery of Collins solution, especially the development of the University of Wisconsin 
preservation solution (UW-CSS) made it possible to better preserve organs statically 
without machine perfusion and maintain organ viability for transplantation (3;4). The 
CS preservation technique made organ preservation and transplantation a standard 
clinical procedure due to its simplicity and low cost. UW-CSS allows CS preservation 
of donor livers for 12 to 18 h in the clinical setting and even storage beyond 48 h in 
laboratory experiments (5-7). The success of the UW-concept and the introduction of 
a number of modifications has significantly contributed to a better understanding of 
ischemia/reperfusion injury. Nevertheless, the limits of static CS preservation in organ 
transplantation appear to be reached.
Currently, the majority of donor livers used for transplantation originate from brain-
dead donors only. Livers from marginal or donation after cardiac death (DCD) donors 
are only occasionally used for transplantation due to expected decreased organ 
viability after transplantation. In kidney preservation, hypothermic machine perfusion 
is now used in a number of centers for preservation of DCD and so-called marginal 
donor kidneys (8-11). In the experimental setting, this technique allowed up to 5-7 
days successful preservation and transplantation of canine kidneys (12;13). Due to 
these successes and the potential to increase the donor pool and prolong storage 
times, continuous preservation of the liver has gained renewed interest. Continuous 
machine perfusion of the liver could contribute to better preservation of brain dead 
donor livers, facilitate the use of marginal donor livers and might result in the use of 
more DCD donors as well (14;15). 
Furthermore, HMP could allow the use of ‘on-line’ viability markers by analysis 
of pressure and flow characteristics and perfusate.  HMP could, thus, allow a refined 
clinical decision to include or discard marginal and non-heart-beating donor organs 
in the transplantation procedure.
In the late 1960’s Belzer, Slapak and Brettschneider experimented with continuous 
hypothermic machine perfusion of the liver in an experimental setting with results 
comparable or even better than livers preserved with static CS (2;16;17). In 1986 
D’Alessandro and later Pienaar and colleagues managed to transplant good quality 
canine livers after 72 h preservation in a HMP dog model (18).
However, despite these successes, until now a clear definition and validation of 
optimal perfusion settings have not become available. Previously, our group reviewed 
the HMP literature for liver, and defined three determining factors for effective HMP: 
the type of preservation solution, the characteristics of perfusion dynamics, and the 
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necessity for oxygenation (19). It was concluded that, to date, Belzer’s University of 
Wisconsin machine preservation solution (UW-MPS) is the most suitable perfusate. 
Perfusion through the portal vein alone has been shown to result in good short term 
liver viability upon transplantation (20-23). 
Nevertheless, to improve single blood vessel perfusion, simultaneous perfusion 
of portal vein and hepatic artery, might prevent ischemic-type biliary lessions leading 
to biliary strictures and retransplantation (24). Data about which pressure and flow 
should be used differ between authors, but there is agreement about the use of a 
lower than physiological perfusion pressure and flow during HMP to limit any shear 
stress induced endothelial cell injury. Based on an educated guess and proved by our 
own experiments comparing different perfusion pressures using fluorescence micros-
copy, it was found that a portal venous perfusion pressure of 4 mmHg and a pulsatile 
hepatic arterial pressure of 30/20 mmHg (systolic/diastolic) at 60 BPM resulted in a 
complete and uniform perfusion of the liver with minimal endothelial and/or hepatocyte 
damage (25). Previously, many authors have pointed at the potential importance of 
additional oxygenation during liver HMP (24;26-30). Based on the data of Fuija 
and colleagues as well as our experiments the required partial oxygen pressure was 
determined at 55 kPa to comply with total liver oxygen demand during HMP (28;30). 
In addition to an adequate perfusion, it was concluded that the hypothermic liver uses 
oxygen and thus oxygenation of the perfusate, even at low temperatures, remains 
necessary. Physiological oxygen distribution in the liver is 65% through the hepatic 
artery and 35% through the portal vein. Mimicking this situation in our HMP system, 
a pO2 of 35.8 kPa and 19.2 kPa is needed in the hepatic arterial and portal venous 
line, respectively.
So far, there is no clinical liver perfusion machine commercially available to 
improve organ viability and seriously challenge the limits of liver preservation by 
optimizing perfusion and transportation during cold storage, comparable to machine 
preservation of kidneys in dedicated transplant centers.
Therefore, a hypothermic liver perfusion machine using oxygenated UW-MPS and 
dual vascular perfusion technique that is able to perfuse the liver for 24 h and attempts 
to maintain the quality of donor livers was developed. The ultimate clinical goal 
with this machine is to obtain an increase of the donor pool, maintain viability and 
prolong storage times. The aim of the study presented here was to test the technical 
performance of a prototype of the Groningen Machine Perfusion (GMP) system. This 
includes adequate perfusion of the liver (i.e. uniform perfusion with no or minor cellular 
injury), maintenance of hypothermia, pressure and sterility, and supply of the liver tissue 
with sufficient oxygenation during 24 h of continuous preservation. Morphological 
changes after preservation were compared to histology after preservation using the 
clinical gold standard: static cold storage.
Evaluation of the Groningen Machine Perfusion system
77
Animals, materials and methods
Animals
Eight female pigs weighing 40-50 kg were used. A porcine model was chosen since 
pigs are phylogenetically more similar to humans than rodents or other domestics. All 
experimental procedures were approved by the Animal Experiments Committee of the 
University of Groningen. The principles of laboratory animal care (NIH publication 
no. 85-23, revised 1985) were followed.
Experimental design
The following groups were studied:
Group 1: 24 h HMP using the GMP system (Fig. 1, n=6);•	
Group 2: 24 h CS using UW-CSS (n=2).•	
The experiment (Fig. 2) started with the procurement and blood wash-out of the 
donor liver. After procurement, the liver was submerged in the reservoir, containing 
UW-MPS and the portal vein, celiac trunc and common bile duct were cannulated. 
The sterilized disposable unit, including the reservoir, pump heads, oxygenator and 
tubing was subsequently attached to the HMP system. The perfusion pressure was 
set at 4 mmHg and 30/20 mmHg for portal vein and hepatic artery, respectively. 
After 24 h perfusion was stopped and the liver was taken out of the reservoir. Just 
prior to and after preservation, biopsies of the liver were taken for histology. During 
preservation, at time points 0, 2, 4, 8, 12 and 24 h, samples of the perfusate were 
taken to assess the partial oxygen pressure and lactate-dehydrogenase (LDH) levels. 
In contrast to the experimental group, livers in the control group were submerged 
in University of Wisconsin cold storage solution (UW-CSS) and subsequently stored 
on ice. Biopsies were taken before and after preservation.
The performance of the GMP system was assessed by judging: 
perfusion dynamics, with a controlled constant pressure and resulting flow, 1. 
maintained temperature at 0-4ºC, and uniform perfusion without loss of tissue 
integrity as compared to controls.
oxygenation, showing pO2. 2 > 35.8 kPa and 19.2 kPa for hepatic artery and 
portal vein, respectively.
microbiology, to demonstrate sterility inside the disposable unit throughout the 3. 
entire preservation period.
Groningen Machine Perfusion (GMP) system
The GMP system consists of a reservoir in which the liver is placed, two miniature 
centrifugal pumps (Deltastream DPII, MEDOS Medizintechnik AG, Stolberg, 
Germany) delivering continuous and pulsatile flow, respectively, a miniature hollow 
fibre membrane oxygenator (HILITE 800LT, MEDOS Medizintechnik AG, Stolberg, 
Germany), an oxygen cylinder, a battery pack and a measurement and control unit 










Figure 1.  Prototype of the Groningen Machine Perfusion (GMP) system for liver preservation.
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directs the preservation solution (UW-MPS) from the reservoir through the oxygenator 
(O2-flow 300 ml/min) the hepatic artery; the continuous pump perfuses the portal 
vein without oxygenation. Both pumps are pressure-controlled, and recirculate the 
preservation solution with a constant perfusion pressure. The sterile disposable unit 
of the GMP system, including the reservoir, pump heads, oxygenator, cannulas and 
tubing, is situated inside a polystyrene cooling box (Wolters kunststoffen, Enter, The 
Netherlands) which is filled with melting ice to secure a hypothermic temperature of 
0-4°C for more than 24 h. 
Operative procedure
After anaesthesia using 10 mg/kg ketamine i.m., the animal was intubated and 
mechanically ventilated with a mixture of oxygen and isoflurane. The procurement 
of the liver followed the standard techniques for human multiorgan retrieval (31). The 
same donor procedure was applied for both experimental and control livers. Briefly, 
the donor operation was performed through a midline laparotomy. The abdominal 
aorta was isolated and encircled with a ligature distally of the renal artery for insertion 
of an infusion cannula (18 Fr, Tyco Healthcare, Zaltbommel, The Netherlands). The 
aorta was dissected from the surrounding tissue cranially of the celiac trunc to allow 
crossclamping during infusion of lactated-Ringer’s solution. The supra- and infrahepatic 
vena cava were dissected and prepared for ligation. The splenic and left gastric 
arteries were dissected and ligated. The celiac trunc was dissected free from its 
surrounding tissue towards the aorta. The common bile duct was mobilized and 
transected. The portal vein was then freed and prepared for cannulation. At this point 
the pig was fully heparinized (20.000 units), the aorta was crossclamped cranially of 
the celiac trunc and was subsequently cannulated caudally of the renal artery followed 
by infusion of lactated-Ringer’s solution. After three liters of aortic infusion a cannula 
(18 Fr, Tyco Healthcare, Zaltbommel, The Netherlands) was placed into the portal 
vein and infused with one liter of lactated-Ringer’s solution. The intrapericardial inferior 
vena cava was transected (31;32). The celiac trunc was dissected in continuity with 
a circumferential piece of aorta.
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Cannulation with an 18 Fr cannula of both the portal vein and aortic stump was 
performed with the liver submerged in 4 liters 0-4°C UW-MPS. The cystic duct was 
ligated and a catheter (6 Fr) was placed in the common bile duct for decompression 
and collection of bile formed during preservation (Fig. 3). At this point samples and 
biopsies were taken for microbiological examination, histology, electron microscopy 
(EM) and fluorescence microscopy (FM). Biopsies were taken in the liver hilus and 
periphery in four liver lobes, i.e. right medial lobe, right lateral lobe, left medial 
lobe, left lateral lobe (Fig. 3). A peripheral biopsy in the left lateral lobe was used 
for EM. Acridine Orange (AO: 5 mg/l) and Propidium Iodide (PI: 10 mg/l) were 
subsequently added to the UW-MPS.
In control livers biopsies were taken at the same locations described above. As in 
the experimental group AO and PI were added to the UW-CSS solution.
Data collection
In the experimental group perfusion pressure (Truwave, Edwards Lifesciences, Irvine, 















Figure 3.  Porcine liver indicating cannula positions and biopsy locations (X).
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BetaTherm, Galway, Ireland) were continuously recorded for 24 h. Samples of the 
perfusion solution were taken at 0, 2, 4, 8, 12 and 24 h of machine perfusion. LDH 
as a marker for liver damage, and partial oxygen pressure (pO 2) were measured in 
these samples. 
In both groups liver biopsies (Fig. 3) were taken after 24 h of preservation close 
to the previous location to determine tissue integrity using light and fluorescence 
microscopy. For the experimental group biopsies for electron microscopy were 
additionally taken.
Microscopic techniques
Cryosections (4 μm) were examined to identify the location and amount of dead 
cells, stained with the exclusion-dye PI and to disclose minute staining with AO. A 
fluorescence microscope (Leica DC300F, Rijswijk, The Netherlands) with 495/519 
nm (FITC) and 547/572 nm (TRITC) filter was used, with a magnification of 20 times. 
PI-positive cells were computer-counted in a blinded fashion using 4 microscopic 
fields at a magnification of 10 times. Light microscopy (magnification 20 times) 
of haematoxylin and eosin stained sections was used to demonstrate changes in 
morphology. Tissue was collected, fixated in 4% formalin, subsequently paraffin 
embedded and cut into 4 μm thick sections. 
Microbiology
Samples of perfusion solution, liver, bile and ice, taken before and after 24 h machine 
preservation, were smeared on blood agar plates and cultured at 37°C in aerobic 
and anaerobic environments for seven days. The agar plates were subsequently 




Statistical analyses were performed using Repeated Measures ANOVA for data 
measured on the same liver at different time steps and Wilcoxon signed ranks tests for 
histological evaluation. For all analyses, a p-value ≤0.05 was considered to indicate 




Temperature measurements showed a constant temperature inside the cooling box of 
0°C at time points 0, 2, 4, 8, 12 and 24 h for all experiments.
Mean hepatic arterial perfusion pressure was constant (25 mmHg) (Fig. 4) at 
these time points. Portal venous perfusion pressure increased gradually over time 
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Figure 5.  Flow during 24 h HMP (mean ± SEM). A significant decrease in both portal venous and 
hepatic artery flow was seen over time.
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Figure 6. Widened sinusoids (black arrows) before (A) and after 24 h of HMP (B) or CS (C) 
preservation shown with light microscopy using hematoxyline-eosine staining. Compared to 




Figure 7.  Rate of perfusion (left) and number of dead cells (right) after 24 h HMP, stained with 
acridine orange (AO, left) and propidium iodide (PI, right), respectively, for the liver hilus 
(top) and periphery (bottom). In control CS grafts no staining was detectable (data not 




Hepatic arterial flow measurements showed an initial increase in the first two 
hours of preservation, from 78 ± 12 ml/min to 91 ±11 ml/min (Fig. 5). After two 
hours, the mean hepatic arterial flow decreased gradually from a maximum of 91 ± 
11 ml/min to a minimum of 63 ± 8 ml/min after 24 h of machine perfusion (p<0.05). 
A similar trend was visible in the portal venous flow, with a small rise between 0 and 
2 h (from 386 ± 30 ml/min to 448 ± 35 ml/min, respectively) and a subsequent 
gradual decrease to 160 ± 65 ml/min after 24 h (p<0.05).  
Histological evaluation of biopsies taken from hilus and periphery revealed 
expanded sinusoidal spaces after 24 h of machine preservation (Fig. 6). At the start 
of preservation, widened sinusoids, indicating congestion, were already visible. No 
differences could be observed in comparison to the control group. 
In the experimental group, fluorescence microscopy resulted in a uniform staining 
pattern in both hilus and periphery (Fig. 7). Staining with propidium iodide (PI), 
showing the number of dead cells, revealed significantly more PI-positive cells in the 
liver hilus compared to the periphery. Hilar counts of PI-positive cells showed 66 ± 14 
PI-positive cells per microscopic field versus 24 ± 5 PI-positive cells in the periphery 
(p<0.05). The dead cells found were determined to be non-parenchymal cells, i.e. 
remaining blood cells, Kupffer cells and endothelial cells. In the control group no 
staining with AO or PI could be detected.
Finally, electron microscopy was conducted to evaluate the condition of the 
sinusoidal endothelial cells (Fig. 8) after HMP. In control biopsies, the endothelial cells 
showed their characteristic orientation, with stretched cytoplasm along the sinusoids. 
After 24 h of HMP, endothelial cytoplasm retracted, creating fenestrations between 
the endothelial cells. The cellular nuclei were still intact. 
LDH released in the perfusate is a marker for cellular injury and showed a 
significant increase from 102 ± 12 U/l to 148 ± 20 U/l over the total preservation 
period in the HMP grouop (Fig. 9). Due to its static character, no LDH data was 
available for the CS group.
Figure 8 
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Figure 8.  Sinusoidal endothelial cells (white arrows) before (left) and after (right) 24 hours of HMP. 
(Transmission electron microscopy, magnification 25000x).
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Figure 10. Partial oxygen pressure in the hepatic arterial line and the portal venous line (mean ± SEM). 
While partial oxygen pressure remained constant in the hepatic artery line, a significant 




The pO2 was constant (95 ± 3 kPa), in the arterial line, in which the oxygenator is 
situated (Fig. 10). The partial oxygen pressure in the portal venous line, which is not 
directly oxygenated, was initially low (17 ± 2 kPa), but increased significantly to a 
mean pO2 of 65 ± 6 kPa after 8 h and remained constant until 24 h.
Microbiology
Samples obtained at 0 h and prior to preservation from liver, bile and perfusion 
solution showed no bacterial colonies after seven days of culturing. In comparison, as 
expected, non-sterile ice samples, however, were found to be largely contaminated 
with bacteria. However, after 24 h of preservation, both the perfusion solution and 
the liver remained sterile.
Discussion
Hypothermic machine perfusion preservation of kidneys is believed to improve 
preservation quality and result in longer preservation times and a reduced incidence of 
delayed graft function (18;33;34). As a consequence, HMP allows inclusion of DCD 
donors in the kidney donor pool. To extend these advantages to the liver donor pool, 
many authors have been studying HMP of the liver as well (14;15;17;18;21;22). 
72 h successful preservation of good quality dog livers has been reported, and the 
first promising experiences with HMP of DCD donor livers in pigs and rats have 
been documented (14;15;35). However, despite these successes, liver HMP has not 
become the clinical standard preservation procedure yet. One of the reasons for this 
is that current machines are non-transportable and/or not easy to use without a stand-
alone possibility requiring continuous supervision.
The GMP system constitutes an attempt towards introduction of machine 
preservation for the liver into clinical practice. New developments and techniques 
allow expansion of the conventional static cold storage procedure to a portable 
continuous perfusion system using miniaturized blood pumps, small oxygenators and 
micro-electronics. Design criteria for the pump system included pressure-controlled 
oxygenated perfusion with arterial and portal venous pressures that are high enough 
to enable a uniform perfusion throughout the liver without compromising endothelial 
cell integrity. Additional design criteria included a continuous cold temperature and 
sterility for the duration of 24 h. 
The prototype of the GMP system is able to maintain a temperature of 0-4°C. 
The cooling box in which the reservoir, oxygenator and pump heads are located, was 
filled with melting non-sterile ice and proved to be able to maintain low temperatures 
without refilling. The disposable unit remains sterile since neither aerobic nor anaerobic 
bacterial colonies were found in the perfusate after 24 h preservation. The control 
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unit manages to maintain hepatic arterial pressure at 30/20 mmHg for 24 h, while 
portal venous pressure will increase to a certain extend after 12 h of perfusion. During 
the total preservation period portal venous flow varied considerably, which was a 
result of altered resistances in the liver. At 24 h, portal venous resistance was at such 
a level that the controller could not maintain a perfusion pressure of 4 mmHg, since 
the minimal rotational speed of the centrifugal pump was reached.
During the first 12 h of the preservation period, the controller maintained a perfusion 
pressure of 4 mmHg with an initial flow of 448 ml/min to a final flow of 160 ml/min 
at 24 h. Since perfusion pressure is maintained, flow variation resembled vascular 
resistance, defined as perfusion pressure divided by resulting flow. This variation of 
mainly portal venous flow was unexpected and, according to our knowledge, it has 
never been reported in literature before. Yamamoto continuously perfused porcine 
livers through the portal vein, but found no increase in resistance during 72 h of 
machine preservation (23). The increase in resistance could have been caused by 
interstitial edema formation. However, light microscopy did not reveal major edema 
formation in the microvascular system of the liver. Some spacing of the sinusoids was 
seen, both in the HMP and CS livers. This phenomenon has been described before 
in hypothermic preservation for both cold storage and machine perfusion (33;36). 
In this first try-out experimental series edema formation in the connective tissue of the 
extrahepatic portal vasculature was found. The extent of perivascular edema could 
explain the increased flow resistance, and the subsequent decrease in flow. This 
finding might be the result of a still too high perfusion pressure. 
Using static cold storage, pig livers have been preserved for 6-8 h and transplanted 
with good survival rates, while 50-80% of the animals die when transplanted after 
10-12 h preservation (37). With 24 h of HMP, the maximum viable preservation 
time of the pig liver could have been reached, reflected by the increased resistances. 
Whether the cause of the decreasing flow during our 24 h HMP is related to a high 
perfusion pressure or to other species-dependent effects remains to be investigated. 
The consequences for liver viability are unknown, since no further major damage to 
the liver was seen. Future experiments in a large animal liver transplantation model 
will, therefore, be performed. 
HMP as such could induce shear stress to the endothelial cells which are already 
more sensitive at low temperature and thus prone to injury (38). Microscopic observation 
and computer counting of PI-positive cells showed significantly more damaged cells in 
the hilum of the liver compared to the periphery, indicating that the perfusion pressure 
was chosen too high. PI-positive cells were found to be of non-parenchymal origin and 
located near the portal triad of the liver lobules. Comparison to CS livers could not be 
made due to lack of AO and PI staining during CS. Probably, the relative short period 
of intravascular flush does not allow adequate staining with either AO or PI. The 
extent of damage to the endothelial cells in the HMP group was studied in more detail 
using electron microscopy. The endothelial cell structure before HMP and after initial 
flushing was normal with a cytoplasm stretched along the sinusoidal wall and aligned 
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to hepatocytes. After 24 h of HMP, the nuclei of the endothelial cells were still intact, 
but the long-stretched cytoplasm was now retracted. This result has been confirmed by 
other authors who also measured decreased function of endothelial cells after HMP 
(33;36). Shear stress-induced endothelial cell injury could be prevented by lowering 
the perfusion pressure. However, staining with acridine orange indicated that the 
perfusion pressure was well chosen to obtain a complete and uniform perfusion of the 
liver. Lowering the perfusion pressure could result in a lower incidence of endothelial 
damage but in an incomplete perfused liver. 
Another important design criterion for the GMP system was to obtain sufficient 
oxygenation. The hollow fibre membrane oxygenator placed in the hepatic arterial 
line managed to saturate the perfusate immediately after starting HMP. The pO2 in 
the portal venous line, without oxygenator, increased slowly from room-air saturation 
to 65 kPa after 8 h and remained then constant during preservation. The oxygen 
pressure complied to the design criterion for oxygenation, for both lines. The difference 
between arterial and portal venous partial oxygen pressures was the amount of oxygen 
consumed by the liver itself, compensating for the saturation time of the total reservoir. 
After 8 h reservoir saturation was reached and oxygen uptake by the liver remained 
constant but still considerable (35 kPa). This finding is in accordance with other 
authors, who showed an improved liver viability after oxygenated vs. non-oxygenated 
HMP indicating that the liver, even under hypothermic conditions, has a considerable 
oxygen demand (26-28).
The injury marker LDH increased during the preservation period. Considering the 
cumulative measurement of LDH, this increase was expected. Combining this finding 
with the low amount of damaged hepatocytes, indicated with fluorescent PI staining 
and electron microscopy, it is concluded that the perfusion regime of the GMP system 
did not induce any major injury to the pig liver. However, liver viability can only be 
judged in a reperfusion model, i.e. either an in vitro isolated reperfused liver model or 
ultimately a transplantation model. 
In summary, the GMP system prototype was able to dually perfuse the liver for 
24 h in a pulsatile (HA) and continuous (PV) manner. The system maintained adequate 
flow at a controlled pressure. Although an increasing resistance of the liver was 
observed, no major endothelial cell or hepatocyte damage was induced compared to 
CS. Some perivascular extrahepatic edema was, however, found. This phenomenon 
could either be pressure-induced or species-specific, which will be investigated in 
another large animal model. The hollow fibre oxygenator oxygenated the arterial 
line satisfactory, and even supplied the portal venous line with a sufficient amount 
of oxygen. Melting non-sterile ice kept the temperature of the disposable section, 
including reservoir, oxygenator, pump heads and liver, below 4°C during 24 h, and 
did not affect the sterility inside the disposable section.
The GMP system has proven to comply with the design criteria and requirements 
that were formulated to optimally preserve a donor liver. Following these functionality 
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tests, the system now must demonstrate the advantages of hypothermic dual perfusion 
of the liver over cold storage in a transplant model. 
If correct, the system allows extended preservation times despite lower quality 
of donors. This would make liver transplantation a semi-emergency procedure. 
Preservation outcome would then be improved in such a way that the incidence of 
initial poor function and primary non-function could decrease and in addition, even 
DCD donor livers ought to be included in the donor pool on a more regular basis.
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Background: The increasing proportion of marginal donors and donation after 
cardiac death necessitates better preservation methods to maintain adequate graft 
viability. Hypothermic machine perfusion (HMP) is a promising alternative to static 
cold storage (CS). Therefore, we have developed and tested a HMP device which 
is portable and actively oxygenates the perfusate via an oxygenator. The aim of the 
present study was to examine the efficacy of the Groningen Machine Perfusion (GMP) 
system in a kidney transplantation experiment. 
Methods: In a porcine autotransplantation model kidneys were retrieved and either 
cold stored in UW-CSS for 20 h at 4°C or subjected to HMP using UW-MPS at 4°C 
with two different pressure settings: 30/20 mmHg or 60/40mmHg. 
Results: HMP at 30/20 mmHg was found to better preserve  the viability of kidneys 
reflected by improved  cortical microcirculation,  less damage to the proximal tubule, 
less damage mediated by reactive oxygen species, less pro-inflammatory cytokine 
expression and better functional recovery after transplantation. However, high perfusion 
pressures (60/40 mmHg) resulted in higher expression of von Willebrand factor and 
monocyte chemotactic peptide-1 in post preservation biopsies and subsequent graft 
thrombosis in two kidneys. 
Conclusion: It is concluded that the GMP system improves kidney graft viability. 
Perfusion pressures during HMP are, however, critically important for outcome. 
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Introduction
Maintaining organ viability between donation and transplantation is of critical importance 
for optimal graft function and survival. To date, static cold storage (CS) is the most widely 
practiced method in organ preservation. Although simple and effective, this method may 
no longer be sufficient to prevent further deterioration of the graft-to-be in an era with 
increasing numbers of older, more marginal and even donation after cardiac death (DCD) 
donors. An alternative method to maintain donor organ viability is hypothermic machine 
perfusion (HMP). HMP is, however, not a frequently used clinical preservation method. 
Based on data from the Organ Procurement and Transplantation Network (OPTN) as 
of October 2006, only 20% of all kidneys in the United States are preserved using 
HMP. Although no accurate data are available, the numbers in Europe, by tradition, 
will be lower compared to the US. In kidney preservation, both animal experiments and 
historical controlled clinical studies have demonstrated that HMP yields better early graft 
function compared to static CS (1;2). Most HMP devices in these studies, however, do 
not actively oxygenate the perfusate which has been demonstrated to be an important 
additional feature of HMP by a number of groups (3;4). Also, and despite of the fact 
that HMP was introduced in the late sixties, uncertainty has remained about the optimal 
pressure settings which vary per series between 30 and 60 mmHg systolic and 6 to 
40 mmHg diastolic pressure (5-12). While low pressure settings could underperfuse the 
kidney, especially the cortex, and lead to a higher delayed graft function, higher arterial 
pressures have been shown to enhance shear stress and damage the endothelium. To 
be able to clinically use HMP within an international organ sharing system, as in Europe, 
and still benefit from its advantages as described by Belzer and others (13;14), a novel 
HMP device for kidney preservation was developed. This compact, simple portable 
pulsatile hypothermic perfusion system incorporates advanced miniature technology and 
actively oxygenates the perfusate. It consists of a disposable unit which fits into the 
conventional polystyrene box as used in static cold storage preservation. 
After completion of the in vitro and liver preservation experiments we have now 
tested the Groningen Machine Perfusion (GMP) system in a large animal model 
comparing oxygenated HMP to CS in kidney transplantation. To detect the optimal 
perfusion pressures we have evaluated both low pressure settings (30/20 mmHg) and 
high pressure perfusion (60/40 mmHg) at 60 beats per minute (BPM). As an additional 
focus of this study we have also assessed the extent of reperfusion injury using urinary 
biomarkers and possible vascular damage during HMP.
Animals, materials and methods
Animals 
All experiments were performed in accordance with federal legislation regarding the 
protection of animals. The principles of laboratory animal care (NIH publication no. 
85-23, revised 1985) were followed.
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Commercially available female German Landrace pigs, weighing 20 to 30 kg, 
were housed in metabolic cages. They were fed ad libitum on a constant nutrient 
laboratory grower diet and were allowed free access to tap water. All animals 
demonstrated normal renal function before the start of the study. 
Experimental Design
The model used was a modification of a well-established porcine renal autotransplantation 
technique, which is a model for heart beating donation with minimal warm ischemia 
(1;15). Pigs underwent a left nephrectomy, after which this kidney was preserved for 
a period of 20 h by either static CS or HMP using two different pressure settings. 
Following preservation, the left kidney was autotransplanted and the right kidney was 
removed. Three experimental groups were studied:
Group 1: CS (n=5);•	
Group 2: HMP 30/20 mmHg, at 60 BPM (n=5); •	
Group 3: HMP 60/40 mmHg, at 60 BPM (n=5).•	
Anesthetic protocol
The anesthetic protocol was identical for nephrectomy and autotransplant operations. 
Animals were pre-medicated with ketamine (10 mg/kg), xylazine (2 mg/kg) and 
atropine (10 μg/kg) intramuscularly. General anesthesia was induced with midazolam 
(0.3 mg/kg), pancuronium (0.15 mg/kg) and fentanyl (10 μg/kg) intravenously 
(IV). After endotracheal intubation using a 7 mm endotracheal tube, anesthesia was 
maintained with isoflurane 1-5% and oxygen administered at 2 to 4 l/min. Animals 
were monitored intra-operatively by means of pulse oximetry using a tail probe.
Kidney recovery and storage
Surgery started with cannulation of the right internal jugular vein with a polyethylene 
(PE) catheter for infusion and collection of blood samples. Via a midline approach, a 
left nephrectomy was performed. The renal artery was cannulated immediately after 
procurement. Kidneys were flushed at a pressure of 100 cm H2O (gravity) with 250 
ml of University of Wisconsin cold storage solution (UW-CSS) at 4°C in the CS group 
or UW-machine perfusion solution (UW-MPS) at 4°C in the HMP groups. 
Groningen Machine Perfusion System
After flush out HMP grafts were connected to the GMP system (16). This system consists 
of a disposable reservoir in which the kidney is placed (organ chamber), a miniature 
magnetic rotary pump (Deltastream DPII, MEDOS Medizintechnik AG, Stolberg, 
Germany) delivering pulsatile flow, a miniature hollow fibre membrane oxygenator 
(HILITE 800LT, MEDOS Medizintechnik AG, Stolberg, Germany), an oxygen cylinder, 
a battery pack and a measurement and control unit which is connected to a palmtop 
computer (Fig. 1). The pulsatile pump directs the preservation solution (UW-MPS) 
from the organ chamber through the oxygenator and into the renal artery. Oxygen 
flow at 100 ml/min resulted in a pO2 > 100 kPa in the venous effluent. The pump is 
pressure-controlled, and re-circulates the preservation solution with constant intra-renal 
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perfusion pressures (30/20 mmHg or 60/40 mmHg) at 60 BPM. Perfusion pressures 
were corrected for cannula resistance in each experiment. Perfusion flow rates were 
continuously monitored using clamp-on flow probes (H7C, Transonic Systems, Ithaca, 
USA). The GMP system is situated inside a standard polystyrene organ box (Wolters 
kunststoffen, Enter, The Netherlands), filled with melting ice to guarantee hypothermia 
for more than 24 h (17). 
Renal autotransplantation
After induction of general anesthesia the abdomen was re-opened, the right kidney 
was removed and the graft was transplanted orthotopically. Prior to reperfusion, 
the graft was flushed with 250 ml of 0.9% NaCl at 4°C to wash out preservation 
solution. Vascular anastomoses were performed end-to-side (left renal vein – vena 
cava) and end-to-end (left renal artery – right renal artery), respectively, using 6-0 
polypropylene running sutures. The ureter was cannulated using polyethylene tubing 
which was subsequently tunnelled through the abdominal wall, allowing continuous 
visual inspection of urine production. Reperfusion was established by release of the 
venous and arterial clamps, followed by infusion of 100 ml glucose 50% to induce 
osmotic diuresis. 10 min after reperfusion, renal tissue perfusion was assessed non-














Figure 1.  Prototype of the Groningen Machine Perfusion (GMP) system for kidney preservation. On 
the left side the organ chamber (black arrow), oxygenator (grey arrow) and centrifugal 
pumphead with click-on system (white arrow). On the right side the oxygen cylinder and 
Personal Digital Assistant (PDA).
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flow monitor DRT4, Moor Instruments, Axminster, England) as described in detail 
previously (4;18). To account for temporal variations in blood flow, we calculated 
the mean flux value over 10s of recording, and in order to eliminate the influence of 
regional heterogeneity, measurements were performed at three distinct locations on 
the renal surface. All flux measurements were expressed as percent variation from 
the baseline value obtained from the non-ischemic native kidney in each individual 
animal.
Postoperative care
Free access to tap water was allowed immediately and supplemented with 2 litres of 
0.9% NaCl solution IV during the first 24 h. Standard food was offered on the first 
postoperative day. Anti-thrombosis therapy was provided by 1 gram acetylsalicylic 
acid on a daily basis. Antibiotic treatment consisted of perioperative and subsequent 
administration of 500 mg ampicillin IV on a daily basis. Venous blood samples were 
taken from the jugular catheter for measurement of renal function in terms of serum 
creatinine and electrolytes. The jugular catheter was flushed with heparin (3000 
IU) after each sample. Daily urine output was measured and urine samples were 
taken. Animals showing any signs of distress or lethargy because of uremia were 
sacrificed by lethal injection of T61 (Intervet, Munich, Germany) IV. Surviving animals 
were sacrificed by injection of T61 on postoperative day 7, after removal of the 
transplanted graft under general anesthesia.
Tissue preparation and biochemical analysis
Kidney biopsies
Cortical renal biopsies were taken at different stages: before explantation 
(control), after preservation prior to transplantation and 10 minutes after reperfusion 
using a 14-gauge biopsy gun (ACECUT biopsy system, TSK Laboratory, Japan). The 
tissue specimen was subsequently halved and stored in 4% formalin or embedded 
(Tissue-Tek, Zoeterwoude, The Netherlands) and snap frozen in isopentane at -80°C. 
Seven days post transplantation renal true cut tissue samples were obtained and 
stored in 4% formalin or snap frozen in isopentane at -80°C.
Microscopic techniques
The collected tissue was paraffin embedded and cut into 4 μm thick sections. 
Light microscopy (20x magnification) of hematoxylin and eosin (HE) and periodic 
acid-Schiff (PAS) stained sections were used to demonstrate changes in morphology. 
Histology was reviewed using the modified ischemia/reperfusion injury (IRI) scale 
(19). This scale quantitatively assesses the following items on a scale of 1-3 points (1 
none, 2 medium, 3 severe): mesangial matrix expansion, brush border loss in proximal 
tubule, edema, tubular dilatation, tubular cell vacuolisation, necrosis, endothelial 
cell swelling and interstitial fibrosis. Points were added to create an IRI score (8-
24 points). Biopsies of healthy pigs were used as reference. Immunohistochemical 
staining for von Willebrand factor was performed as follows: incubation for 30 
minutes in pepsin solution 0.2%, pH 2,0 at a temperature of 37°C. Primary antibody: 
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polyclonal vWF 1:200 (Dako, Glostrup, Denmark), secondary antibody: GARPO 
1:20 (Dako, Glostrup, Denmark). The findings were graded semiquantitatively on a 
scale of 1 to 4 for the following features: vWF staining in glomerular endothelium, 
subendothelium, mesangium and  cortical vessels as previously described (20). The 
origin of all specimens remained blinded to the investigator during evaluation by light 
microscope.
Endothelial activation and inflammation
Real-Time Quantitative Taqman RT-PCR analysis of von Willebrand factor (vWF), 
monocyte chemotactic protein (MCP-1), E-Selectin and P-Selectin gene expression was 
performed to detect pro-inflammatory and/or pro-coagulatory activation, reflecting 
endothelial injury. All analyses were performed on tissue samples taken before and 
after preservation, 10 minutes after reperfusion and 7 days after transplantation. 
Total RNA was extracted from snap frozen tissue using TRIzol (Invitrogen, Breda, 
The Netherlands). Total RNA was treated with DNase I, Amp Grade (Invitrogen, 
Breda, The Netherlands). First-strand cDNA synthesis, RT-PCR and primer synthesis 
were essentially the same as described previously (21). All samples were assayed in 
triplicate. Results were normalized with the average value of the respective gene in 
control biopsies, arbitrarily set to 1. 
Kidney injury biomarkers
Thiobarbituric acid reactive substances (TBARS) in urine were analyzed as an 
indication of increase in lipid peroxidation by reactive oxygen species (ROS) after 
reperfusion (22). Malondialdehyde binds to thiobarbituric acid and the subsequently 
formed TBARS were extracted in a butanol layer, measured with a fluorescence 
spectrophotometer at 485/590 nm (Baun de Ronde FL 600, Abcoude, The 
Netherlands).  Urinary protein content was assayed via the method of Lowry and 
colleagues (23). Activity of brush border enzymes alanine aminopeptidase (AAP) and 
lysosomal enzyme N-acetyl-β-D-glucosaminidase (NAG) in urine and perfusate were 
measured using colorimetric assays (24-26). 
Statistics
Data are expressed as mean ± standard error of mean (SEM). Statistical significance 
of differences was assessed using the Kruskal-Wallis test followed by a Mann-Whitney 
test. A p-value ≤0.05 was considered to indicate statistical significance.
Results
No significant differences in cold ischemic times (CIT) and anastomosis times were 
observed between groups. The mean (± SEM) CIT for the CS, HMP 30/20 and HMP 
60/40 groups were 20:26 ± 0:16, 20:23 ± 0:13 and 20:26 ± 0:10 h, respectively. 
The mean ± SEM anastomotic times were 32 ± 1, 30 ± 1, 35 ± 1 min respectively. 
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The first warm ischemia time (time between arterial clamping and cold flush out) 
ranged from 2-6 minutes and did not differ significantly between groups. In both CS 
and HMP 30/20 groups all animals survived the seven day follow up period. In 
contrast, only three out of five animals survived in the HMP 60/40 group. Both deaths 
were due to renal transplant failure. 
 































































































































Figure 2. Urinary damage markers (mean + standard error of the mean) measured in first 2 ml of 
urine after reperfusion. Thiobarbituric acid-reactive substances (TBARS) (A), proteinuria 
(B), alanine-aminopeptidase (AAP) (C) and N-acetyl-β-D-glucosaminidase (NAG) 
(D). * p<0.05.
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Perfusion dynamics
Renal artery flow measurements during HMP showed a significant increase in flow, 
from 38 ± 2 ml/min initial to 65 ± 4ml/min after 20 h in the HMP 30/20 group. 
This indicates a reduction of vascular resistance over time. In the HMP 60/40 group 
a similar pattern was observed with an initial flow of 49 ± 7 ml/min rising to 104 
± 10 ml/min at 20 h. Continuous temperature registration showed a stabilization of 
graft core temperature at 2-4°C after 2 h of HMP in both groups.
Reperfusion injury
ROS formation
Measurement of TBARS in urine produced immediately after reperfusion allowed 
detection of ROS production. TBARS levels in urine from CS grafts were significantly 
higher compared to HMP 30/20 and HMP 60/40 groups. Urinary TBARS after CS 
were 21.9 ± 2.2 mmol/l compared to 9.8 ± 1.2 and 10.3 ± 1.8 mmol/l after, 
respectively, HMP 30/20 and HMP 60/40 (Fig. 2). 
Proximal tubule damage
Detection of NAG and AAP activity in urine allowed an assessment of injury to 
the proximal tubule immediately after reperfusion. Urine concentrations of NAG were 
significantly higher in urine from CS grafts compared to both HMP groups. Urinary 
NAG concentrations were 84.2 ± 27.1 U/l after CS compared to 8.5 ± 1.7 U/l 
after HMP 30/20 and 8.9 ± 2.3 U/l after HMP 60/40. The results with AAP and 
proteinuria showed a similar pattern (Fig. 2).
Microcirculation
Microcirculatory tissue perfusion of the renal cortex 10 minutes after reperfusion 
showed significant differences between groups. Cortical erythrocyte flux was 
significantly higher in both HMP groups, averaging 130 ± 10% (HMP 30/20) and 












Figure 3.  Representative section of kidney cortex biopsies after preservation immunostained 
(arrows) for von Willebrand factor (vWF) in CS (A), HMP 30/20 (B) and HMP 60/40 (C) 
preserved grafts. Significantly more vWF staining was observed in HMP 60/40 preserved 




















































Figure 4.  Monocyte chemotactic protein (MCP-1) relative gene expression in kidney cortex after 
preservation. A significantly lower expression of MCP-1 was seen in HMP 30/20 grafts 
compared to HMP 60/40 preserved kidneys. * p<0.05.
Renal histology
The modified ischemia/reperfusion injury (IRI) score did not differ significantly 
between groups. Overall, low scores (maximum 12/24) were observed. Although 
a moderate increase of damage was seen over time, this did not reach statistical 
significance. 
Endothelial activation and inflammation
Three endothelial injury markers and one pro inflammatory cytokine were studied to 
examine the influence of CS and HMP on endothelial cell activation and inflammation. 
Biopsies were taken at four time points: before and after preservation, after reperfusion 
and at autopsy.  In kidney grafts preserved with HMP 30/20 von Willebrand factor 
(vWF) mRNA expression in the post preservation biopsy was similar to CS.  An 
almost two fold increase vWF mRNA expression was, however, seen in HMP 60/40 
preserved kidneys compared to CS grafts (p<0.05). These findings were confirmed 
with immunohistochemical staining showing increased vWF staining in HMP 60/40 
(3.75 ± 0.25) grafts compared to CS (0.8 ± 0.5) and HMP 30/20 (0.6 ± 0.25) 
(p<0.05, Fig. 3). Furthermore, HMP 30/20 preserved kidneys showed a significant 
lower expression of MCP-1 compared to HMP 60/40 in the post preservation biopsy 
(p<0.05, Fig. 4). In contrast to vWF and MCP-1 expression, E-Selectin and P-Selectin 
mRNA expression did not differ significantly between groups. 
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Renal function
Post-transplant renal function data are presented in Figure 5. Preservation by HMP 
resulted in a significant improvement of renal function after transplantation. Peak serum 
creatinine levels as well as time to peak serum creatinine were significantly lower 
in both HMP groups. Animals with transplanted kidney grafts after CS preservation 
showed a peak serum creatinine of 940 ± 90 μmol/l on postoperative day 3.4 ± 
0.89. In contrast, animals that received HMP 30/20 kidneys had a significantly lower 
peak creatinine of 463 ± 127 μmol/l on postoperative day 1.8 ± 1.1. Surviving 
pigs in the HMP 60/40 group showed similar results to HMP 30/20 animals with 
a peak creatinine of 428 ± 129 μmol/l on postoperative day 1.7 ± 0.6. However, 
only three animals survived with adequate renal function in this group. The autopsy on 
two animals with renal failure, as demonstrated by rising creatinine levels, revealed 


















































Figure 5.  Post-transplant serum creatinine values in pigs after 20 h CIT with CS (n=5) or HMP 30/20 
(n=5) or HMP 60/40 (n=3/5) (mean + standard error of the mean) showing lower values 
in HMP grafts compared to the CS group. In HMP 60/40 group only surviving animals were 




Since many centers, due to the persistent donor shortage, will accept older, more 
marginal and even donation after cardiac death donors, conventional static cold 
storage might not be sufficient anymore to maintain organ viability during preservation. 
This study demonstrates that hypothermic machine perfusion at a pressure of 30/20 
mmHg using the portable Groningen Machine Perfusion (GMP) system with pulsatile 
perfusion and oxygenation improves 20 h cold preservation of porcine kidneys. In the 
past, several experimental studies have addressed the role of machine perfusion in 
renal preservation using large animal models. Most studies available, however, have 
used canine kidneys, which are in contrast to man, relatively resistant to cold ischemic 
injury (27). The porcine kidney appears to be more sensitive to cold preservation as 
demonstrated by Nicholson and colleagues (1).  For this reason, we have limited cold 
ischemia time to 20 h in our model. The pig was also chosen as an experimental model 
because its renal anatomy and physiology resemble the human situation (1;28;29). 
An autotransplant model was used to rule out allogeneic immune responses allowing 
unbiased investigation of ischemia/reperfusion injury. To determine renal function of 
the autotransplanted kidney a simultaneous contralateral nephrectomy was performed. 
Figure 6 
















Figure 6.  Macroscopic aspect of kidney grafts at different stages in the experiment. In the HMP 60/40 
group a different post-reperfusion aspect was observed when compared to the CS and HMP 
30/20 group. In two 60/40 cases this resulted in a thrombosed graft, without evidence of 
technical anastomosis faillure.
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Cold storage preservation was chosen as a control since 80% of all kidneys is still 
preserved using CS (OPTN data, October 2006). The rationale for the preservation 
solutions used was as follows. UW-CSS and UW-MPS are quite similar solutions. 
UW-CSS contains lactobionate as an impermeant versus gluconate in UW-MPS and 
has an intracellular instead of an extracellular sodium/potassium ratio. UW-CSS is 
at present considered to be the ‘gold standard’ solution for static cold storage. In a 
direct comparison in the CS setting, UW-lactobionate (UW-CSS) was found to have 
a slightly better composition for suppression of hypothermia induced cell swelling 
compared to UW-gluconate (UW-MPS) (30). For this reason we used UW-CSS in the 
control group.
In the HMP 30/20 group, five out of five animals survived. Recovery of renal 
function was significantly improved compared with the CS group, with an approximate 
50% reduction of peak creatinine and time to reach this maximum creatinine. As 
mentioned above, this improvement of post transplant viability cannot be explained 
by the small differences between the solutions. Compared to the study of Nicholson, 
values obtained in the present experiment are better, which can be explained either 
by the shorter CIT, i.e. 20 h versus 24 h,  or the use of the GMP system instead of the 
Waters HMP system (1). Moreover, we could demonstrate improved microvascular 
tissue perfusion upon reperfusion after HMP, whereas the lower erythrocyte flux in the 
CS groups indicated a reduced vascular viability of these grafts. This finding is in line 
with previous observations that high oxygen availability during preservation improves 
microcirculatory parameters (4). The use of oxygen, in the GMP system, with a venous 
pO2 > 100 kPa, may be especially beneficial for endothelial cells since these cells 
are critically sensitive to anoxia which leads to endothelial cell swelling and the so-
called ‘no-reflow’ phenomenon. This effect may account for the impaired vascular 
performance of CS grafts (31-33).
Another beneficial effect of active oxygenation during preservation was seen in 
reduced ROS formation after reperfusion in both HMP groups. This is in accordance 
with earlier findings in rodent models (3;34-36). In addition to the reduced level of 
toxic ROS formation, less urinary release of proximal tubule injury markers AAP and 
NAG was observed after reperfusion of especially the HMP 30/20 preserved grafts 
compared to CS. Both enzymes were not detectable in UW-MPS (data not shown), 
thus demonstrating that the enzymes had not been already washed out during HMP. 
Many studies have pinpointed the damage to tubular cells as an important risk factor 
for the presence of delayed graft function (37). The fact that proximal tubules were 
less injured in the HMP 30/20 group could very well explain the earlier and better 
functional recovery of kidneys preserved by HMP. 
A potential negative effect of HMP in general could be the occurrence of vascular 
injury due to shear stress (38-40). Shear stress is a parallel frictional drag force that 
is linearly proportional to the flow and the viscosity of the fluid (41). Obviously, shear 
stress can easily negatively affect the integrity of vascular endothelial cells and cause 
cellular detachment. In this study, pulsatile pressures of 30/20 mmHg and 60/40 
mmHg were applied at 60 BPM during 20 h HMP. We could not demonstrate 
any significant differences between surviving animals in these groups in terms of 
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morphology, quantified using the modified ischemia/reperfusion injury scale. Renal 
function of surviving 60/40 animals was comparable to 30/20 grafts. Quantitative RT-
PCR analysis and immunohistochemical staining revealed, however, a higher expression 
and staining of von Willebrand factor (vWF) mRNA in biopsies after preservation in the 
HMP 60/40 group compared to CS. The release of vWF is regarded as an important 
marker of endothelial cell disturbance. Perturbation of endothelial cells during HMP can 
indeed stimulate the synthesis of vWF (42). Platelets will subsequently adhere to vWF 
and initiate thrombus formation (43). This cascade might explain the observation of 
a more bluish aspect during reperfusion of HMP 60/40 grafts compared to CS and 
HMP 30/20 groups. Furthermore, the higher vWF synthesis might also explain the 
lower microcirculation in the HMP 60/40 group compared to HMP 30/20. More 
important, a marked difference in survival was seen: in the HMP 60/40 group two 
animals died of renal failure vs. none in the other groups. At autopsy black grafts were 
observed without any evidence for technical failure, e.g. arterial or venous anastomotic 
occlusion or complications. This observation suggests diffuse vascular damage, 
presumably secondary to overexpression and synthesis of vWF during HMP at 60/40 
mmHg due to higher shear rates. Thus, pulsatile pressure of 60/40 mmHg using 
UW-MPS might damage the endothelial cells during HMP in porcine kidneys. There 
are some studies from the early seventies showing a relationship between perfusion 
pressure and endothelial damage. These studies, however, were performed with 
different perfusates and using rabbit or canine kidneys (39;44;45). The conclusion of 
these early experiments was to use a low systolic pressure of approximately 40 mmHg. 
Despite these studies, however, a systolic pressure of 60 mmHg is still common practice 
in human kidney perfusion. The present study, again, underscores the importance of 
perfusion pressures. Although our numbers are small and porcine kidneys are possibly 
more susceptible to endothelial injury, this primarily indicates that perfusion settings in 
human kidneys ought to be reconsidered and may be lowered. 
To study the immunogenicity of the graft following preservation we measured 
the expression of the pro-inflammatory chemotactic cytokine MCP-1. This cytokine 
is important in neutrophil dependent injury and is expressed by a variety of cells 
including vascular endothelial cells (46).  HMP 30/20 showed the lowest expression 
of MCP-1. Several experimental models have shown upregulation of pro-inflammatory 
cytokines and selectins in kidney grafts during cold ischemia (47;48). We postulate 
that oxygenation during preservation at low shear rates minimizes pro-inflammatory 
cytokine expression. Similar, in a rat liver model of oxygenated machine perfusion a 
marked lower expression of ICAM-1 was found in HMP grafts compared to CS (49). 
The higher expression of MCP-1 in the HMP 60/40 group is most probably due to 
shear stress which is also reflected in the higher expression and synthesis of vWF in 
this group.
The portable GMP uses simple but new miniature technology that will fit in the 
conventional organ box as currently used in transplantation. Special features include 
back-up with cold storage in case of total power failure and an option of normothermic 
perfusion by using a heat exchanger and blood compatible disposable components. The 
total added weight of the prototype compared to cold storage concerns only 4.8 kg. 
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In summary, this study demonstrates that the GMP system using pulsatile 
oxygenated perfusion of 30/20 mmHg at 60 BPM allows kidney preservation for 
20 h in a pressure controlled manner. More important, the GMP system improved 
post-transplant kidney function of heart beating porcine kidneys compared to standard 
static cold storage with UW-CSS. Pre-set perfusion pressures, however, are found to 
be critically important for successful outcome after HMP. Too high perfusion pressures 
during HMP provoke an inflammatory response, harm the endothelium and can cause 
subsequent diffuse thrombosis of the graft. In contrast, if a pressure of 30/20 mmHg 
during HMP is applied less toxic ROS are generated, less injury to the proximal tubule 
occurs, less pro-inflammatory cytokines are expressed and the cortical microcirculation 
is improved. As we have now shown the practical feasibility of the GMP system, future 
studies will focus on its application in DCD donors and on a clinical comparison to 
other portable HMP devices. 
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Background: Static cold storage (CS) is the most widely used organ preservation 
method for deceased donor kidney grafts. Preservation by hypothermic machine 
perfusion (HMP) may lead to improved outcome after renal transplantation. However, 
there is a lack of sufficiently powered prospective studies to test the presumed 
superiority of HMP.
Methods: In an international prospective randomized controlled trial kidney pairs of 
336 consecutive deceased donors were enrolled. One organ was randomly assigned 
to HMP and the contralateral kidney to CS preservation. All 672 recipients were 
followed up for one year. The primary endpoint was delayed graft function (DGF). 
Secondary endpoints were functional DGF, duration of DGF, primary non-function, 
serum creatinine and creatinine clearance, acute rejection, calcineurin inhibitor 
toxicity, length of hospital stay, and graft and patient survival post-transplant. This 
trial is registered as an International Standard Randomized Controlled Trial, number 
ISRCTN83876362.
Results: No serious adverse events directly attributable to HMP were encountered. 
HMP significantly reduced the risk of DGF (HMP-arm 70/336, CS-arm 89/336; 
adjusted OR 0.57; p=0.01), and of functional DGF. In the event that DGF occurred, 
its duration was shorter after HMP. Serum creatinine values were lower for HMP kidney 
recipients in the first two weeks post-transplant. HMP reduced the risk of graft failure 
in the first year after transplantation (HR 0.37; p=0.02). One year graft survival was 
superior in the HMP group (98% versus 94%; p=0.03). No significant differences 
were found for the other secondary endpoints.
Conclusion: In all common types of deceased donor kidney transplantation, HMP 
reduced the risk of DGF. In addition, HMP improved graft survival in the first year after 
transplantation.
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Introduction
To date, in kidney transplantation two different organ preservation modalities are 
clinically used for grafts retrieved from deceased donors. In static cold storage (CS) 
the kidney is flushed, cooled with one of several cold preservation solutions, and 
transported on ice. In hypothermic machine perfusion (HMP), after an initial wash-out 
of blood, the kidney is connected to a perfusion device and a solution is continuously 
pumped through the vasculature of the organ at temperatures between 1 and 10°C 
(1). Compared to several decades ago, the average deceased kidney donor today 
is older and has been exposed to more concomitant morbidity which may have a 
detrimental effect on graft quality (2;3). Also, the use of organs derived from donation 
after cardiac death is increasing in most countries (4). Such donor grafts are known 
to have significantly higher rates of delayed graft function (DGF) (4;5). Evidence 
suggests that organs which do not function immediately after transplantation have 
an increased risk of acute rejection and may show worse graft survival, irrespective 
of the preservation solution used with static CS (6;7). In addition, DGF increases the 
costs of kidney transplantation (8;9). Recent retrospective studies have suggested that 
HMP may result in a better short-term outcome, with lower DGF rates after kidney 
transplantation from all types of deceased donors (9-11). Therefore, interest in HMP 
is increasing. In this chapter the results of the first large international prospective 
randomized controlled trial (RCT) comparing HMP with CS preservation in deceased 
donor kidney transplantation are presented. The primary endpoint is DGF.
Methods
Study design
An investigator-driven, international prospective randomized controlled trial (RCT) was 
designed. Donor inclusion regions were The Netherlands, Belgium and the federal 
state of North Rhine Westphalia in Germany. All consecutive deceased donors kidney 
pairs retrieved in these regions that met the initial inclusion criteria were eligible for 
randomization by Eurotransplant. Since the aim was to include the whole spectrum 
of deceased donors, no initial selection of donor types to be included was made. 
Thus, the study reflects the effect of HMP versus CS in everyday practice within an 
international organ exchange organization. A strictly paired design was chosen: from 
each donor, one kidney was randomized to HMP, and the contralateral organ to CS.
Follow-up data were collected from all recipients of randomized trial kidneys. 
Due to international sharing, these recipients were transplanted anywhere within 
Eurotransplant (12). Approval for the study was obtained from ethical review boards 




Trial coordination and trial sponsor
An independent scientific steering committee with clinicians and scientists from each 
trial region was solely responsible for the design and the scientific conduct of this 
study. The steering committee met monthly to monitor progress and discuss any issues 
at hand. The study was sponsored by Organ Recovery Systems, Des Plaines, IL, 
USA.
Inclusion and exclusion criteria
Organ donors had to be ≥16 years of age. Only kidney pairs from deceased donors 
were included in the study, from either donation after brain death (DBD), or donation 
after cardiac death (DCD). DCD donors had to be Maastricht category III or IV (13). Due 
to the paired study design, kidney pairs were only included if both organs were actually 
transplanted into two different recipients. If one kidney was transplanted together with 
another organ into the same recipient, this kidney pair was excluded. The only exclusion 
criterion for recipients was patient death in the first week after transplantation.
Randomization
To avoid regional imbalances between the two study arms due to slightly different 
allocation algorithms (12), a randomization scheme based on permuted blocks within 
regions was used with separate randomization lists for each of the three trial regions. 
Randomization lists were available only to the 24 h Eurotransplant duty desk. Upon 
report of a kidney donor, the allocation officer first checked its eligibility and then 
assigned the left kidney to treatment with either HMP or CS following one of the three 
randomization schemes, which automatically assigned the right kidney to preservation 
with the other method. Then both kidneys were offered according to the match list, 
without revealing the preservation method. Only if the kidney assigned to be machine 
perfused had a too small aortic patch or too many renal arteries preventing a reliable 
connection to the HMP device, surgical teams were allowed to switch randomization 
during organ procurement.
Logistics
In each trial region a team of trained perfusionists was available 24 h per day, 
7 days per week to respond to donor reports. Perfusionists transported the HMP 
device to the donor hospital, assisted donor surgeons with placing one kidney on the 
machine. No changes were made to existing Eurotransplant organ allocation rules or 
to transportation protocols. Both HMP and CS preserved kidneys were transported 
stand-alone to their respective recipient center. After transplantation, empty HMP 
devices were returned to the nearest of the three regional coordinating centers.
Hypothermic machine perfusion
LifePort® Kidney Transporter (Organ Recovery Systems, USA) machines were used 
for HMP with a pulsatile flow of University of Wisconsin machine perfusion solution 
(Kidney Preservation Solution-1; KPS-1®) (14) at 1-8°C. Systolic perfusion pressure 
was fixed at 30 mmHg. Kidneys were machine perfused from organ procurement 
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until transplantation. To prevent any bias in clinical decisions about transplanting or 
discarding an organ, HMP dynamics data -such as renal vascular resistance and flow 
readings- were never revealed to the transplant team. A safety board of experienced 
transplant surgeons was installed and consulted on three occasions: In two out of three 
cases it felt the need to reveal HMP dynamics data to the recipient center. In both 
of these cases the recipient centers saw no reason for organ discard based on the 
additional information and transplanted the kidney.
Cold storage
No changes were made to standard CS protocols; grafts were cold stored according 
to established Eurotransplant routine. After an initial vascular flush-out, kidneys were 
submerged in the preservation solution and stored on melting ice.
Data collection
Donor procedure-related data were collected by the perfusionist on duty. Recipient 
follow-up data were provided by all 60 participating transplant centers within 
Eurotransplant through a secure online database. A random sample of 10% of all 
cases was checked for accuracy by means of an external independent data audit. 
No relevant irregularities were found.
Endpoints
The primary endpoint was DGF, defined as dialysis requirement in the first week after 
transplantation. Secondary endpoints were: duration of DGF, primary non-function, 
area under the curve of daily serum creatinine at days 1–14, creatinine clearance at 
day 14, biopsy proven acute rejection, calcineurin inhibitor (CNI) toxicity, recipient 
length of hospital stay, and graft and patient survival up to one year post-transplant. 
Graft survival was censored upon patient death with a functioning graft. To filter 
out those graft faillures that were due to surgical-technical complications rather than 
the biological conduct of the graft, all graft analyses were condtioned on 14 days’ 
graft survivaI (15). In addition to the primary endpoint we have also examined 
DGF by a more functional definition from Boom (16). Functional DGF (f-DGF) was 
adopted as secondary endpoint and defined as the absence of a decrease in serum 
creatinine of at least 10% per day for at least three consecutive days in the first week 
after transplantation, not including patients who developed acute rejection and/or 
calcineurin inhibitor toxicity in this first week. All endpoints mentioned above were 
pre-specified in the study protocol, except primary non-function, which was added 
post hoc.
Statistics
This study was powered to find a reduction in DGF of at least 10%, based on a 
presumed 35% DGF incidence in CS kidney recipients. With a power of 0.8 and 
a type I error of 0.05, the minimum required sample size was 300 kidney pairs. 
The primary analysis of the DGF endpoint consisted of a logistic regression model, 
which examined whether HMP versus CS, in the context of other relevant donor-, 
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preservation-, and recipient-related factors, influenced DGF risk (7;17). Covariates 
for this model (Table 2) were pre-specified in the study protocol, and their choice was 
based on literature. The final model was determined by entering all covariates at once 
in the analysis, with a built-in normal gamma frailty term for the donor to account for 
the paired study design (18). For endpoint variables, univariate differences between 
groups were assessed with the McNemar test (discrete variables), or the Wilcoxon 
signed rank test (continuous variables). For demographic variables, univariate 
differences were assessed with Fisher’s exact test, or the Mann-Whitney test. The 
Kaplan–Meier method analyzed graft and patient survival. Differences between 
survival curves were determined using log-rank tests. A Cox proportional hazards 
model was applied to examine which variables significantly influenced the risk of graft 
failure. To construct this model, a similar approach as for the logistic regression model 
for DGF was followed: The same set of covariates was entered all at once, and a 
normal gamma frailty term for the donor was included to account for the within-donor 
dependence structure of the data.
Prespecified subgroup analyses of DCD versus DBD, and expanded criteria 
donation (ECD) versus standard criteria donation (SCD) were performed for the 
treatment effect on the primary endpoint. Interaction terms were added to the logistic 
regression model described above, to test whether the magnitude of the effect of 
HMP on DGF differed significantly between subgroups (19). ECD was defined as 
donor age ≥60, or donor age between 50 and 60, with at least two of the following 
additional donor characteristics: (a) history of hypertension, (b) cerebrovascular cause 
of death, (c) pre-retrieval serum creatinine >132 μmol/l (20). No other subgroup 
analyses were performed than those reported in this chapter.
For all analyses, a p-value ≤0.05 was considered to indicate statistical 
significance. All reported p-values are two-sided, and not adjusted for multiple testing. 
Analyses were conducted using SPSS, SAS, and R software packages and are based 
on all organ pairs that met the inclusion criteria. 
No interim analyses of study endpoints were carried out. A confidential safety 
analysis was performed at regular intervals, which compared reported adverse event 
rates between the two trial arms. 
Results
From 1 November 2005 through 31 October 2006, 654 potential deceased kidney 
donors aged ≥16 years in the three trial regions were reported to the Eurotransplant 
desk. Figure 1 shows how 336 kidney pairs (672 recipients) were finally included in the 
analysis. No serious adverse events directly attributable to HMP were encountered. Table 3 
povides an overview of reported adverse events. In 4.6% of all cases, initial randomization 
was switched due to aberrant vascular anatomy of the kidney to be machine perfused. 
We checked whether vascular anomalies had any influence on this study’s primary 
outcome or on the risk of graft failure. No significant effect on DGF was found. 
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Donor age (yr) 51 (16-81) -
Donor type (DBD / DCD) 294 / 42 -
Donor type (SCD / ECD) 242 / 94 -
Recipient demographics
Age (yr) 53 (11-79) 52 (2-79) 0.21
Duration of pre-transplant dialysis (yr) 4.5 (0.15-18) 4.4 (0.19-24) 0.59
Previous transplants (%)† 23 21 0.38
PRA levels (0-5% / 6-84% / >84%) 297 / 35  / 4 304 / 29 / 3 0.68
Immunosuppressive drugs (%)
Prednisolon 98 99 0.77
Cyclosporin 50 54 0.25
Tacrolimus 49 46 0.39
Azathioprine 1 2 0.18
Mycophenolate mofetil 86 87 0.73
Anti-thymocyte globulin 14 13 0.82
Interleukin-2 receptor antagonists 42 47 0.18
Transplant demographics
HLA mismatches (% of 0 mismatches)‡ 16 15 0.90
Cold ischemic time (h) 15.0 (3.5-29.7) 15.0 (2.5-29.7) 0.30
Primary endpoint – univariate
Delayed graft function (%) 20.8 26.5 0.05
Secondary endpoints – univariate
f-DGF# 22.9 30.1 0.03
Primary non-function (%) 2.1 4.8 0.08
Duration of DGF (days) 10 (1-48) 13 (1-41) 0.04
Creatinine clearance at day 14 (ml/min) 42 (0-171) 40 (0-175) 0.25
CNI toxicity within 14 days (%) 6.3 5.7 0.86
Acute rejection within 14 days (%) 13.1 13.7 0.91
Post-transplant hospital stay (days) 19 (4-392) 18 (6-382) 0.78
* If not indicated otherwise, values are expressed as median (range). For endpoint variables, p-values 
were obtained by McNemar test for discrete variables and by the Wilcoxon signed rank test for 
continuous variables. For baseline characteristics, p-values were obtained by Fisher’s exact test for 
discrete variables, and by the Mann-Whitney test for continuous variables.
† Indicates the percentage of recipients who had undergone one or more renal transplants prior to 
the one included in this analysis.
‡ Indicates the percentage of transplants with zero HLA A/B/DR mismatches.
# f-DGF was defined as the absence of a decrease in serum creatinine of at least 10% per day for 
at least three consecutive days in the first week after transplantation, not including patients who 
developed acute rejection and/or calcineurin inhibitor toxicity in this first week.
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Aberrant vascular anatomy did have a significant detrimental effect on graft survival 
(HR 2.41; p=0.03), but addition of this factor to the Cox model had no effect on the 
HMP versus CS hazard ratio (see also the supplementary appendix).
Figure 1
 
1 November 2005 – 31 October 2006
n=654 consecutive potential deceased
donors ≥16 yrs reported within trial region
Excluded (n=60 )
• Not assessed by mistake (n=20)




• Could not be reached in time (n=47)
• Donor center refusal (n=3)
• Donor family refusal (n=1)
Randomization
one kidney to HMP
contralateral kidney to CS
(n=543 kidney pairs)




Excluded (n=184 kidney pairs)
• Donor procedure cancelled (n=14)
• One (n=25) or both (n=45) kidneys
not transplantable
• Combined organ offer† (n=80)





Allocation Excluded (n=21 )
• Kidney rejected at
transplant center (n=10)
• Due to exclusion of contra-
lateral organ (n=11)
Excluded (n=21 )
• Kidney rejected at
transplant center (n=4)
• Technical failure HMP# (n=7)
• Due to exclusion of contra-
lateral organ (n=10)
HMP kidney
recipients ( n=338 )
CS kidney
recipients ( n=338 )
Follow-up Excluded (n=2 )
• Patient died one day after
transplantation¶ (n=1)
• Lost to follow-up (n=1)
Excluded (n=2 )
• Death of contralateral
organ recipient (n=1)
• Due to contralateral organ
lost to follow-up (n=1)
Analyzed ( n=336 patients)
none excluded from analysis
Analyzed ( n=336 patients)
none excluded from analysis
Analysis
Transplantation
Figure 1. Enrollment, group assignment, follow-up and analysis.
 * Switching randomization was only allowed when vascular anatomy made one kidney less 
suitable for the machine.
  † Whenever one or both kidneys were offered together with another organ to one recipient, 
e.g. for combined pancreas–kidney or liver–kidney transplantation.
 ‡ Other reasons for exclusion were: Twelve of the adverse events reported in table 3, and 
in addition five cases in which the donor was monorenal, two cases in which consent for 
kidney donation was withdrawn just before procurement, and one DCD Cat. III procedure 
which was converted to a DCD Cat. II procedure.
  # None of these failures rendered the graft unsuitable for transplantation. When HMP failed, 
the kidney was automatically cold stored inside the machine.
   ¶ Cause of death was a non-transplant related event.
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Demographics
Table 1 summarizes characteristics of the study groups. All DCD donors were Maastricht 
category III. For the recipient variables age, pre-transplant dialysis duration, previous 
transplants, and panel-reactive antibodies (PRA), values did not significantly differ 
between the two arms. There were no significant differences between the two arms in 
HLA mismatches and cold ischemic time (CIT).
Delayed graft function
In the HMP-arm 70 recipients developed DGF, and in the CS-arm DGF occurred in 
89 patients (20.8% versus 26.5%, p=0.05). Table 2 shows the logistic regression 
model. Compared to CS, HMP significantly reduced the DGF risk with an odds ratio 
(OR) of 0.57 (p=0.01). In addition, donor age (OR 1.03; p=0.04), CIT (OR 1.08; 
p=0.003), duration of pre-transplant dialysis (OR 1.16; p=0.01), re-transplantation 
versus first transplant (OR 3.01; p<0.001), and DCD versus DBD donation (OR 17.2; 





No. of events (%) 




Odds Ratio p-value 
 Overall 672 (100) 70 (21) 89 (27) 0.57 (0.36–0.88) 
 Donor criteria 0.75
      Standard criteria donation 484 (72) 48 (20) 60 (25) 0.59 (0.35–1.02) 
      Expanded criteria donation 188 (28) 22 (23) 29 (31) 0.51 (0.24–1.09) 
 Donation procedure 0.42
      Donation after brain death 588 (88) 48 (16) 61 (21) 0.61 (0.37–1.00) 
      Donation after cardiac death 84 (13) 22 (52) 28 (67) 0.39 (0.14–1.06) 
 Donation procedure (ext. dataset)* 0.26
      Donation after brain death 588 (78) 48 (16) 61 (21) 0.59 (0.36–0.97) 




Figure 2.  Subgroup analysis. 
 Number of DGF events per study arm, and adjusted odds ratios (black squares) with 95% CIs 
(horizontal lines) for DGF. P-values for the interaction between the treatment effect (HMP 
versus CS) and any subgroup variable. The scale of the x-axis is logarithmic. All subgroup 
analyses shown in this figure were pre-specified.
 * Extended dataset refers to the main dataset, plus the 80 additional DCD kidney recipients 
who were enrolled after main inclusions had ended. This extended dataset (n = 752 




Table 2. Multivariate risk analysis for delayed graft function and graft failure*





HMP vs. CS 0.57 (0.36 – 0.88) 0.01
PRA level (%) 1.01 (0.99 – 1.02) 0.29
Recipient age (yr) 1.01 (0.99 – 1.03) 0.28
Donor age (yr) 1.03 (1.00 – 1.06) 0.04
ECD donor vs. SCD donor 1.04 (0.46 – 2.34) 0.92
Cold ischemic time (h) 1.08 (1.03 – 1.14) 0.003
Duration of pre-transplant dialysis (yr) 1.16 (1.03 – 1.31) 0.01
Number of HLA mismatches 1.13 (0.94 – 1.37) 0.18
Re-transplant vs. first transplant 3.01 (1.75 – 5.18) <0.001
DCD donor vs. DBD donor 17.2 (8.16 – 36.2) <0.001
Graft failure within one year post-transplant‡
HMP vs. CS 0.37 (0.16 – 0.86) 0.02
Duration of pre-transplant dialysis (yr) 0.94 (0.78 – 1.14) 0.54
Recipient age (yr) 0.96 (0.93 – 0.99) 0.02
Donor age (yr) 1.04 (0.98 – 1.10) 0.16
Cold ischemic time (h) 1.06 (0.97 – 1.15) 0.20
PRA levels (%) 1.01 (0.99 – 1.03) 0.55
Number of HLA mismatches 1.32 (0.97 – 1.81) 0.08
DCD donor vs. DBD donor 1.50 (0.38 – 5.92) 0.56
Re-transplant vs. first transplant 1.77 (0.72 – 4.32) 0.21
ECD donor vs. SCD donor 2.44 (0.66 – 9.04) 0.18
* Logistic regression model for delayed graft function and Cox proportional hazards model for 
graft failure.
† Odds ratios apply to delayed graft function and hazard ratios apply to graft failure.
‡ Censored upon death with a functioning graft and conditioned on 14 days’ graft survival.
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Table 3. Adverse events reported in the first year after transplantation 
Event HMP-arm CS-arm
Adverse events during donor procedure* Number of cases (%)
Both kidneys had vascular anatomy unsuitable for HMP† 7 (2)
Surgical team insisted to put both kidneys on HMP† 4 (1)
Surgical team refused to cooperate with study 3 (1)
13 Year old donor randomized by mistake† 1 (0)
Renal polar artery overlooked during procurement# 1 (0)
Adverse events during organ preservation
Technical failure / malfunction HMP‡ 7 (2) n.a.
Delayed delivery of crossmatch material¶ 1 (0) 0 (0)
Serious adverse events in recipients
Any serious event 77 (23) 88 (26)
Severe urinary tract infection 11 (3) 10 (3)
Sepsis due to any cause 9 (3) 10 (3)
Diabetes mellitus 9 (3) 10 (3)
Severe respiratory tract infection 8 (2) 14 (4)
Postoperative bleeding 8 (2) 8 (2)
Peritonitis 6 (2) 5 (2)
Any arterial thrombosis 6 (2) 4 (1)
Any venous thrombosis 6 (2) 4 (1)
Any cancer 4 (1) 9 (3)
Severe gastro-intestinal tract infection 4 (1) 5 (2)
Cardiac decompensation 3 (1) 3 (1)
Myocardial infarction 2 (1) 2 (1)
Ileus 1 (0) 3 (1)
Gastro-intestinal bleeding 0 (0) 2 (1)
Minor adverse events in recipients
Any minor event 170 (51) 148 (44)
Uncomplicated urinary tract infection 43 (13) 47 (14)




In September 2006, when donor inclusions into the study were nearly complete, the 
scientific steering committee expected that insufficient DCD donors would be enrolled 
at trial completion to conduct a meaningful subgroup analysis for this donation type. 
With permission of all centers, inclusions of only DCD donors were extended, until a 
total of 82 were enrolled on 17 August 2007. A Consort diagram and demographics 
for the two eras of DCD donor inclusions can be found in the supplementary appendix. 
Solely for the DBD/DCD subgroup analysis, these additional inclusions were added 
to the main set of cases to provide more statistical power. The main set of cases 
Event HMP-arm CS-arm
Minor adverse events in recipients
Uncomplicated gastro-intestinal tract infection 22 (7) 21 (6)
Seroma 20 (6) 13 (4)
Ureteral stenosis (graft) 12 (4) 5 (2)
Anemia 11 (3) 8 (2)
Elektrolyte disturbances 9 (3) 5 (2)
Leukopenia 7 (2) 2 (1)
Wound abscess 5 (2) 3 (1)
Hydronephrosis of unknown cause (graft) 5 (2) 2 (1)
Mild cardiac arrhythmia 5 (2) 2 (1)
Incisional hernia 4 (1) 5 (2)
Upper respiratory tract infection 2 (1) 6 (2)
Renal capsular hematoma due to biopsy§ 2 (1) n.a.
All serious adverse events except study endpoints are listed in this table. No serious adverse events 
directly attributable to HMP were reported. Of all minor adverse events, only those that occurred in 
≥1% of all cases are listed. No statistical tests were performed on data shown in this table.
* All these events led to exclusion of the kidney pair from the study (see also Fig. 1).
† Part of exclusions for “other reasons”, as reported in Figure 1.
‡ None of these events rendered the graft unsuitable for transplantation. When HMP failed, the kidney 
was automatically cold stored inside the machine.
# One kidney was unsuitable for transplantation due to insufficient length of the remaining polar 
artery.
¶ Transplantation was postponed for three hours due to delayed crossmatch.
§ For an amendment to the study protocol, addressing additional research questions not reported in 
this chapter, cortical biopsies were taken from several machine perfused kidneys. Capsular hematomas 
did not compromise function of these kidneys.
Table 3. Adverse events reported in the first year after transplantation (continued)
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consisted of 336 kidney pairs (672 recipients), of which 42 (84 recipients) came 
from DCD donors. The extended dataset comprised a total of 376 kidney pairs (752 
recipients). This total includes the 80 recipients of 40 DCD kidney pairs who were 
later added to the main set for this analysis only. Therefore, the total number of DCD 
kidney pairs in the extended dataset was 82 (164 recipients). The same logistic 
regression model for DGF with an interaction term for HMP and DCD was applied to 
the extended dataset. Figure 2 shows a forest plot of the treatment effect in subgroups. 
First, interactions for subgroups SCD/ECD and DBD/DCD are shown, based on the 
main set of inclusions. No significant difference in the magnitude of the treatment 
effect was found for these subgroups (p=0.75 and p=0.42, respectively). When the 
DBD/DCD interaction test was performed on the extended dataset, there was also 
no significant difference between the impact of HMP versus CS in DBD versus DCD 
kidney grafts (p=0.26). 
Figure 3 
 
No. of values available 
CS-arm 327 329 328 319 322 309 316 282 295 268 266 242 248 278 
HMP-arm 322 324 325 326 316 313 314 296 286 281 273 251 245 274 
Median serum creat. (µmol/l)
CS-arm 592 507 406 327 283 248 221 210 200 195 180 180 177 166 



































Figure 3.  Time course of serum creatinine after transplantation.
 Below the x-axis, the sample size available per post-transplant day, and median serum 
creatinine values per day are indicated. For each recipient, the area under the curve (AUC) 
was calculated. Missing values (12%) were imputed by means of linear interpolation. The 
median AUC of HMP recipients (1456; range 385–5782) was significantly lower than the 




Table 1 also shows univariate statistics for all secondary endpoints. f-DGF occurred 
in 77 recipients in the HMP-arm and in 101 recipients in the CS-arm (22.9% versus 
30.1%, p=0.03). The incidence of primary non-function in CS recipients was more 
than two times higher than in HMP recipients, but this difference did not reach statistical 
significance (4.8% versus 2.1%, p=0.08). When recipients developed DGF, the 
duration was three days shorter after HMP than after CS (10 days versus 13 days; 
p=0.04). Creatinine clearance at 14 days post-transplant, length of hospital stay of 
recipients, the incidence of CNI toxicity, and acute rejection rate in the first 14 days 
after transplantation showed no significant differences between the two study arms. 
The curve of daily serum creatinine evolution in the first two weeks post-transplant 
(Fig. 3) was significantly lower for HMP kidney recipients (p=0.01).
HMP 
CS 
No. at risk 
HMP-arm 324 323 322 319 317 315 314 314 312 311 310 309 309 
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Figure 4.  Death censored graft survival. 
 Both curves are conditioned on 14 days’ graft survival. Below the graph, the number of 
recipients at risk for graft failure is indicated for each month post-transplant. Vertical 
lines indicate cases censored upon death with a functioning graft. HMP versus CS: p=0.03 
(log-rank test). 
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Patient and graft survival
At one year post-transplant, patient survival was 97% for both, HMP and CS kidney 
recipients. One year graft survival (Fig. 4) in the HMP-arm was significantly higher 
than in the CS-arm (98% versus 94%, p=0.03). In the Cox regression analysis (Table 
2), HMP significantly reduced the risk of graft failure in the first year post-transplant 
with a hazard ratio of 0.37 (p=0.02). To test the hypothesis that this beneficial effect 
of HMP on the risk of graft failure could be mediated through a reduction in DGF, a 
post hoc analysis was conducted: DGF was added as a time dependent covariate 
to the Cox model. DGF proved to be a significant determinant of an increased risk of 
graft failure (HR 1.63; p<0.001), the hazard ratio of HMP versus CS increased to 




Static cold storage is the easiest and currently most widely used preservation method 
in kidney transplantation (USA: 80%,  Eurotransplant: ~100%) (21;22). Although 
recent retrospective studies have suggested HMP superiority (9;10), these registry 
analyses are biased due to selection of donor kidneys to be pumped and organ 
discard based on perfusion parameters (23). To date, no reliable prospective RCTs 
have been conducted to test the presumed superiority of HMP. Only a limited number 
of prospective studies have been performed, unfortunately either without adequate 
randomization or with equivocal results due to small sample sizes (24-28). 
This study is the first large, prospective RCT to show that HMP significantly 
reduces the risk of DGF. Due to its size and strictly paired design, the study was 
probably better capable of detecting even modest differences in outcome between 
HMP and CS preservation. The rather large number of exclusions is typical for a 
paired study in organ preservation: Randomization inevitably had to be carried out at 
a very early stage in the donation cascade, when there was merely a potential kidney 
donor. Only after both kidneys had actually been transplanted could it be determined 
whether a donor would meet the inclusion criteria. Exclusion of donors of whom one 
kidney was discarded may have led to a mild bias toward the “better” kidney donor 
in our study. The same might be true for donors who were not included because the 
donor hospital could not be reached in time by the perfusionist: Theoretically, these 
donors may have been more unstable ICU patients, in whom organ procurement had 
to be performed as a quick emergency procedure. Conversely, excluding donors 
from whom combined kidney-pancreas transplants were performed may have slightly 
biased the data in the opposite direction, as in general only the most optimal donors 
are considered for these procedures. In a small number of cases initial randomization 
was switched for anatomical reasons. It is unlikely that this practice has significantly 
biased the study’s outcomes: Aberrant vascular anatomy did not have a significant 
effect on DGF, and although it did influence graft survival, addition of this factor to 
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the Cox model did not cause a relevant change in the observed effect of the HMP 
versus CS covariate. In the design of this study, we chose to employ a multivariate 
model as the primary analysis of DGF, because of the anticipated heterogeneity 
which is common for transplant recipient populations (22;29).
The assumed 10% reduction we initially powered for (35% to 25% = OR 0.62) 
was not demonstrated in a univariate analysis (26.6% to 20.8% = OR 0.73). 
However, when in the logistic regression model relevant confounding factors were 
taken into account, the effect of HMP versus CS on DGF risk had an OR under 
0.62. The effect found is slightly stronger than the associations observed in major 
retrospective studies and meta-analyses (OR 0.62-0.73) (9;10). Median CIT in both 
treatment arms (15.0 h) was relatively short when compared to other data-sets (22).
This may explain why the incidence of DGF in the CS-arm of this study was 8.5% 
lower than the originally anticipated 35%. In addition, it is conceivable that the effect 
of HMP would have been stronger if cold ischemic times had been longer (22). Of 
interest is that HMP reduced the incidence of f-DGF in a more pronounced fashion 
(30.1% versus 22.9%) than found for the primary endpoint. Hence, the magnitude 
of the beneficial short term effect of HMP appears to depend to some extent on how 
DGF is defined.
The impact of HMP on DGF did not differ between subgroups of deceased 
donors. It can be argued that failure to detect a significant interaction does not imply 
the absence of subgroup differences. However, based on the evidence coming from 
the present and other studies (11), it is probably most legitimate to assume that the 
impact of HMP versus CS on DGF in various subgroups is at or near overall OR of 
0.57. With this assumption, HMP can be considered to have a beneficial effect on 
short term outcome in all common types of deceased donor kidney transplantation. 
Nevertheless, DGF has a higher incidence in DCD and ECD kidney recipients (30). 
Hence, the absolute number of patients that will actually benefit from HMP could be 
larger in these subgroups. DCD donors in our study were solely controlled Maastricht 
category III donors, the effect of HMP might be more pronounced in uncontrolled, 
category I, II or IV DCD donor grafts that have suffered from more warm ischemic 
injury. Unfortunately, multicenter series of such donor categories are rare and therefore 
difficult to study prospectively.
Even when early graft failures are not considered, HMP has a significant 
protective effect against graft loss, which becomes apparent within one year after 
transplantation. The hazard ratio of 0.37 found in this trial indicates a remarkably 
stronger effect than the “mild benefit” Schold and collaegues have reported in their 
large retrospective study (10). The post hoc addition of DGF as a covariate to the 
Cox model shows that DGF renders a kidney recipient more at risk for graft failure 
within the first year post-transplant. In addition, it caused an increase in the HMP 
versus CS hazard ratio, and this covariate became non-significant in the model. 
Therefore, we conclude that the beneficial effect of HMP on graft survival could in 
part be explained by the reduction in DGF that is also caused by HMP.
The number of primary non-function cases was half as high in the HMP versus the 
CS group, but the difference was not statistically significant. This may be explained by 
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the low overall incidence of primary non-function. Although no definitive conclusions 
can be drawn from this observation, the phenomenon deserves close attention in 
future analyses. In this trial, HMP characteristics were not allowed to be used as a 
diagnostic tool. If they are relevant, it can be expected that such an extra selection 
opportunity will further increase the effect of HMP on transplant outcome due to 
discard of organs diagnosed to be at risk for poor outcome(23). 
In conclusion, this prospective RCT comparing two preservation modalities for 
kidney transplantation from deceased donors found that HMP reduces the incidence 
of delayed graft function in all common types of deceased donor kidneys. In addition, 
HMP reduces the duration of DGF, in case it occurs. Machine perfused renal grafts 
had a lower risk of graft failure in the first year post-transplant and, as a result, these 
kidneys showed an improved one year graft survival versus those preserved by static 
cold storage.
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Supplementary Appendix 
List of participating transplant centers (centers and names)
Austria (4 centers, 17 recipients) – Landeskrankenhaus Graz: H. Holzer, I. Spiegl, 
V. Trunk; Universitätsklinik für Chirurgie Innsbruck: R. Margreiter, C. Bösmüller, W. 
Mark, H. Fetz; Allgemeines Krankenhaus der Stadt Linz: B. Schmekal; Allgemeines 
Krankenhaus Wien: F. Mühlbacher, I. Kristo, M. Pones, G. Györi.
Belgium (7 centers, 183 recipients) – Universitair Ziekenhuis Antwerpen: D. Ysebaert, 
J.L. Bosmans, G. Van Beeumen, W. Van Donink; Universitair Ziekenhuis Brussel: 
J. Lamote, J. Sennesael, B. Amerijckx; Hôpital Erasme Bruxelles: A.D. Hoang, D. 
Mikhalski, D. Abramovicz, V. Brulein; Universitair Ziekenhuis Gent: C. Randon, P. 
Peeters, M. VanderVennet; Cliniques Universitaires St. Luc Bruxelles: M. Mourad, M. 
de Meyer, J. Malaise, L. De Pauw; Centre Hospitalier Universitaire Liège: J.P. Squifflet, 
L. Weekers, O. Detry, M.H. Delbouille; Universitaire Ziekenhuizen Leuven: J. Pirenne, 
Y. Vanrenterghem, F. van Gelder, B. Desschans.
Germany (38 centers, 327 recipients) – Universitätsklinikum Aachen: G. Jakse, D. 
Rohrmann, J. Floege, A. Homburg; Knappschaftskrankenhaus Bochum: R. Viebahn, 
O. Vonend, P. Schenker, A. Wunsch; Universitätsklinik Bonn: S.C. Müller, H. Klehr; 
Universitätsklinikum Düsseldorf: W. Sandmann, K. Ivens, A. Voiculescu, K. Balser; 
Universitätsklinikum Essen: A. Paul, O. Witzke, J. Treckmann, A. Jonait-Borkenhagen; 
Medizinische Universitätsklinik Köln-Lindenthal: D. Stippel, Th. Benzing, K. Prenzel, 
B. Hoppe; Städtische Krankenanstalten Köln-Merheim: M. Ströhlein, W. Arns, R. 
Hackenberg, U. Lange; Westfälische WU Klinikum Münster: H. Wolters, B. Suwelack; 
Zentralklinikum Augsburg: E. Nagel, H. Weihprecht, R. Eser, T. Breidenbach; Charité 
Berlin - Campus Benjamin Franklin: K. Miller, M. Van der Giet, E. Krusic, M. Tölle; 
Charité Berlin - Campus Mitte: F. Fuller, K. Budde; Charité Berlin - Campus Virchow: 
J. Pratschke, P. Reinke, Th. Mehlitz; Zentralkrankenhaus Bremen: S. Melchior, F.A. 
Zantvoort, Ch. Bahrs, S. Meier; Universitätsklinikum Carl Gustav Carus Dresden: 
M. Wirth, S. Milde; Klinikum der JW Goethe Universität Frankfurt: M. Probst, E.-H. 
Scheuermann; Klinikum der AL Universität Freiburg: P. Pisarski, P. Gerke, M. Geyer, S. 
Hils; Universitätsklinikum Halle: A. Hamza, O. Rettkowski, K. Fischer, A. Haberland; 
Klinikum der Universität Heidelberg: J. Schmidt, M. Zeier, B. Schmied, C. Sommerer; 
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Nephrologisches Zentrum Niedersachsen: J. Küster, V. Kliem; Medizinische Hochschule 
Hannover: F. Lehner, A. Schwarz, M. Hiss, N. Mogilewskaja; Universitätsklinik 
des Saarlandes Homburg/Saar: M. Stöckle, M. Girndt, M. Janssen, U. Sester; 
Medizinische Fakultät/Klinikum Jena: Th. Steiner, O.H. Undine, J. Schubert, G. Wolf; 
Universitätsklinikum Schleswig-Holstein Kiel: D.C. Bröring, U. Kunzendorf, P. Glass, F. 
Braun; Westpfalz-Klinikum Kaiserslautern: T. Rath, A. Dahms; Universitätskrankenhaus 
Leipzig: J. Hauss, P. Martin, D. Weinert; Universitätsklinikum Schleswig-Holstein 
Lübeck: J. Steinhoff, J. Schlieter; Klinikum der Stadt Mannheim: M. Schwarzbach, 
P. Schnülle; Klinikum Rechts der Isar München: M.C. Raggi; Klinikum Grosshadern 
München: M. Rentsch; Klinikum Lahnberge Marburg/Lahn: J. Geks, U. Kuhlmann, 
T. Maier, J. Hoyer; Klinikum der Joh. Gutenberg Universität Mainz: J. Thüroff, O. 
Schreiner, J. Jones, K. Allers; Universitätskrankenhaus Erlangen-Nürnberg: G. 
Schott, Ch. Hugo, K. Pressmar, K. Hirsch; Medizinische Fakultät Rostock: K. Stein, 
M. Burde; Katharinenhospital Stuttgart: M. Schock, G. Hasche, Ch. Olbricht, M. 
Kalus; Chirurgische Universitätsklinik Tübingen: W. Steurer, N. Heyne, Ch. Thiel, K. 
Knubben; Universitätskrankenhaus Ulm: D. Henne-Bruns, H.W. Fuchs; Klinikum der 
Bayerischen J-M-U Würzburg: K. Lopau, R. Bonfig.
Luxemburg (1 center, 4 recipients) – Centre Hospitalier de Luxembourg: S. Lamy, P. 
Duhoux, E. Tasch, J. De Sousa.
The Netherlands (8 centers, 136 recipients) – Academisch Medisch Centrum 
Amsterdam: M.M. Idu, F.J. Bemelman, I. ten Berge, K. van Donselaar; Universitair 
Medisch Centrum Groningen: R.J. Ploeg, J.J. Homan van der Heide, C. Moers, M. 
van Dijk; Leids Universitair Medisch Centrum: J. Ringers; Academisch Ziekenhuis 
Maastricht: E. van Heurn, J. van Hooff, M. Christiaans; UMC St. Radboud Nijmegen: 
J.A. van der Vliet, A.J. Hoitsma; Erasmus Medisch Centrum Rotterdam: J.N.M. 
Yzermans, W. Weimar, J. Kal-van Gestel; Universitair Medisch Centrum Utrecht: 
R.W.H. van Reedt Dortland, R.J. Hené, V. Leydekkers, C. van Straalen; Wilhelmina 
Kinderziekenhuis Utrecht: M.R. Lilien.




























1 November 2005 – 31 October 2006
n=119 consecutive potential DCD Cat. III-IV
donors ≥ 16 yrs reported within trial region
1 November 2006 – 17 August 2007
n=102 consecutive potential DCD Cat. III-IV 
donors ≥16 yrs reported within trial region
Excluded (n=8) (n=14 )
• Not assessed by mistake (n=1) (n=6)




Excluded (n=33 donors) (n=4 donors)
• Could not be reached in time (n=31) (n=4)
• Donor center refusal (n=2) (n=0)
• Donor family refusal (n=0) (n=0)
Randomization
one kidney to HMP
contralateral kidney to CS
(n=78 kidney pairs)
(n=84 kidney pairs)
randomization intact (n=75) (n=81)
randomization switched * (n=3)  (n=3)
Donor procedure
(n=78) (n=84 )
Excluded (n=31 kidney pairs) (n=36 kidney pairs)
• Donor procedure cancelled (n=9) (n=11)
• One or both kidneys not transplan-
table (n=15) (n=18)
• Combined organ offer † (n=0) (n=1)









• Kidney rejected at
transplant center (n=2) (n=5)
• Due to exclusion of contra-
lateral organ (n=2) (n=1)
Excluded (n=4) (n=6)
• Kidney rejected at
transplant center (n=1) (n=0)
• Technical failure ‡ (n=1) (n=1)
• Due to exclusion of contra-







• Patient died first week after
transplantation # (n=1) (n=1)
• Death of contralateral
organ recipient (n=0) (n=1)
• Lost to follow-up (n=0) (n=0) 
Excluded (n=1) (n=2)
• Patient died first week after
transplantation # (n=0) (n=1)
• Death of contralateral
organ recipient (n=1) (n=1)
• Lost to follow-up (n=0) (n=0)
Analyzed ( n=42 patients)
Analyzed ( n=40 patients)
none excluded from analysis
Analyzed ( n=42 patients)
Analyzed ( n=40 patients)
none excluded from analysis
Analysis
Transplantation
Figure S1. Enrollment, group assignment, follow-up and analysis of DCD inclusions.
 Text and numbers in italics refer to the second era of DCD inclusions, after main consecutive 
inclusions (DBD and DCD mixed) had ended. These extra DCD cases were solely used for 
a subgroup analysis of the effect size of HMP versus CS in DCD versus DBD kidney grafts.
 * Switching randomization was only allowed when vascular anatomy made one kidney less 
suitable for the machine.
  † Whenever one or both kidneys were offered together with another organ to one recipient, 
e.g. for combined pancreas–kidney or liver–kidney transplantation.
 ‡ None of these failures rendered the graft unsuitable for transplantation. When HMP failed, 
the kidney was automatically cold stored inside the machine.
  # Causes of death were one transplant related and two non-transplant related events. 



























































































































































































































































































































































































































































































































































































































































































































































































































































Table S3. Multivariate risk analysis for delayed graft function*
 Variable Hazard Ratio
(95% CI)
p-value
 Delayed Graft Function
 HMP vs. CS 0.57 (0.36–0.88) 0.01
 PRA level (%) 1.01 (0.99–1.02) 0.29
 Recipient age (yr) 1.01 (0.99–1.03) 0.28
 Aberrant vascular anatomy† 1.02 (0.62–1.66) 0.95
 Donor age (yr) 1.03 (1.00–1.06) 0.04
 ECD donor vs. SCD donor 1.04 (0.46–2.36) 0.92
 Cold ischemic time (h) 1.08 (1.03–1.14) 0.003
 Number of HLA mismatches 1.13 (0.94–1.37) 0.18
 Duration of pre-transplant dialysis (yr) 1.16 (1.03–1.31) 0.01
 Re-transplant vs. first transplant 3.02 (1.75–5.22) <0.001
 DCD donor vs. DBD donor 17.2 (8.17–36.6) <0.001
Table S4. Multivariate risk analysis for graft failure*
 Variable Hazard Ratio
(95% CI)
p-value
 Graft Failure within one year post-transplant†
 HMP vs. CS 0.39 (0.17–0.91) 0.03
 Duration of pre-transplant dialysis (yr) 0.95 (0.79–1.14) 0.57
 Recipient age (yr) 0.96 (0.93–0.99) 0.02
 PRA level (%) 1.01 (0.99–1.03) 0.60
 Donor age (yr) 1.03 (0.98–1.09) 0.22
 Cold ischemic time (h) 1.06 (0.98–1.15) 0.17
 Number of HLA mismatches 1.35 (1.00–1.83) 0.05
 DCD donor vs. DBD donor 1.40 (0.37–5.29) 0.62
 Re-transplant vs. first transplant 2.05 (0.85–4.97) 0.11
 Aberrant vascular anatomy‡ 2.41 (1.07–5.45) 0.03
 ECD donor vs. SCD donor 2.77 (0.78–9.80) 0.11
* Cox proportional hazards model for the risk of graft failure within one year post-transplant, with 
aberrant vascular anatomy as extra covariate, added post hoc.
† Censored upon death with a functioning graft and conditioned on 14 days’ graft survival.
‡ Aberrant vascular anatomy was defined as >1 renal artery of the kidney graft.
* Logistic regression model for the risk of DGF, with aberrant vascular anatomy as extra covariate, 
added post hoc.
† Aberrant vascular anatomy was defined as >1 renal artery of the kidney graft.
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Table S5. Multivariate risk analysis for graft failure*
 Variable Hazard Ratio
(95% CI)
p-value
 Graft Failure within One Year Post-transplant†
 DCD donor vs. DBD donor 0.64 (0.22–1.80) 0.39
 HMP vs. CS 0.66 (0.37–1.16) 0.15
 Duration of pre-transplant dialysis (yr) 0.94 (0.82–1.07) 0.33
 Recipient age (yr) 0.97 (0.95–0.99) 0.01
 PRA level (%) 1.00 (0.99–1.02) 0.89
 Cold ischemic time (h) 1.01 (0.95–1.08) 0.68
 Re-transplant vs. first transplant 1.03 (0.53–2.02) 0.92
 Donor age (yr) 1.03 (1.00–1.07) 0.07
 Number of HLA mismatches 1.19 (0.96–1.48) 0.10
 ECD donor vs. SCD donor 1.34 (0.54–3.35) 0.52
 Delayed Graft Function‡ 1.63 (1.29–2.05) <0.001
* Cox non-proportional hazards model for the risk of graft failure within one year post-transplant, with 
DGF as extra covariate, added post hoc.
† Censored upon death with a functioning graft.
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Towards normothermic preservation: 
effects of hemodilution on endothelial 
activation in vital organs
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Background: Preservation techniques based on hypothermia such as static cold 
storage (CS) or hypothermic machine perfusion (HMP) have traditionally dominated 
organ preservation. The increase of older, marginal and ischemically damaged 
organs, however, has redirected attention towards novel techniques that do not induce 
hypothermia related damage. Normothermic preservation (NMP) provides oxygen 
delivery at physiologic or near-physiologic temperature and allows near-normal 
metabolism. Since traditional hypothermic preservation solutions cannot provide 
physiologic metabolic demands, diluted donor blood is often used as a preservation 
solution in experimental and clinical normothermic machine perfusion (NMP). In this 
study the effects of diluted blood were studied in a porcine hemodilution model.
Methods: Acute isovolemic hemodilution (IHD; 30 ml/kg exchange-transfusion 
with colloid-solutions) was induced in 15 pigs. Hypoxic oxidative stress (plasma 
malondialdehyde, ex-vivo oxygen radicals production in heart, lung, kidney, liver 
and ileum tissue biopsies), erythrocyte aggregation (LORCA), and endothelial 
activation (Real-Time quantitative RT-PCR on von Willebrand Factor (vWF), E- and 
P-Selectins, endothelial nitric oxide synthase gene-expression in tissue biopsies) were 
investigated.
Results: The production of superoxide and hydroxyl radicals, measured as H2O2 
generation, was similar at all times in sham-operated and hemodiluted animals, proving 
a maintained oxygen delivery to tissues. Acute IHD was followed by a dramatic drop 
in erythrocyte aggregation and immediate pro-thrombotic (significant vWF mRNA 
up-regulation in heart, lung, kidney, liver and ileum) and pro-inflammatory (significant 
E- and P-Selectins mRNA up-regulation in lung and ileum) endothelial activation. Low 
erythrocyte aggregation was significantly correlated with increased mRNA-expression 
of vWF (heart, liver and ileum) and P-Selectin (lung, ileum and heart). 
Conclusion: The results suggest that low erythrocyte aggregation during hemodilution 
triggers endothelium-dependent thrombogenic and pro-inflammatory responses. 
Given the potential impact of inflammation and coagulation upon reperfusion of 
a normothermic preserved graft the use of diluted donor blood as a normothermic 
preservation solution should be considered suboptimal. 
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Introduction
Organ preservation has always been crucial for transplant outcome, but will become 
even more important in the present era with increasing numbers of older, more marginal 
and organs derived from donation after cardiac death (DCD) donors. Although static 
cold storage (CS) has proven its efficacy in the past, it seems that the limitations 
of this technique have been reached. To maintain organ viability, more efforts are 
necessary to reduce ischemia/reperfusion injury and initiate repair. Hypothermic 
machine perfusion (HMP) might be able to improve organ preservation, but suffers 
from the negative side effects of hypothermia such as acidosis, cell swelling, and 
formation of radical oxygen species. Ideally, organ preservation should facilitate 
the use of marginal, older and DCD organs, provide real-time viability assessment 
before transplantation without causing damage to the graft. Normothermic (37°C) or 
sub-normothermic (25-32°C) machine perfusion (NMP) is a preservation alternative 
that may indeed achieve these goals (1). Preservation at (near) normothermic 
temperatures provides more adequate ways to test and optimize graft viability and 
allows elimination of hypothermia induced injury (2;3). Normothermic perfusion of 
abdominal organs using a cardiopulmonary bypass (CPB) system followed by CS has 
already been applied in human kidney transplantation. This so called normothermic 
recirculation protocol showed significant improvements in a group of 44 DCD kidneys. 
PNF and DGF rates were 0% and 12.5%, respectively, compared to 22.5% and 
55% for conventional preservation techniques. Despite the fact that this study was 
retrospective and included patients over a 12 year period, it suggests a potential 
benefit for clinical application of normothermic techniques (4). In experimental liver 
preservation, normothermic perfusion of porcine livers subjected to 60 min of warm 
ischemia resulted in functioning liver grafts, whereas the animals transplanted with CS 
livers all died. Normothermic perfused livers demonstrated stable metabolic function 
with adequate production of coagulation factors, hyaluronic acid clearance, glucose 
metabolism and significantly lower transaminases compared to CS grafts (1;5;6). 
Most groups use diluted whole (donor) blood as a preservation solution during 
NMP. Donor blood is easy to obtain, facilitates oxygen and nutrient delivery and 
is fully compatible with the preserved organ. From clinical observations in CPB 
patients, however, it is known that perfusion with diluted blood can cause endothelial 
activation. Hemodilution decreases red blood cell (RBC) aggregation and plasma 
viscosity and thereby modifies rheological variables resulting in a constant shear 
stress and mechanical endothelial activation (7). The pathogenicity of hemodilution 
could have major implications for the use of diluted blood as an organ preservation 
solution. Therefore, before testing the feasibility of NMP using the Groningen Machine 
Perfusion (GMP) system this study examines the effects of diluted blood with a special 
focus on endothelial activation.
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Animals, materials and methods
Animals
Fifteen female Landrace pigs, weighing 60 to 80 kg, were used in this study. All 
experimental procedures were approved by the Animal Experiments Committee of the 
University of Groningen. The principles of laboratory animal care (NIH publication 
no. 85-23, revised 1985) were followed.
Experimental design
The experimental design was based on previous studies showing different effects of 
different molecular weights of hydroxyethyl starches (HES) on human RBCs, showing 
more RBC aggregation with increasing molecular weights of the colloid (8;9). 
Therefore, two commonly used clinical plasma expanders with different HES weights 
were used to induce acute isovolemic hemodilution (IHD). 
The following groups were studied: 
Group 1: 30 ml/kg isovolemic exchange transfusion with HAES-sterile•	 ® 3% 
(HES 200/0.5, median molecular weight 200 kDa, supplemented with 
lactated Ringers to a final concentration of 3%, n=6);
Group 2: 30 ml/kg isovolemic exchange transfusion with Voluven•	 ® 3% (6% 
HES 130/0.4, median molecular weight 130 kDa, supplemented with 
lactated Ringers to a final concentration of 3%, n=6);
Group 3: control group sham-operated animals (n=3). •	
Anesthesia was induced with ketamine (i.m. 10 mg/kg) and diazepam (i.m. 
1 mg/kg). Before intubation, ventilation was performed using a mixture of O2 and 
isoflurane 4%. After tracheal intubation, ventilation was performed with isoflurane 
1.5-2%.
Isovolemic hemodilution was induced after cannulation of the jugular vein and the 
carotid artery, by infusing HES at the arterial site, and a simultaneous venous blood 
withdrawal of an equal volume of blood. Hematocrit (Hct) and hemoglobin (Hb) 
were monitored throughout the experiment, and adjusted to a constant value of 40% 
of the initial value (Fig.1). No inotropic support was used. After 3 h of maintaining 
isovolemic hemodilution, tissue biopsies were obtained from the small intestine (ileum, 
luminal site), a randomly selected kidney (cortex), liver, lung and heart. Biopsies were 
snap frozen in liquid nitrogen and stored at -80ºC to study organ-specific endothelial 
activation. Blood samples were collected at three time points: baseline (5 min 
after placement of the cannulas), post-infusion (5 min after induction of isovolemic 
hemodilution), and at the end of the experiment (3 h of isovolemic hemodilution). 
Test of RBC aggregation
RBC aggregation measurements were performed on fresh arterial blood samples, 
using a Laser-assisted Optical Rotation Cell Analyzer (LORCA, R&R Mechatronics, 
Hoorn, The Netherlands), and quantified as Aggregation Index (AI) (10). For the 
determination of red cell aggregation, the blood was brought under a shear rate 
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of 500 s-1, after which shear was stopped at t=0. The backscattered intensity of 
the blood layer was measured during 120 s after shear stop. The intensity dropped 
because of red blood cell aggregation (11). 
Viscosity measurements
Viscosity measurements of plasma samples were performed with an automated dynamic 
shear rheometer with cone-plane geometry (AR1000 Rheometer, TA Instruments, New 
Castle, USA). During measurements temperature was set at 37°C and shear rate of 
operation at 100 s-1.
Hypoxic oxidative stress
Plasma malondialdehyde (MDA) 
Enzymatic detection, according to the method described by Esterbauer and 





production in tissue biopsies
A fluorophore-nitroxide (Molecular Probes, Eugene, USA) was used to image 
ex-vivo superoxide and hydroxyl radicals generated by cells (13). The reaction of 
fluorophore-nitroxide with superoxide results in loss of electron spin resonance signal 
intensity concurrent with an increase in fluorescence emission. Fluorophore-nitroxide 
also reacts with methyl radicals generated by the reaction of hydroxyl radicals with 
dimethyl sulfoxide (DMSO) (14). 
Biopsies from tissue of approximately 2 mm3 and dry weight of 2-5 mg were 
incubated for 10 min in a microtiter plate in 50 µl of 0.1M Tris-HCl buffer (pH 
8.0), containing 2.5 mM pyruvate and 5 mM succinate to stimulate mitochondrial 
activity (15). Then 50 µl Tris-buffer containing 2 µM fluorescamine and DMSO (final 
concentration 2.5%) was added. The reaction was started after the addition of 5 µl 
FeII-EDTA (final Fe concentration 2 µM) in Tris buffer. In this way, both superoxide and 
hydroxyl radicals were converted and measured as H2O2 (16). The biopsies were 
incubated in this mixture for 10 min at room temperature. After removal of the biopsies 
the fluorescence was measured in a multilabel counter (Victor2, EG&G Wallac, Turku, 
Finland) by using 390 nm excitation and 510 nm emission filters. Standard curves 
were obtained by adding known amounts of H2O2 to the assay medium. 
During incubation Hb was released from the biopsies, resulting in quenching 
of the fluorescence signal. Thus, a separate standard curve was prepared including 
stepwise diluted Hb ranging from 0.1 to 1.2 g/l. The linear relationship between 
Hb concentrations and fluorescence signal was used to correct for the Hb signal 
quenching. Hb concentration in the supernatant of the incubated biopsies was 
measured by the method of Harboe (17). Finally, measured H2O2 concentration was 
corrected for the dry weight of the biopsy. 
Diaminobenzidine (DAB) staining
The production of H2O2 by cells in paraformaldehyde-fixed sections of ileum 
mucosa was histochemically demonstrated by incubating them for 30 min with 25 
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mg DAB/50 ml Tris/HCL pH 7.6, at 60°C. Catalase (150 µg/ml, 1400 U/ml) 
inhibited the reaction, indicating that H2O2 was required to produce the chromogenic 
DAB staining. 
Endothelial activation
Real-Time quantitative Taqman RT-PCR on von Willebrand factor (vWF), E- Selectin, 
P-Selectin, and endothelial nitric oxide synthase (eNOS) gene expression in heart, lung, 
kidney, liver and intestinal tissue biopsies. Total RNA was extracted using RNeasy Mini 
Kits (Qiagen, Venlo, The Netherlands), as recommended by the supplier. Total RNA was 
treated with 2 U of DNase I (RNase-Free DNase, Qiagen, Venlo, The Netherlands) in 
a volume of 15 µl to remove contaminating DNA (15 min at 37°C). First-strand cDNA 
synthesis: the mix of RNA (1 µg), 0.25 µg random hexamer primers and 2 ng of dNTPs 
(Promega, Leiden, The Netherlands) was heated for 5 min at 65°C and incubated on 
ice for at least 1 min; subsequently. The master mix (200 U SuperScript III, Invitrogen, 
Breda, The Netherlands) with 4 µl of 5x first-strand buffer, 1 µl 0.1M dithiothreitol, and 
40 U RNaseOUT ribonuclease inhibitor (Invitrogen) was added to the samples in a total 
volume of 20µl; finally a reverse transcriptase program was performed (5 min at 25°C, 
60 min at 50°C, 15 min at 70°C, 4°C).
Quantitative PCR amplifications were performed on an ABI Prism 7900HT Sequence 
Detection System (Applera Nederland, Nieuwekerk a/d IJssel, The Netherlands). Primers 
and probes for von Willebrand factor, E and P-Selectin, eNOS, CD31 (endothelial 
marker) and GAPDH (house keeping gene) were developed commercially (Custom 
TaqMan Assays, Applied Biosystems-Applera Nederland BV, Nieuwekerk a/d IJssel, The 
Netherlands). The mRNA coordinates for the exon-exon boundaries were determined by 
aligning the human genomic sequences with pig mRNA sequences (Spidey alignment 
program, http://www.ncbi.nlm.nih.gov). As a precaution to prevent amplification 
of genomic DNA, primer/probe sequences were chosen such that they span exon 
junctions or lie in distant exons separated by long introns. The PCR step contained 1 
µl of the appropriate RT reaction, 10 µl of TaqMan universal PCR master mix (Applied 
Biosystems), 200 nM primers, and 100 nM TaqMan probe in a final volume of 20 µl. 
The PCR cycling conditions were 2 min at 50°C, 10 min at 95°C, and 40 two-step 
cycles of 15 s at 95°C and 60 s at 60°C. All samples were assayed in triplicate. 
Relative quantification of the mRNA levels was done by subtracting the GAPDH  CT 
(threshold cycle) from the investigated gene CT value (ΔCT = C T gene
 – C T GAPDH). Results 
were normalized with the average value of the respective gene in control sham-operated 
animals, arbitrarily set at 1. Results were finally expressed as 2–ΔCTgene / 2–ΔCT CD31 which 
represents an index of the relative amount of mRNA expressed in each tissue, corrected 
for the amount of endothelial cells presented in each biopsy. Plasma concentrations 
of endothelial vWF were investigated by means of ELISA (von Willebrand Factor kit, 
Nodia BV, Amsterdam, The Netherlands).
Statistical Analysis 
Variations over the study period were investigated using repeated measures ANOVA. 
To investigate differences between groups, continuous variables where compared 
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by means of parametric (Student’s T-Test) or nonparametric tests (Mann-Whitney). 
Correlation between nonparametric variables was performed with Spearman’s 
correlation test. Results are presented as mean ± SEM (unless stated otherwise). For 
all analyses, a p-value ≤0.05 was considered to indicate statistical significance.
Results
Immediately post-infusion the hematocrit (Hct, Fig.1) reached 39.9 ± 1.9% of baseline 
values in HES 130/0.4 hemodiluted animals and 41.3 ± 2.2% of baseline values 
in HES 200/0.5 hemodiluted animals. Hct partially recovered by the end of the 3 
experimental hours to 65.5 ± 5.9% and 57.9 ± 4.3% of baseline values, respectively. 
The extraordinary compensating capacity of the circulating number of erythrocytes was 
probably achieved by mobilization of spleen-trapped erythrocytes. This observation 
was supported by a smaller size and pale color of spleens in hemodiluted animals, 
as compared with those of the sham-operated animals. To exclude the possibility 
of hemoconcentration due to loss of infused fluid through urine or extra vascular 



























Figure 1.  Hematocrit (%) variation during 3 h of acute isovolemic hemodilution, infused with either 
3% HES 130/0.4 solution (n=6) or 3% HES 200/0.5 solution (n=6). The control group (n=3) 
is represented by sham-operated animals. The values are represented as mean (symbols) 
and standard error of the mean (bars). * p<0.05 vs. control.
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viscosity levels (1.7 ± 0.05 mPa·sec) dropped in the hemodiluted animals immediately 
after infusion (1.3 ± 0.06 mPa·sec HES 130/0.4; 1.4 ± 0.07 mPa·sec HES 200/0.5) 
and remained low until the end the experiment (1.3 ± 0.1 mPa·sec and 1.4 ± 0.06 
mPa·sec, respectively), proving a comparable level of plasma dilution during the entire 
experiment.
Hemodynamics 
Mean arterial pressure (MAP) and heart rate (HR) were monitored throughout the 
experiment (Table 1). MAP decreased gradually and significantly (p<0.001) in all 
animals during the experiment. Immediately post-infusion, MAP was significantly 
lower in the HES 130/0.4 group (p=0.024) than the control group; after 3 h of 
hemodilution no significant differences between groups were seen anymore. Heart 
rate increased gradually, with a stronger rise in hemodiluted animals (p=0.009). At 
the end of the experiment, the HES 130/0.4 group had significantly higher heart 
rates than the control group (p=0.024). 
RBC aggregation
RBC aggregation (Fig. 2) decreased significantly after induction of hemodilution 
(p=0.002), with an overall lower aggregation index (AI) in the experimental animals 
as compared with sham-operated animals (p=0.001). In the HES 130/0.4 group, AI 
dropped to 39.2 ± 4.8% of baseline values and maintained low during the experiment 
with values of 37.05 ± 3.3% of baseline values at the end of experiment. In HES 
200/0.5, AI declined post-infusion to 49.3 ± 5.9% of baseline values and maintained 
low with 47.7 ± 6.5% of baseline values at the end of experiment. Although the AI 
tended to be higher in the HES 200/0.5 group than in the HES 130/0.4 group, these 
differences were not statistically significant at any time point.  
Table 1. Hemodynamic parameters
Baseline Post-infusion 3 hours IHD
MAP (mmHg)
          Control
          HES 130/0.4
          HES 200/0.5
   71.8 ± 13.1
   71.0 ± 16.6
  67.3 ±  9.0
 64.3 ± 6.3
  46.1 ± 4.8b
   52.6 ± 17.4
    53.3 ± 2.7a
    48.3 ± 5.5a
   49.5 ± 5.5a
HR (beats/min)
          Control
          HES 130/0.4
          HES 200/0.5
100 ± 4
   90 ± 10
 91 ± 9
  99 ± 1
  108 ± 13
  106 ± 10
106 ± 9
    138 ± 11a,b




          Control
          HES 130/0.4
          HES 200/0.5
 70.1 ± 2.8
 63.9 ± 6.5
 62.4 ± 7.1
 70.7 ± 3.1
 70.1 ± 6.8




ap<0.05 compared to baseline; bp<0.05 compared to control.
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Hypoxic oxidative stress
Arterial pO2 increased moderately but not significantly after hemodilution (Table 1), 
reflecting either an improvement in pulmonary gas exchange or decreased diffusional 
oxygen exit. 
Plasma malondialdehyde (MDA, Fig. 3A) dropped significantly directly after 
infusion, due to the dilution effect. For sham operated animals (control group) the 
MDA values were 2.3 ± 0.05 µmol pre-anesthesia (baseline), and 2.7 ± 0.3 µmol 
after 3h anesthesia. 
For HES 130/0.4 group the MDA values were 2.8 ± 0.08 µmol at baseline, 
1.42 ± 0.09 µmol immediately after hemodilution, and 1.83 ± 0.1 µmol after 3h of 
hemodilution.
For the HES 200/0.5 group, MDA values were 2.8 ± 0.2 µmol at baseline, 
1.19 ± 0.09 µmol immediately after hemodilution, and 1.58 ± 0.1 µmol after 3 h 
of hemodilution. 
Relative increase in plasma MDA during the three experimental hours was 
comparable in sham-operated animals (0.34 ± 0.09 µmol), HES 130/0.4 infused 



























Figure 2.  Red blood cell aggregation measured in fresh blood ex-vivo, as Aggregation Index in adult 
pigs during 3 h of acute isovolemic hemodilution (IHD), infused with either 3% HES 130/0.4 
solution (n=6) or 3% HES 200/0.5 solution (n=6). The group (n=3) is represented by sham-
operated animals. The boundary of the box closest to zero indicates the 25th percentile, 
the line within the box marks the median of 6 measurements, and the boundary of the box 
farthest from zero indicates the 75th percentile. Whiskers above and below the box indicate 
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Figure 3.   Hypoxic oxidative stress during 3 h of acute isovolemic hemodilution. 
(A) Plasma malondialdehyde (MDA): The values are represented as mean (symbols) and 




) production in 
heart, lung, kidney, liver and ileum tissue biopsies reflecting mitochondrial dysfunction in 
tissues pre-exposed to ischemia in vivo. Box plots graph data represent statistical values 




- producing cells (brown 
coloration) in paraformaldehyde-fixed frozen sections of ileum mucosa of hemodiluted and 
(D) sham-operated animals. * p<0.05 vs. control.
       DC    
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All animals showed a statistically significantly higher H2O2 production in the 
abdominal organs (ileum, kidney and liver) than in heart and lung tissue (Fig. 3B). 
Oxygen radicals production was similar in all animals, with no statistically significant 
difference at any time point between hemodiluted and sham-operated animals. 
DAB staining of H2O2 producing cells in the ileum was performed, as the ileum 
seemed to be one of the organs exposed to oxidative stress. Figure 3 shows a similar 
villi morphology, comparable staining intensity and distribution of H2O2 producing 






























































Figure 4. von Willebrand factor (vWF) (A) vWF relative gene expression of in the heart, lung, 
kidney, liver and ileum tissue biopsies at the end of the experiment. Box plots graph data 
represent statistical values (see legend Fig. 2). (B) vWF plasma concentrations. The values 





Von Willebrand Factor (vWF) mRNA after 3 h of hemodilution (Fig. 4A) was 
significantly up-regulated in HES 130/0.4 hemodiluted animals when compared with 
sham-operated animals in all organs studied (ileum, kidney, lung and heart p=0.024, 
liver p=0.048). A similar outcome was found in HES 200/0.5, with the exception of 
lung, where differences did not reach statistical significance (ileum, kidney, and heart 
p=0.024, liver p=0.048 and lung p=0.095). vWF mRNA responses did not differ 
between HES 130/0.4 and HES 200/0.5 treated animals. 
Plasma vWF systemic release (Fig. 4B) reflects the information found at mRNA 







































































ileum               kidney               liver                 lung                 heart
Figure 5.   E-Selectin (A) and P-Selectin (B) relative gene expression of in the heart, lung, kidney, liver 
and ileum tissue biopsies at the end of the experiment. Box plots graph data represent 
statistical values (see legend Fig 2). * p< 0.05 vs. control.
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hours in HES 130/0.4 group (30.32 ± 4.6%) and in HES 200/0.5 group (27.9 
± 1.3%) were significantly higher than the control values (0.1 ± 0.01%) in sham 
operated animals (p=0.024 for both comparisons). 
E-Selectin mRNA after 3 h of hemodilution (Fig. 5A) was significantly up-regulated 
in the ileum and lung of HES 130/0.4 hemodiluted animals, as compared with 
the sham-operated ones (p=0.048, and p=0.024 respectively). HES 200/0.5 
hemodilution resulted in significantly up-regulated E-Selectin mRNA in the ileum 
(p=0.024) when compared with control levels. 
P-Selectin mRNA after 3 h of hemodilution (Fig. 5B) was significantly up-regulated 
in ileum and lung of both groups of hemodiluted animals (HES 130/0.4: ileum, 
lung p=0.024, HES 200/0.5: ileum p=0.024, lung p=0.048). Additionally for 
HES 200/0.5, levels measured in the kidney reached statistical significance when 
compared with control animals (p=0.048). 
Endothelial nitric oxide synthase (eNOS) mRNA after 3 h of hemodilution 
(Fig. 6) was significantly up-regulated in ileum and lung in the of HES 130/0.4 group 
(p=0.024 for both organs). In the HES 20/0.5 group, eNOS was only significantly 
up-regulated in the lung (p=0.024).
Correlations 
A statistically significant negative correlation was found between the RBC aggregation 
index post-infusion and different markers of endothelial activation measured after 3 h 
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Figure 6.   Endothelial nitric oxide synthase (eNOS) relative gene expression in the heart, lung, kidney, 
liver and ileum tissue biopsies at the end of the experiment. Box plots graph data represent 




Acute isovolemic hemodilution caused a dramatic drop in erythrocyte aggregation. 
This drop in RBC aggregation was followed by an immediate pro-thrombotic and 
pro-inflammatory endothelial activation in all vital organs. Erythrocyte aggregability 
correlated significantly with markers of endothelial activation suggesting a causality 
effect. RBC hyper-aggregation is nowadays a generally recognized pathogenic 
factor in  disorders associated with macro and/or microvascular impairment, e.g. 
hypertension, diabetes mellitus, and chronic venous insufficiency (18-20). Hypo-
aggregation of RBCs has never been described in a pathologic context. Given the 
impact of RBC aggregation on blood rheology, and thus on shear stress-dependent 
endothelial activation, low RBC aggregation might be an important pathogenic co-
factor in endothelial activation during acute isovolemic hemodilution. 
Hemodilution is expected to decrease the oxygen-carrying capacity of blood 
and oxygen delivery to the tissue. However, during moderate levels of hemodilution, 
reduction of the systemic hematocrit up to 50% is compensated with an increased 
blood flow and decreased diffusional oxygen exit from arterioles, resulting in 
augmented or maintained oxygen delivery to tissue (21). In an experimental animal 
study, Deem and colleagues showed that acute isovolemic hemodilution in healthy 
rabbits resulted in improved gas-exchange efficiency, as shown by higher arterial 
pO2, lower alveolar-arterial pO2 difference, and increased expired NO (22). They 
postulated that the improvement in oxygenation appeared to be related to increased 
uniformity of pulmonary blood flow, and/or an increase in concentration of the 
vaso- and bronchodilator substance NO. The present data support this assumption 
and consistently show an up-regulation of eNOS in the lung tissue during acute 
hemodilution. 
In the present study changes in tissue oxygenation were quantified by assessing 
mitochondrial (dys)function in vital organs (heart, lung, kidney, liver and ileum) of 
hemodiluted animals. The production of superoxide and hydroxyl radicals, measured 
as H2O2 generation, was similar at all time points in sham-operated and hemodiluted 
Table 2. RBC aggregation and endothelial activation
Spearman’s correlation Aggregation index
post-infusion
P Selectin- ileum Correlation Coefficient -0.614 (p=0.015)
vWF- ileum Correlation Coefficient -0.539 (p=0.038)
eNOS- ileum Correlation Coefficient -0.486 (p=0.066)
vWF- liver Correlation Coefficient -0.546 (p=0.035)
P Selectin- lung Correlation Coefficient -0.582 (p=0.023)
P Selectin- heart Correlation Coefficient -0.496 (p=0.060)
vWF- heart Correlation Coefficient -0.632 (p=0.011)
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animals. This finding indicates that a similar hypoxic oxidative stress was present, 
and that oxygen delivery to the tissue was maintained during hemodilution. However, 
different organs seemed to have different exposure to hypoxia, with a more profound 
mitochondrial dysfunction in abdominal organs (ileum, kidney and liver) versus a 
preserved function of mitochondria in the myocardium and lung tissue. The results 
found in tissue biopsies were mirrored by the plasma MDA measurements, that 
showed similar relative increase in systemic lipid peroxidation products during three 
experimental hours when hemodiluted animals and sham-operated animals were 
compared. Given the negligible amount of hypoxic stress and the strong statistical 
correlation between red blood cell aggregation and markers of endothelial activation, 
low erythrocyte aggregation might be the trigger for endothelial activation.
In this experiment, acute isovolemic hemodilution resulted in immediate pro-
thrombotic endothelial activation as shown by a systemic increase in plasma vWF 
levels. Analysis of vWF mRNA expression levels in different vital organs showed an 
up-regulation in heart, lung, kidney, liver and small intestine. In addition, low red 
blood cell aggregation was significantly associated with high vWF mRNA expression 
in heart, liver and ileum suggesting a causality effect. 
RBC hypo-aggregation was associated with an up-regulation of endothelial 
adhesion molecules, E- and P-Selectins, especially in lung and small intestine. Selectins 
play important roles in the inflammatory responses by facilitating leukocyte rolling and 
leukocytes activation (23;24). 
Although diluted blood was able to provide sufficient oxygenation and metabolic 
support, the data presented in this study show that acute isovolemic hemodilution triggers 
endothelial activation. An inflammation and coagulation prone endothelium will most 
certainly result in extra damage upon reperfusion of the graft. All this qualifies diluted 
donor blood as a suboptimal preservation solution. Optimization of normothermic 
preservation solutions is therefore necessary to be able to fully utilize the NMP potential. 
One strategy to improve the use of diluted donor blood in normothermic preservation 
might be to filter out certain cell types. Harper and colleagues showed that depleting 
leukocytes during whole blood normothermic kidney preservation resulted in improved 
kidney graft function after transplantation (25). Another approach might be to develop 
a novel, synthetic normothermic preservation solution. Such a solution might contain 
artificial oxygen carriers like perfluorocarbon chemicals for adequate oxygen delivery 
and several saccharides, aminoacids and vitamins for nutritional support. Additional 
colloids will prevent edema formation. The group of Kootstra has performed some 
promising experiments with an acellular synthetic normothermic preservation solution. 
By using their protocol called Exsanguinous Metabolic Support (EMS) they could 
successfully transplant canine kidneys that had suffered from 120 minutes of warm 
ischemia (26). Similar to the situation in the late sixties when cryoprecipitated donor 
plasma was replaced by the first static cold storage solution of G.M. Collins, history 
may repeat itself and a synthetic alternative for diluted donor blood will become 
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Clinical kidney and liver transplantation has evolved from an experimental procedure 
in the early 1950s to a routine clinical practice for treatment of end stage organ 
disease. With an increasing number of patients on the waiting list, future advances in 
this field are constrained by both the numbers of donor organs available as well as 
their quality. Improved road safety, the use of airbags and improvements in intensive 
care medicine have led to a plateau in the number of organ donors. In order to make 
ends meet, organ donation criteria have been expanded. As a result, the average 
deceased donor is nowadays older, has suffered from a cerebrovascular accident 
(CVA) rather than isolated head trauma, and therefore has more associated morbidity, 
which negatively influences graft quality. In order to close the widening gap between 
supply and demand the usage of organs derived from donation after cardiac death 
(DCD) is increasing in most countries. The combined effect of these negative changes 
in organ donor demographics has led to a decrease in organ viability and an increase 
in delayed graft function (DGF) after transplantation. A slow initiation of graft function 
after transplantation has a negative impact on a kidney recipient but is often fatal to 
a liver transplant recipient. While patients receiving a DGF kidney can be supported 
with dialysis, delayed function of a liver graft can only be treated with urgent re-
transplantation since no adequate long-term artificial liver support is available yet. 
Limiting the incidence of DGF will have a major impact on transplantation medicine. 
Improving organ preservation, which is the topic of this thesis, might be a way 
to achieve this goal. Organ preservation allows bridging from donor to recipient 
and is therefore pivotal to transplantation logistics. Present day hypothermic organ 
preservation, however, is both friend and foe to organ viability. Hypothermia, which is 
currently the main stay of clinical organ preservation, protects the graft from ischemia/
reperfusion injury by slowing down the metabolic demand. Unwanted harmful side-
effects of hypothermia, however, include cell swelling, acidosis and the formation of 
reactive oxygen species which all injure the graft. Damage inflicted by the cold has 
to be counteracted by using tailor made preservation solutions. At this moment clinical 
organ preservation is most frequently performed with the static cold storage (CS) 
method using the University of Wisconsin cold storage solution (UW-CSS), which was 
developed in the late 1980s. Although static cold storage using UW-CSS allowed 
expansion of organ transplantation programs all over the world, it might well be that 
both CS and UW-CSS have reached their limits given the present composition of the 
donor pool. Improving organ preservation by using better preservation solutions or an 
improved preservation method will therefore help to reach the goal of reducing the 
incidence of DGF and thereby improving outcome after transplantation. 
Chapter I
In the introduction of this thesis (Chapter I) the importance of maintaining organ 
viability after donation until transplantation is illustrated. To date, static cold storage 
using UW-CSS is the most widely used form of organ preservation. Although simple 
and effective, it is questionable whether this method is able to prevent deterioration 
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of organ quality in the present era with increasing numbers of organs retrieved from 
older, marginal and DCD donors. Basic principles involved in effective preservation 
and effective components and methods of organ preservation in abdominal organ 
transplantation are reviewed. A new preservation solution is Institut Georges Lopez-1 
(IGL-1), which was developed at the Edouard Herriot Hospital in Lyon, France, in the 
late 1990s. The design of IGL-1 is based on UW-CSS with two important changes. 
First, in UW-CSS hydroxyethyl-starch (HES) is used as a colloid. Several groups, 
including our own, have shown that HES causes red blood cell aggregation during 
wash-out of the organ. This aggregational behaviour of HES negatively influences 
wash-out efficacy of UW-CSS. IGL-1 uses polyethylene glycol (PEG) as a colloidal 
substance, which does not induce red blood cell aggregation. The second important 
difference in the IGL-1 solution is the so called extracellular sodium/potassium ratio. 
Compared to UW-CSS, which has an intracellular sodium potassium/ratio, IGL-
1 has a low potassium content. The high potassium content in UW-CSS is known 
to provoke an arterial vasospasm. IGL-1 might be able to reduce this effect. Apart 
from different solutions this chapter also focuses on a different preservation method: 
hypothermic machine perfusion (HMP). Although not a new approach -clinical organ 
preservation in the early 1960s started with HMP- this method might be able to 
improve preservation of the present day damaged donor organs. Despite the fact that 
HMP might be superior to static cold storage, organs are still exposed to hypothermia 
induced damage. Therefore, recent experimental studies point towards the benefits of 
normothermic machine perfusion (NMP) as a new perspective in organ preservation 
and transplantation.
Chapter II
In this chapter the rationale of the studies which are included in this thesis 
is presented. The first part of this thesis concerns static cold storage preservation 
experiments using IGL-1 in rat models of kidney preservation and transplantation, 
focussing on vasomotor function (Chapter III) and organ viability (Chapter IV), and 
comparing this to UW-CSS. The second part focuses on the development and 
functional evaluation of the Groningen Machine Perfusion (GMP) system (Chapter V) 
and its subsequent application in a porcine kidney transplantation model (Chapter 
VI). In November 2005 a randomized clinical trial was initiated within Eurotransplant 
to determine the efficacy of the HMP concept in clinical kidney preservation and 
transplantation. The first results of this clinical trial are presented in Chapter VII. In 
preparation of using the GMP system in a normothermic mode, the use of diluted 
donor blood as preservation solution is studied in a porcine model (Chapter VII) with 
an emphasis on endothelial damage.
Chapter III
Although ischemia/reperfusion injury to kidney parenchyma has been extensively 
studied, little is known about the functional effects of warm and cold ischemia on the 
renal vascular bed. In this chapter, rat kidney preservation using IGL-1 was compared 
to UW-CSS with a special focus on vasomotor functions. The influence of warm 
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Chapter IX
and cold ischemia on vasomotor functions was studied under controlled conditions 
in an isolated perfused kidney (IPK) model. Six groups of rat DCD donor kidneys 
were studied with increasing duration of warm ischemia of 0, 15 or 30 minutes 
followed by 0 or 24 h CS preservation in IGL-1 or UW-CSS at 4°C. Endothelial 
dependent vasodilation was studied using acetylcholine (ACH), smooth muscle cell 
constriction was assessed using phenylephrine (PE) and finally endothelial independent 
relaxation was tested using papaverine-sulphate. The experiments demonstrated that 
smooth muscle cells were significantly affected by cold ischemia showing a 50% 
reduction of PE mediated constriction after preservation. This rapid decline in smooth 
muscle cell function might be the first step towards intima hyperplasia as seen in 
late transplant dysfunction. Additional warm ischemia did not influence SMCs. After 
IGL-1 preservation, endothelial dependent vasodilation was negatively affected by 
both warm and cold ischemia. In the UW-CSS groups only the combination of warm 
and cold ischemia significantly reduced the ACH response. Both IGL-1 and UW-
CSS rendered equal results after 24 h preservation. These results demonstrated that 
vasomotor functions are negatively influenced by the combination of warm and cold 
ischemia, as is clinically seen in DCD organs. 
Chapter IV
In this chapter the effect of IGL-1 preservation on organ viability after preservation 
and transplantation in rats was studied and compared to the results obtained with 
UW-CSS. The influence of warm and cold ischemia on renal damage and graft 
function was evaluated in a rat Lewis-Lewis transplant model with a follow up of 14 
days. Eight groups of donor kidneys were studied with warm ischemia of 0 and 
15 minutes followed by 0 or 24 h cold storage preservation in IGL-1 or UW-CSS 
at 4°C. Blood was collected daily during the first week and at day 14. Recipients 
were placed in metabolic cages at day 4 and 14 after transplantation allowing 
urine collection and adequate measurement of glomerular filtration rate. Focussing 
on inflammation, reactive oxygen species production, proximal tubule damage, 
proteinuria, histology, and renal function after transplantation we could not show any 
relevant difference between IGL-1 and UW-CSS. Furthermore, the combination of 15 
min warm ischemia and 24 h cold ischemia did not result in life sustaining kidney 
function after transplantation, irrespective of the used solution. These results confirm 
the findings in Chapter III and demonstrated that static cold storage preservation of 
ischemically damaged rat kidneys in either IGL-1 or UW-CSS render equal results after 
preservation and transplantation. 
Chapter V
Since CS might have reached its limits in liver preservation, a new portable 
HMP system was developed in a close collaboration between our laboratory and the 
department of Biomedical Engineering at the University Medical Center Groningen. 
In this chapter, a prototype of the Groningen Machine Perfusion (GMP) system was 
evaluated with a focus on functionality and tissue morphology after 24 h preservation. 
Evaluation criteria included adequate pressure controlled perfusion, sufficient 
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oxygenation, a temperature of 0-4°C and sterile conditions. In a porcine heart 
beating donor model livers were preserved with the GMP system using University of 
Wisconsin machine perfusion solution (UW-MPS) or with CS using UW-CSS during 
24 h. During HMP, livers were perfused with pump pressures set at 4 mmHg for the 
portal vein and 30/20 mmHg, at 60 BPM, for the hepatic artery. In the HMP group, 
pressure, flow and temperature were continuously monitored for 24 h. At time-points 
0, 2, 4, 8, 12 and 24 h samples of UW-MPS solution were taken for measurement of 
partial oxygen pressure (pO2) and lactate-dehydrogenase (LDH). Liver biopsies were 
taken for histology and electron microscopy; samples of ice, preservation solution, 
liver surface and bile were taken and cultured to determine sterility. During 24 h 
preservation using the GMP system temperature was maintained at 0-4°C. Arterial 
pO2 was kept at 100 kPa throughout the experiment while venous pO2 reached 
appropriate levels (>20 kPa) within 2 h. Histological evaluation showed a complete 
perfusion of the liver with no differences in tissue morphology when compared to CS 
livers. These results showed that the GMP system complied with the design criteria. 
The proof of principle will have to be demonstrated in a transplantation experiment.
Chapter VI
The merits of a new preservation method like the GMP system can only be 
properly assessed in a transplantation model that includes reperfusion of the graft. 
The porcine liver transplantation model is, however, a very demanding, complex 
and expensive experimental model. Therefore in this chapter the principle of HMP 
preservation using the GMP system is assessed in a porcine kidney transplantation 
model.  A re-design of the liver GMP system was developed for kidney preservation 
and the aim of the present study was to examine the efficacy of this system compared 
to CS using UW-CSS. In a porcine autotransplantation model kidneys were retrieved 
and either cold stored in UW-CSS for 20 h at 4°C or subjected to HMP using UW-
MPS at 4°C with two different pressure settings: 30/20 mmHg or 60/40mmHg. 
HMP at 30/20 mmHg was found to better preserve the viability of kidneys reflected by 
improved  cortical microcirculation,  less damage to the proximal tubule, less damage 
mediated by reactive oxygen species, less pro-inflammatory cytokine expression and 
better functional recovery after transplantation. However, high perfusion pressures 
(60/40 mmHg) resulted in higher expression of von Willebrand factor and monocyte 
chemotactic peptide-1 in post preservation biopsies and subsequent graft thrombosis 
in 2 kidneys. It is concluded that the GMP system improves kidney graft viability, 
however, perfusion pressures are critically important for outcome. In this experiment a 
perfusion pressure of 30/20 mmHg during HMP rendered the best results.
Chapter VII
Retrospective analyses have indicated that preservation by hypothermic machine 
perfusion (HMP) may lead to improved outcome after renal transplantation. However, 
there is a lack of sufficiently powered prospective studies to test the presumed superiority 
of HMP. In this chapter the results of an international prospective randomized controlled 
trial are reported. This trial is registered as an International Standard Randomized 
164
Chapter IX
Controlled Trial, number ISRCTN83876362. Kidney pairs of 336 consecutive 
deceased donors were enrolled. One organ was randomly assigned to HMP and the 
contralateral kidney to CS preservation. All 672 recipients were followed up for one 
year. The primary endpoint was delayed graft function (DGF). Secondary endpoints 
were functional DGF, duration of DGF, primary non-function, serum creatinine and 
creatinine clearance, acute rejection, calcineurin inhibitor toxicity, length of hospital 
stay, and graft and patient survival post-transplant. 
No serious adverse events directly attributable to HMP were encountered. HMP 
significantly reduced the risk of DGF (HMP-arm 70/336, CS-arm 89/336; adjusted 
OR 0.57; p=0.01), and of functional DGF. In the event that DGF occurred, its duration 
was shorter after HMP. Serum creatinine values were lower for HMP kidney recipients 
in the first two weeks post-transplant. HMP reduced the risk of graft failure in the first 
year after transplantation (HR 0.37; p=0.02). One year graft survival was superior 
in the HMP group (98% versus 94%; p=0.03). No significant differences were found 
for the other secondary endpoints. It was concluded that in all common types of 
deceased donor kidney transplantation, HMP reduced the risk of DGF. In addition, 
HMP improved graft survival in the first year after transplantation.
Chapter VIII
While machine perfusion was shown to improve clinical kidney preservation, it is 
still based on hypothermia with its well known deleterious side effects. A new concept in 
organ preservation which does not induce hypothermia related injury is normothermic 
machine perfusion (NMP). NMP provides oxygen delivery at physiologic or near-
physiologic temperature (37°C) and allows near-normal metabolism. Since traditional 
hypothermic preservation solutions cannot provide physiologic metabolic demands, 
diluted donor blood is often used as a preservation solution in experimental and clinical 
normothermic machine perfusion (NMP). In this chapter the effects of diluted blood 
were studied in a porcine isovolemic hemodilution (IHD) model. Acute IHD (30ml/
kg exchange-transfusion with colloid-solutions) was induced in 15 pigs. Hypoxic 
oxidative stress (plasma malondialdehyde, ex-vivo oxygen radicals production in heart, 
lung, kidney, liver and ileum tissue biopsies), erythrocyte aggregation (LORCA), and 
endothelial activation (Real-Time quantitative RT-PCR on von Willebrand Factor (vWF), 
E- and P-Selectins, endothelial nitric oxide synthase gene-expression in tissue biopsies) 
were investigated. The production of superoxide and hydroxyl radicals, measured as 
H2O2 generation, was similar at all times in sham-operated and hemodiluted animals, 
proving a maintained oxygen delivery. Acute IHD was followed by a dramatic drop 
in erythrocyte aggregation and immediate pro-thrombotic (significant vWF mRNA 
up-regulation in heart, lung, kidney, liver and ileum) and pro-inflammatory (significant 
E-and P-Selectins mRNA up-regulation in lung and ileum) endothelial activation. Low 
erythrocyte aggregation was significantly correlated with increased mRNA-expression 
of vWF (heart, liver, ileum) and P-Selectin (lung, ileum and heart). The results suggest 
that low erythrocyte aggregation during hemodilution triggers endothelium-dependent 
thrombogenic and pro-inflammatory responses. Given the potential impact of 
inflammation and coagulation upon reperfusion of a normothermic preserved graft 
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the use of diluted donor blood as a normothermic preservation solution should be 
considered suboptimal.
Future perspective
Multidisciplinary research at the interface of organ preservation and biomedical 
engineering is both exciting and rewarding to the scientist. Equally important to 
the scientific significance is the fact that this type of applied science is directed at 
improving the quality of donor organs and thus the quality of life of transplant patients. 
The interaction of biology, technology and medicine creates a broad and challenging 
research area where bridges between the individual disciplines have to be built every 
day. Given the fact that the strength of a bridge is inversely correlated to its length 
we can consider ourselves fortunate in Groningen. The small distance and close 
collaboration between the departments of BioMedical Engineering, the Surgical 
Research Laboratory and clinical units have created a strong and stable research 
environment with a promising future.
Improving static cold storage preservation
This thesis describes studies which aim to enhance organ preservation in order 
to improve outcome after kidney and liver transplantation. A key factor in organ 
preservation is the mismatch between metabolic demand and supply which occurs 
when an organ is disconnected from systemic circulation. Current organ preservation 
strategies aim at limiting the metabolic demand of the organ by cooling to 0-4°C. 
This causes a decrease in metabolism of approximately 90%. The collateral damage 
of hypothermia, however, is limiting further improvement of hypothermia-based organ 
preservation techniques. Novel strategies should focus on a reduction of metabolic 
demand or improved metabolic support or combine both approaches.
Instead of lowering metabolism by hypothermia, new pathways will have to be 
elucidated which will lead to a reversible induction of ‘hypo-metabolism’. Much can 
be learned from nature at this point. Novel insights to improve organ preservation 
may arise from studies concerning hibernating animals that experience low body 
temperature and metabolic depression for longer periods of time. Hibernation is a 
condition involving dramatic changes in the function of organ systems and individual 
tissues. An important aspect of this process is a significant reduction in both energy 
production and energy consumption. During hibernation the body temperature 
decreases close to ambient temperature (0-10°C), body functions are reduced to a 
minimum, metabolism is depressed and animals enter a lethargic state lasting several 
days or weeks. In this state, organisms are resistant to environmental stresses including 
temperature extremes and oxygen deprivation. Interestingly, damage to livers of non-
hibernating (summer) ground squirrels after 72 h of cold storage is much greater than 
for hibernating ground squirrels. Thus, within the same species, there is a switch from 
a less tolerant (summer) phenotype to a super tolerant (hibernating) phenotype. This 
suggests that systemic and cellular pathways that increase organ tolerance to cold 
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ischemia/reperfusion are repeatedly induced within the same individual on an annual 
basis. Elucidation of the increased tolerance to cold storage displayed by torpid 
hibernators could have a profound effect on organ preservation. A novel compound 
that is able to induce a hibernation-like state in non-hibernating species (Szabó C, 
Nature Reviews 2007) is hydrogen sulphide (H2S). This colourless and water soluble 
gas with a characteristic smell of rotten eggs has primarily gained attention as being 
a toxic gas emanating from swamps. H2S is, however, also produced in mammals 
including humans and belongs to a family of biological mediators which are called 
gasotransmitters. Well known other gasotransmitters are carbon monoxide (CO) and 
nitric oxide (NO). H2S has a wide variety of biological effects resulting in cytotoxic 
effects or cytoprotective actions depending on dose and target. Its action as an inhibitor 
of cytochrome c oxidase, a critical step in ATP synthesis, is probably responsible for the 
H2S induced hibernation-like state. When mice were exposed to low concentrations 
of H2S gas, a dose-dependent reduction in the core body temperature and metabolic 
rate of the animals were observed. Their breathing rate slowed from 120 breaths per 
minute to fewer than 10. Body temperature reached as low was 15°C. When H2S 
exposure ended, animals fully recovered without notable permanent damage. Given 
these effects of H2S, the application of this gas during (machine) preservation needs 
to be tested. In the GMP system H2S can be given through the oxygenator or by 
coating the tubing or organ chamber with an H2S-donor. When applying H2S in static 
applications, coating of the organ bag might be an attractive way to deliver this gas 
during organ preservation. It is likely that, similar to the situation in squirrels, organs 
in a hibernation-like state will be more tolerant to ischemia/reperfusion injury. Many 
questions regarding the small therapeutic window of H2S and the late effects of H2S 
exposure have to be answered before clinical organ preservation can benefit from 
metabolic management by H2S. Also, by that time, some anti-odour will be available 
to protect the transplant team from the smell of rotten eggs. 
Future developments concerning the Groningen Machine Perfusion system
In this thesis the GMP prototypes for liver and kidney preservation were designed 
and tested in a liver preservation and a kidney autotransplantation model. While in 
kidney preservation the GMP system proved superior over CS, this data is lacking 
for liver transplantation. In Chapter VI, where we tested the GMP system for kidney 
preservation and autotransplantation, pristine kidneys were used that had neither 
suffered from warm ischemia nor from allo-immune responses after transplantation. 
Future experiments should include DCD kidney and liver transplantation in an allo-
transplantation model. Furthermore, a direct comparison between the GMP system 
and other commercially available kidney HMP devices should be made. This will 
allow assessment of the contribution of perfusate oxygenation and centrifugal pulsatile 
perfusion which are unique for the GMP system. 
Many authors have stated that renal vascular resistance (RVR) changes during 
HMP might be useful for viability prediction. Although some retrospective data is 
available the data and samples from the randomized controlled clinical trial (Chapter 
VII) will allow verification of this hypothesis and identification of new viability markers. 
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Figure 1.  Prototype of the Extra Coporeal Organ Procurement System (ECOPS).
Based on the recorded RVR during HMP and clinical outcome after transplantation, 
correlations can be calculated. This will answer the question whether RVR is truly a 
predictor for outcome and which cut-off levels for RVR changes should be applied. 
Trial samples from the UW-MPS at different time points can be used for the detection 




Instead of lowering the metabolic demand future strategies could also aim at 
more metabolic support during organ preservation. If one could offer physiologic 
levels of oxygen, nutrients and removal of metabolites the insult to the organ will 
be as low as possible. Some initial results of experimental studies using the GMP 
system for normothermic preservation (NMP) of porcine livers at the University of 
Barcelona, Spain, are promising. Diluted donor blood was used as preservation 
solution in these experiments. Compared to CS, significant less parenchymal damage 
and a better synthetic function after liver transplantation were seen. Application in 
the clinical setting is currently limited because of the voluminous set-up and technical 
complexity. Future studies should address these problems in close conjunction with 
the used preservation solution. As shown in Chapter VIII of this thesis, diluted blood 
causes endothelial activation and may therefore disqualify as a preservation solution. 
Novel solutions for NMP may be synthetic and contain culture media compounds for 
metabolic support, colloids for edema prevention and oxygen carriers. 
While studies in this thesis focussed on improving preservation of the isolated 
organ, optimal organ preservation should start earlier, i.e. in the donor. Optimizing 
organ procurement techniques will help to improve organ viability after preservation. 
In current clinical practice 6-14 liters of preservation solution at 0-4°C is rinsed through 
the vasculature of the donor at a pressure of 75-100 cm H2O to wash-out blood and 
cool the organs. Application of a modified version of the GMP system for this purpose 
would allow a pressure controlled, oxygenated and continuous wash-out during donor 
surgery (Fig. 1). Instead of isolated perfusion of the kidney or liver, the entire abdominal 
compartiment of the donor can be perfused by cannulating the aorta and caval vein. 
By using this so called ‘in-situ machine perfusion’ the availability of oxygen would 
provide more metabolic support, while the continuous circulating preservation solution 
could result in improved wash-out and better cooling of all organs. The combined 
effect would be a reduction of the mismatch between metabolic demand and supply. 
When isolated organ preservation is then continued using HMP an optimal and 








Orgaantransplantatie heeft in de afgelopen decennia grote vooruitgang geboekt 
bij de behandeling van eindstadium nier- en leverfalen. Nier- en levertransplantaties 
worden tegenwoordig wereldwijd routinematig uitgevoerd en bieden goede 
overlevingskansen. Helaas dreigt de transplantatiegeneeskunde slachtoffer van haar 
eigen succes te worden, met als gevolg dat de vraag naar donororganen het aantal 
beschikbare organen ruim overstijgt waardoor de wachtlijsten gestaag groeien. Het 
donorpotentieel is door een toegenomen verkeersveiligheid en verbeteringen op de 
intensive-care afdelingen al jaren stabiel. Om de discrepantie tussen vraag en aanbod 
zo klein mogelijk te houden zijn orgaandonatiecriteria de afgelopen jaren verruimd. 
Wanneer we de huidige ‘gemiddelde’ donor vergelijken met die van een aantal jaren 
geleden valt een aantal zaken op. Ten eerste zijn donoren tegenwoordig ouder. Ten 
tweede is de doodsoorzaak tegenwoordig vaker een cerebrovasculair accident (CVA) 
dan een geïsoleerd hoofdtrauma. En ten slotte is er tegenwoordig sprake van meer 
co-morbiditeit. Hoewel het merendeel van de donororganen nog steeds afkomstig 
is van hersendode donoren, neemt het gebruik van organen die gedoneerd zijn na 
hartstilstand (donation after cardiac death; DCD) toe. Deze DCD organen zijn echter 
van mindere kwaliteit dan organen afkomstig van een hersendode donor. 
Een lagere orgaankwaliteit leidt tot een verhoogde incidentie van het vertraagd 
op gang komen van het orgaan in de ontvanger (delayed graft function; DGF). In het 
geval van niertransplantaties resulteert DGF als gevolg van de benodigde intensieve 
zorg in een tijdelijk lagere kwaliteit van leven voor de ontvanger. Tevens leidt DGF tot 
hogere kosten voor de samenleving en een kortere overleving van het transplantaat. 
Door middel van nierdialyse kan de ontvanger van een donornier tijdens DGF in 
leven worden gehouden. Leverdialyse is echter onvoldoende ontwikkeld, zodat een 
ernstige DGF bij de levertransplantatiepatiënt alleen met een acute re-transplantatie 
behandeld kan worden. 
Het beperken van de incidentie van DGF na transplantatie is dan ook cruciaal 
voor een verdere verbetering van de transplantiegeneeskunde. Verbeteren van 
orgaanpreservatie, het onderwerp van dit proefschrift, is een manier om dit te 
bereiken. Orgaanpreservatie heeft als doel de kwaliteit van het orgaan na uitname en 
tijdens transport van donor- naar ontvangerziekenhuis te behouden. De op dit moment 
gebruikte statische koude preservatietechniek (cold storage; CS) is gebaseerd op het 
afremmen van het celmetabolisme door het orgaan onder hypotherme condities (4°C) te 
bewaren. Hypothermie heeft echter ook een aantal nadelige effecten: het veroorzaakt 
cel-oedeem, acidose (verzuring) en initieert de productie van zuurstofradicalen. Om 
deze effecten zoveel mogelijk tegen te gaan zijn preservatievloeistoffen ontwikkeld 
die een aantal specifieke celbeschermende componenten bevatten. Zo werd na 
jaren van systematisch onderzoek in 1986 door Belzer en collega’s in de Verenigde 
Staten de ‘University of Wisconsin cold storage solution’ (UW-CSS) ontwikkeld. Op 
basis van een in 1989 uitgevoerde prospectief gerandomiseerde multicenter studie 
in Europa werd duidelijk dat preservatie met UW-CSS resulteerde in een betere korte 
en lange termijn functie van donornieren in vergelijking met de EuroCollins oplossing, 
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de toenmalige gouden standaard. Aansluitend werd bekend dat UW-CSS ook voor 
lever, dunnedarm en pancreas de meest geschikte preservatievloeistof was. Sindsdien 
wordt voor klinische orgaanpreservatie UW-CSS het meest gebruikt. 
Het is de vraag of CS met UW-CSS nog voldoet aan de eisen van deze tijd. 
Immers, de huidige ‘gemiddelde’ donor is ouder en heeft meer co-morbiditeit dan de 
‘gemiddelde’ donor in het tijdperk waarin UW-CSS werd ontwikkeld. De hypothese 
van dit proefschrift is dat het verbeteren van orgaanpreservatie door gebruik van 
nieuwe vloeistoffen of van nieuwe preservatietechnieken bijdraagt aan het verlagen 
van de incidentie van DGF. 
Hoofdstuk I
In dit inleidende hoofdstuk wordt het belang van orgaanpreservatie in de 
transplantatieketen benadrukt. Op dit moment worden de meeste organen met behulp 
van de statische koude preservatietechniek in UW-CSS gekoeld bewaard. Alhoewel 
deze techniek simpel en effectief is, is het zeer de vraag of deze methode in het huidige 
donortijdperk - met een slechtere orgaankwaliteit - nog afdoende werkt. Mogelijkerwijs 
zijn de huidige donoren gebaat bij een andere preservatietechniek. In dit hoofdstuk 
worden enkele concepten en criteria voor adequate abdominale orgaanpreservatie 
besproken. Eind jaren negentig werd door het Edouard Herriot Hospital in Lyon, 
Frankrijk een nieuwe preservatievloeistof ontwikkeld, de zogenaamde Institut Georges 
Lopez-1 (IGL-1) vloeistof. IGL-1 is gebaseerd op het UW-CSS concept, maar kent een 
tweetal belangrijke wijzigingen. In UW-CSS wordt hydroxyethyl zetmeel (hydroxyethyl 
starch; HES) als colloïd gebruikt. Verschillende groepen, waaronder wijzelf, hebben 
aangetoond dat het gebruik van HES aggregatie van rode bloedcellen tijdens het 
uitspoelen van het donororgaan kan veroorzaken. In IGL-1 wordt polyethyleenglycol 
(PEG) gebruikt als colloïd. PEG leidt, in tegenstelling tot HES, niet tot aggregatie 
van rode bloedcellen. Het tweede verschil tussen de beide vloeistoffen is het 
kaliumgehalte. Het hoge kaliumgehalte in UW-CSS kan leiden tot een vasospasme 
(vaatvernauwing), hetgeen een nadelig effect op preservatie kan hebben. IGL-1 heeft 
een lager kaliumgehalte dan UW-CSS waardoor er tijdens uitspoelen en preservatie 
geen spasme optreedt. 
Naast diverse vloeistoffen behandelt dit hoofdstuk ook een andere 
preservatiemethode: hypotherme machinale preservatie (HMP). HMP werd in de 
jaren zestig van de vorige eeuw als orgaanpreservatietechniek gebruikt, maar 
vervolgens in de zeventiger jaren grotendeels door CS vervangen.  Echter, door 
de huidige donororgaanproblematiek is voor HMP een hernieuwde belangstelling 
ontstaan. Om te voorkomen dat donororganen nog steeds blootgesteld worden aan 
de beschadigende effecten van hypothermie, zijn diverse onderzoeksgroepen in een 
experimentele setting bezig met het ontwikkelen van normotherme (37°C) machinale 
preservatie als een nieuwe modaliteit in orgaanpreservatie. 
Hoofdstuk II
In dit hoofdstuk worden de doelstellingen van de verschillende studies die deel 
uitmaken van dit proefschrift beschreven. Het eerste gedeelte van dit proefschrift 
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bestaat uit experimenten in het rattenmodel naar het effect van IGL-1 op de renale 
vaatfunctie (Hoofdstuk III) en nierfunctie (Hoofdstuk IV) in vergelijking tot UW-CSS. 
Het tweede gedeelte van dit proefschrift bestaat uit de ontwikkeling en functionele 
evaluatie van het Groningse Machinale Perfusie (GMP) systeem (Hoofdstuk V) en de 
toepassing hiervan in een niertransplantatiemodel bij het varken (Hoofdstuk VI). In 
november 2005 werd begonnen met een gerandomiseerde klinische studie binnen de 
Eurotransplant regio om de effectiviteit van HMP in nierpreservatie en -transplantatie te 
onderzoeken. De eindresultaten van deze studie zijn weergegeven in Hoofdstuk VII. In 
voorbereiding op normotherme preservatie met het GMP systeem wordt in Hoofdstuk 
VIII het effect van verdund donorbloed als preservatievloeistof op het endotheel in een 
varkensmodel onderzocht.
Hoofdstuk III
Alhoewel de effecten van ischemie/reperfusieschade op het nierparenchym 
uitgebreid bestudeerd zijn, is er relatief weinig bekend over de functionele effecten 
van warme en koude ischemie op het renale vaatbed. In dit hoofdstuk worden de 
functionele vasomotor-effecten van IGL-1 preservatie van de nier in een rattenmodel 
vergeleken met UW-CSS preservatie. De invloed van warme en koude ischemie 
op vasomotor-functies werd onder gecontroleerde condities in kaart gebracht met 
behulp van het geïsoleerd geperfundeerde niermodel (isolated perfused kidney; 
IPK). Zes groepen DCD donornieren met oplopende warme ischemietijden van 0, 
15 of 30 minuten, gevolgd door 0 of 24 uur CS in IGL-1 of UW-CSS bij 4°C 
werden bestudeerd. Toegediende oplopende doseringen acetylcholine resulteerden 
in endotheel afhankelijke vasodilatatie. Phenylephrine injecties gaven gladde spiercel 
constrictie te zien en tot slot werd endotheel onafhankelijke relaxatie door papaverine 
geïnitieerd. De experimenten lieten zien dat gladde spiercellen significant minder 
functioneerden na blootstelling aan 24 uur CS, onafhankelijk van de gebruikte vloeistof. 
De snelle functionele achteruitgang van gladde spiercellen na 24 uur CS zou mogelijk 
de eerste stap kunnen zijn in de ontwikkeling van intima hyperplasie zoals wordt 
gezien bij chronisch transplantaatfalen. Warme ischemie had geen nadelig effect op 
de functie van gladde spiercellen. Na preservatie in IGL-1 resulteerde geïsoleerde 
warme ischemie en de combinatie van warme en koude ischemie in een afgenomen 
respons op acetylcholine. In de UW-CSS groepen leidde alleen de combinatie van 
warme en koude ischemie tot een significante afname in acetylcholine respons. De 
resultaten laten zien dat de combinatie van warme en koude ischemie, zoals klinisch 
gezien wordt in een DCD donor, vasomotor-functies nadelig beïnvloeden. Er was 
na 24 uur preservatie geen verschil in vasomotor-functies tussen IGL-1 en UW-CSS 
gepreserveerde nieren. 
Hoofdstuk IV
In dit hoofdstuk wordt de nierfunctie na transplantatie volgend op 24 uur CS 
preservatie in IGL-1 vergeleken met de resultaten na 24 uur UW-CSS preservatie in 
een DCD rattenmodel. De effecten van warme en koude ischemie werden onderzocht 
in een Lewis-Lewis transplantatiemodel met 14 dagen overleving. Acht groepen 
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donornieren met warme ischemie perioden van 0 of 15 minuten, gevolgd door 0 of 
24 uur CS preservatie bij 4°C in IGL-1 of UW-CSS werden bestudeerd. Tijdens de 
eerste postoperatieve week werd dagelijks bloed afgenomen en daarna op dag 14 na 
transplantatie. Door de ontvangers op dag 4 en 14 na transplantatie in zogenaamde 
metabole kooien te plaatsen, kon urine gecontroleerd worden opgevangen. De 
glomerulaire filtratie kon hierdoor nauwkeurig worden gemeten. Er was geen verschil 
tussen IGL-1 en UW-CSS preservatie in ontsteking, zuurstofradicaal productie, proximale 
tubulus schade, eiwitlekkage, histologie en nierfunctie na transplantatie. Onafhankelijk 
van de gebruikte preservatievloeistof, resulteerde de combinatie van 15 minuten warme 
ischemie en 24 uur koude ischemie in zeer ernstige nierbeschadiging met de dood van 
de ontvanger tot gevolg. Net als in Hoofdstuk III werd er na preservatie en transplantatie 
van rattennieren geen verschil tussen IGL-1 en UW-CSS aangetoond.
Hoofdstuk V
In ons laboratorium werd in samenwerking met de afdeling BioMedical Engineering 
van het Universitair Medisch Centrum Groningen een nieuw draagbaar HMP systeem 
voor leverpreservatie ontwikkeld. In dit hoofdstuk wordt de evaluatie van het prototype 
van het Groningse Machinale Perfusie (GMP) systeem beschreven. De functionaliteit 
werd beoordeeld op: drukverloop, oxygenatie-graad, temperatuurverloop, steriliteit 
en histologie van de organen na 24 uur preservatie. In een varkensmodel zonder 
additionele warme ischemie, werden zes levers uitgenomen en gepreserveerd met 
behulp van het GMP systeem. Voor het GMP systeem werd de ‘University of Wisconsin 
machine perfusion solution’ (UW-MPS) gebruikt. In de controlegroep werden twee 
levers met behulp van CS in UW-CSS gedurende 24 uur gepreserveerd. Perfusie vond 
plaats met een constante druk van 4 mmHg in de vena porta en een pulserende druk 
van 30/20 mmHg en 60 slagen per minuut in de arteria hepatica. In de HMP groep 
vond continue druk-, flow- en temperatuurregistratie plaats. Na 0, 2, 4, 8, 12 en 
24 uur werden monsters van de UW-MPS genomen om de partiële zuurstofspanning 
(pO2) en lactaatdehydrogenase (LDH) concentratie te meten. Leverbiopten werden 
zowel centraal als perifeer genomen ten behoeve van histologisch onderzoek (licht- 
en elektronenmicroscopie). Afgenomen monsters van het ijs, de preservatievloeistof, 
het leveroppervlak en gal werden op kweek gezet om eventuele bacteriegroei aan 
te tonen. De resultaten lieten zien dat het GMP systeem gedurende 24 uur in staat 
was de temperatuur op 0-4°C te houden. De arteriële pO2 was vanaf het begin 
boven de 100 kPa. De veneuze zuurstofspanning was na 2 uur perfusie op niveau 
(>20 kPa). Bestudering van de histologie liet een complete perfusie van de lever zien 
zonder aantoonbare morfologische verschillen tussen HMP en controle levers. Het 
GMP systeem voldeed aan de vooraf opgestelde toetsingscriteria. Echter, het bewijs 
van superioriteit van het geoxygeneerde HMP principe zal in een transplantatie-
experiment moeten worden geleverd.
Hoofdstuk VI
Zoals hierboven reeds beschreven kan de meerwaarde van een nieuwe 
preservatiemethode zoals het GMP systeem alleen maar worden aangetoond in 
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een transplantatiemodel. Een levertransplantatie bij het varken is echter een zeer 
ingewikkelde, kostbare en complexe experimentele procedure. Daarom wordt in dit 
hoofdstuk het principe van het GMP systeem aangetoond in een niertransplantatiemodel 
bij het varken. Een herontwerp van het GMP systeem resulteerde in een prototype dat 
geschikt was voor machinale nierpreservatie. Het doel van deze studie was om het 
transplantatieresultaat na preservatie met het GMP systeem te vergelijken met CS. In 
een autotransplantatiemodel werden varkensnieren uitgenomen en verdeeld in drie 
groepen. Nieren werden gedurende 20 uur gepreserveerd bij 0-4°C. In de eerste 
groep vond preservatie plaats met CS in UW-CSS. In de tweede groep werden nieren 
gepreserveerd met het GMP systeem met een pulserende druk van 30/20 mmHg 
en 60 slagen per minuut. In de laatste groep werd een druk van 60/40 mmHg 
gebruikt. HMP met een druk van 30/20 mmHg resulteerde in een beter behoud 
van nierkwaliteit. Een betere microcirculatie van de cortex, minder schade aan de 
proximale tubulus, minder zuurstofradicaal productie, minder pro-inflammatoire gen-
expressie en een beter functioneel herstel in vergelijking met CS preservatie konden 
worden aangetoond. HMP met een perfusiedruk van 60/40 mmHg resulteerde 
echter in endotheelschade. Het gevolg was een statistisch significant hogere expressie 
van von Willebrandfactor en monocyte-chemotactic-peptide-1 in de post-preservatie 
biopten van deze groep. Niertrombose trad vervolgens op in twee van deze nieren. 
Geconcludeerd werd dat het GMP systeem varkensnieren beter preserveerde dan 
CS. Perfusiedrukken tijdens HMP zijn echter van cruciaal belang. In dit experiment 
gaf een perfusiedruk van 30/20 mmHg de beste resultaten.
Hoofdstuk VII
Alhoewel diverse retrospectieve studies suggereren dat HMP beter is dan CS, 
zijn er tot op heden geen prospectieve klinische studies die deze twee methoden 
voor nierpreservatie vergelijken. In dit hoofdstuk worden de eindresultaten van een 
gerandomiseerde multicenter studie gerapporteerd. Deze studie is geregistreerd als een 
‘International Standard Randomized Controlled Trial’, nummer ISRCTN83876362. 
Nierparen (672 nieren) van 336 opeenvolgende overleden donoren konden 
worden geïncludeerd in deze studie. Van dezelfde donor werd één van beide nieren 
gerandomiseerd voor HMP. Preservatie van de andere nier van dezelfde donor 
vond vervolgens door middel van CS plaats. De 672 ontvangers van deze nieren 
konden allemaal worden vervolgd. Het primaire eindpunt was het vertraagd op gang 
komen van de nier (DGF). Secundaire eindpunten waren functionele-DGF, duur van 
de DGF, primaire non-functie, serum creatinine en creatinine-klaring, acute rejectie, 
calcineurine remmer toxiciteit, duur van de ziekenhuisopname en transplantaat- en 
patiëntoverleving na transplantatie. HMP resulteerde in een significante reductie van 
het optreden van DGF (HMP: 70/336, CS: 89/336; OR 0.57; p=0.01). Indien 
er sprake was van DGF, duurde dit bij HMP gepreserveerde nieren korter dan bij 
CS. Serum creatinine waarden van HMP gepreserveerde nieren waren lager dan CS 
nieren in de eerste twee weken na transplantatie. Tevens verkleinde HMP het risico 
op transplantaatfalen in het eerste jaar na transplantatie (HR 0.37; p=0.02). De 
transplantaatoverleving in het eerste jaar was beter bij HMP gepreserveerde nieren 
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(98% versus 94%; p=0.03). Voor de overige secundaire eindpunten werden geen 
significante verschillen gevonden. Samenvattend kan gesteld worden dat HMP het 
risico op DGF in alle typen overleden donoren verkleind. Verder resulteert HMP in een 
betere transplantaatoverleving in het eerste jaar na transplantatie.
Hoofdstuk VIII
In het voorgaande hoofdstuk is beschreven dat hypotherme machinale preservatie 
leidt tot betere klinische nierpreservatie. De HMP methodiek is echter nog steeds 
gebaseerd op hypothermie. Dit betekent dat alle nadelige effecten van hypothermie 
nog steeds een rol spelen. Een nieuw concept in orgaanpreservatie is normotherme 
machinale preservatie (NMP). Gedurende NMP wordt de temperatuur van het orgaan 
op 37°C gehouden en wordt het metabolisme nauwelijks geremd. Tijdens NMP 
treedt vanzelfsprekend geen hypotherme schade op. Omdat de huidige (hypotherme) 
presevatievloeistoffen onvoldoende in staat zijn om het hogere metabolisme en 
zuurstofverbruik tijdens NMP te ondersteunen wordt verdund donorbloed vaak 
gebruikt als preservatievloeistof. In dit hoofdstuk worden de effecten van verdund 
bloed (haemodilutie) als preservatievloeistof beschreven. Gelet op de gevoeligheid 
van het endotheel op verschillen in rheologie, veronderstellen we dat een lage rode 
bloedcelaggregatie zal leiden tot activatie van het endotheel na isovolemische 
haemodilutie (IHD). Inductie van acute IHD (30 ml/kg wisseltransfusie met colloïdale 
vloeistoffen) vond plaats in 15 varkens. Hypoxische schade (plasma malondialdehyde, 
ex-vivo zuurstofradicaal productie in hart-, long-, nier-, lever- en ileumbiopten), rode 
bloedcel aggregatie (LORCA) en endotheel activatie (Real-Time quantitatieve RT-
PCR voor von Willebrandfactor (vWF), E- en P-selectines, eNOS gen expressie 
in weefselbiopten) werden onderzocht. De vorming van superoxide en hydroxyl-
radicalen, gemeten door H2O2-productie, was op alle tijdspunten en in alle groepen 
gelijk. Dus, ondanks de haemodilutie, was er sprake van adequate oxygenatie van 
de weefsels. Acute IHD resulteerde in een verlaging van rode bloedcelaggregatie 
en een onmiddellijke pro-trombotische (significante vWF mRNA opregulatie in hart, 
long, nier, lever en ileum) en pro-inflammatoire (significante E- en P-selectines mRNA 
opregulatie in long en ileum) endotheel activatie. Een lage rode bloedcel aggregatie 
was significant gecorreleerd met een toegenomen mRNA-expressie van vWF (hart, 
lever en ileum) en P-selectine (long, ileum en hart). Deze resultaten suggereren dat 
een lage rode bloedcel aggregatie een endotheel afhankelijke trombogene en pro-
inflammatoire respons kan induceren. Een trombogeen en pro-inflammatoir endotheel 
resulteert tijdens de reperfusiefase van een getransplanteerd orgaan waarschijnlijk in 
additionele schade door een heftigere immuunrespons van de ontvanger. Al met al 
werd geconcludeerd dat het gebruik van verdund donorbloed als preservatievloeistof 




Het verrichten van onderzoek op het grensvlak van orgaanpreservatie en biomedische 
technologie biedt fantastische uitdagingen voor de onderzoeker. Door de interactie 
van biologie, technologie en geneeskunde ontstaat een breed onderzoeksgebied 
waarbij kruisbestuivingen van en vanuit de diverse disciplines dagelijks plaatsvinden. 
Ervan uitgaande dat de kans op bestuiving omgekeerd evenredig is met de afstand, 
kunnen we ons in Groningen gelukkig prijzen. De geringe afstand tussen de afdeling 
BioMedical Engineering, het Chirurgisch Onderzoekslaboratorium en de kliniek 
heeft geresulteerd in een vruchtbare onderzoeksomgeving waarbij de toekomst met 
vertrouwen tegemoet kan worden gezien.
Verbeteren van statische koude preservatie
Dit proefschrift beschrijft een aantal studies dat er op gericht is orgaanpreservatie 
te verbeteren om op die manier de klinische resultaten na nier- en levertransplantatie 
te verbeteren. Het centrale dilemma in orgaanpreservatie is de disbalans die ontstaat 
tussen metabole vraag en aanbod die optreedt wanneer een orgaan uit de circulatie 
wordt genomen. De huidige (klinische) strategieën zijn erop gericht de metabole 
vraag te verminderen door het afkoelen van het orgaan tot 0-4°C. Dit resulteert in 
een afname van het metabolisme van ongeveer 90%. De bijkomende schade van 
hypothermie, celoedeem, acidose en zuurstofradicaal productie, zal echter altijd een 
rem blijven zetten op verdere ontwikkelingen in hypotherme preservatietechnieken. 
Nieuwe strategieën moeten zich focussen op een reductie in de metabole vraag van 
het orgaan óf een verbetering in metabole ondersteuning tijdens preservatie óf een 
combinatie van beide.
In plaats van hypothermie moeten andere mechanismen worden onderzocht 
om het metabolisme reversibel te verlagen. Dit is geen eenvoudige opdracht, maar 
de natuur kan ons een handje helpen. Orgaanpreservatie-onderzoekers zouden 
(winter)slapend rijk kunnen worden door de kunst af te kijken van bijvoorbeeld 
de eekhoorn. Dieren in winterslaap (hibernatie) zijn in staat lange perioden van 
extreem lage lichaamstemperatuur en bijbehorend laag metabolisme te overleven. 
Hibernatie is een conditie waarbij grote veranderingen in orgaanfunctie optreden. 
Een belangrijk aspect van deze processen is een significante reductie in zowel de 
energieproductie als -consumptie. Tijdens hibernatie zakt de lichaamstemperatuur naar 
omgevingstemperatuur (0-10°C), worden lichaamsfuncties en metabolisme tot een 
minimum beperkt en raken organismen in een lethargische staat. Dit kan enkele dagen 
tot weken duren. Gedurende deze periode zijn organismen beschermd tegen diverse 
omgevingsinvloeden zoals extreem lage temperaturen en zuurstofgebrek. Interessant 
is dat levers van eekhoorns, op het moment dat deze eekhoorns niet hiberneren 
(zomer), na 72 uur CS veel meer beschadigd zijn dan levers van dezelfde eekhoorns 
in hibernatie (winter). Dus, binnen dezelfde soort vindt er een transitie plaats van 
een minder tolerant (zomer) fenotype naar een super tolerant (winter) fenotype. Dit 
suggereert dat systemische en cellulaire mechanismen die leiden tot een toegenomen 
tolerantie voor ischemie/reperfusie, aan en uit kunnen worden gezet binnen één 
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individu. Het ophelderen van deze mechanismen kan grote implicaties hebben voor 
orgaanpreservatie. Een nieuwe stof waarvan inmiddels bekend is geworden dat het 
hibernatie kan induceren, in van origine niet-hibernerende soorten (Szabó C, Nature 
Reviews 2007), is waterstofsulfide (H2S). Dit kleurloze en wateroplosbare gas met de 
karakteristieke geur van rotte eieren is voornamelijk bekend geworden als het giftige 
gas dat uit moerassen omhoog borrelt. H2S wordt echter ook in kleine hoeveelheden 
in mensen geproduceerd. Het behoort tot de biologische familie van mediatoren 
die gasotransmitters worden genoemd. Koolstofmonoxide (CO) en stikstofoxide 
(NO) behoren eveneens tot deze groep. H2S heeft een breed scala aan biologische 
effecten die uiteindelijk leiden tot cytotoxische of cytoprotectieve effecten, afhankelijk 
van de dosering en het doelorgaan. De remmende werking op cytochroom-c-oxidase, 
een belangrijke stap in de ATP synthese, is waarschijnlijk verantwoordelijk voor 
de door H2S geïnduceerde hibernatie. Als muizen worden blootgesteld aan lage 
concentraties van H2S, vindt er een dosis afhankelijke reductie in lichaamstemperatuur 
en metabolisme plaats. De ademhalingsfrequentie daalt van 120 ademhalingen per 
minuut naar onder de 10 per minuut en de lichaamstemperatuur zakt tot 15°C. Op het 
moment dat de blootstelling aan H2S eindigt, herstellen de dieren zonder meetbare 
restschade. 
Al deze effecten van H2S zouden kunnen bijdragen aan het verbeteren van 
(machinale) preservatie en moeten worden onderzocht. In het GMP systeem kan H2S-
gas via de oxygenator worden toegediend of middels het coaten van de slangen of 
orgaankamer met een H2S-donor. Wanneer H2S wordt toegepast tijdens statische 
preservatie technieken zou het coaten van de orgaanzak met een H2S-donor een 
aantrekkelijke optie kunnen zijn. Het ligt voor de hand dat - naar analogie van de 
hibernerende eekhoorn - organen in hibernatie meer tolerant zijn voor ischemie/
reperfusie schade. Veel vragen rondom de smalle therapeutische breedte van H2S 
en de lange termijn effecten van blootstelling aan H2S moeten worden onderzocht 
en beantwoord voordat klinische orgaanpreservatie gebruik kan gaan maken van de 
effecten van H2S. Hopelijk is er tegen die tijd ook een oplossing gevonden om het 
transplantatieteam te beschermen tegen de stank van rotte eieren.
Toekomstige ontwikkelingen rondom het Groningse Machinale Perfusie (GMP) 
systeem
In dit proefschrift werden GMP prototypes ontwikkeld en onderzocht in een 
leverpreservatie- en een nier autotransplantatiemodel. Hoewel voor de nier kon 
worden aangetoond dat preservatie met het GMP systeem beter was dan statische 
koude preservatie, ontbreekt deze data voor de lever. In Hoofdstuk VI werd het systeem 
bovendien getest met onbeschadigde, perfecte donornieren van jonge varkens. Deze 
werden zonder warme ischemie en zonder kans op eventuele afstoting getransplanteerd. 
Toekomstige experimenten moeten ook preservatie en allo-transplantatie van DCD 
nieren en levers onderzoeken. Om de positie van het GMP systeem te bepalen moeten 
er vergelijkende studies met andere commercieel verkrijgbare (nier) HMP machines 
plaatsvinden. Hierdoor kan de relatieve bijdrage van de centrifugaal pompen en 
perfusaat oxygenatie, die uniek zijn voor het GMP systeem, worden bepaald. 
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Chapter X
Verschillende auteurs hebben beschreven dat veranderingen in de renale 
vaatweerstand (RVW) tijdens HMP voorspellend zouden kunnen zijn voor de 
nierfunctie na transplantatie. Alhoewel enige retrospectieve data beschikbaar zijn 
kunnen alleen de prospectieve data en monsters van de gerandomiseerde klinische 
studie (Hoofdstuk VII) deze hypothese staven. Door de gemeten RVW tijdens HMP 
te correleren met de klinische resultaten na niertransplantatie kan de waarde van 
RVW worden vastgesteld. Indien er een correlatie bestaat zal er een drempelwaarde 
kunnen worden berekend. De monsters van UW-MPS op diverse tijdspunten tijdens 
HMP kunnen worden gebruikt om nieuwe biomarkers te ontdekken. Deze kunnen 
dan, eventueel samen met de RVW, bijdragen aan een betere voorspelling van het 
transplantatieresultaat.
In plaats van het verlagen van de metabole vraag, zouden nieuwe technieken 
zich ook kunnen richten op het verbeteren van de metabole support tijdens preservatie. 
Wanneer tijdens preservatie de fysiologische omstandigheden van oxygenatie, 
beschikbaarheid van voedingsstoffen en het uitscheiden van metabolieten kunnen 
worden nagebootst zal de schade aan het orgaan zo klein mogelijk zijn. Het GMP 
systeem is op de Universiteit van Barcelona in Spanje al met succes gebruikt voor 
normotherme machinale perfusie (NMP) van varkenslevers. Als preservatievloeistof 
werd verdund donorbloed gebruikt. Vergeleken met CS, werd minder schade aan 
het lever parenchym en een betere synthetische functie na transplantatie gezien. 
Toepassing van NMP in de klinische situatie wordt momenteel beperkt door de 
volumineuze machinerie en de technische complexiteit. Toekomstige studies moeten 
zich richten op het verkleinen van de opstelling en op het gebruik van een andere 
preservatievloeistof. Want, zoals in Hoofdstuk VIII werd aangetoond, leidt verdund 
bloed tot endotheel activatie waardoor het wellicht niet de meest geschikte vloeistof 
is voor het normotherm machinaal preserveren van donororganen. Wellicht moeten 
nieuwe oplossingen voor normotherme preservatie synthetisch van aard zijn. 
Componenten van celkweekmedia kunnen dan zorgen voor metabole ondersteuning, 
colloïden moeten worden toegevoegd om oedeem te voorkomen en zuurstofdragers 
faciliteren de oxygenatie van het orgaan. 
Terwijl alle studies in dit proefschrift zich richten op het verbeteren van de preser-
vatie van het reeds uitgenomen donororgaan, begint orgaanpreservatie eigenlijk al 
eerder, namelijk in de donor. Het optimaliseren van de initiële uitwas tijdens de donor-
operatie zal bijdrage aan de kwaliteit van de uitgenomen organen. In de huidige 
klinische praktijk wordt 6-14 liter van een preservatievloeistof bij 0-4°C met een 
hydrostatische druk van 75-100 cm H2O in de donor geïnfundeerd om bloed uit 
te spoelen en de organen te koelen. Het toepassen van een gemodificeerd GMP 
systeem voor deze toepassing zal resulteren in een drukgestuurde, geoxygeneerde en 
continue perfusie van het gehele abdominale compartiment tijdens de donor-operatie 
(Fig. 1). In plaats van geïsoleerde perfusie van nier of lever kunnen alle buikorganen 
geperfundeerd worden door de aorta en vena cava te cannuleren. Door deze zoge-
naamde ‘in-situ machine perfusie’ zal de beschikbaarheid van zuurstof leiden tot meer 
metabole support, terwijl de continue perfusie zorgt voor een verbeterde uitwas van 
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bloed en koeling van de organen. Het gecombineerde effect zal een reductie in de 
disbalans tussen metabole vraag en aanbod zijn. Als vervolgens de geïsoleerde or-
gaanpreservatie wordt gecontinueerd met HMP, ontstaat er een optimale en technisch 
haalbare preservatiemethode voor klinisch gebruik. 




αSMA   alfa-smooth muscle actin    
AAP   alanine aminopeptidase    
ACH   acetylcholine     
ADP   adenosine diphosphate    
AI   aggregation index    
AMP   adenosine monophosphate    
AQP  aquaporin
ATP   adenosine triphosphate    
BPM   beats per minute     
CEL  Celsior solution
CIT   cold ischemic time     
CNI  calcineurin inhibitor
CO    carbon monoxide     
CPB   cardio pulmonary bypass    
CS   cold storage     
CSS   cold storage solution    
DBD  donation after brain death
DCD   donation after cardiac death   
DGF    delayed graft function    
EC    EuroCollins     
ECD  expanded criteria donation
ED-1   ectodysplasin-1, infiltrating macrophage specific antibody
eNOS   endothelial nitric oxide synthase   
f-DGF  functional DGF
FGS   focal glomerulosclerosis    
GFR  glomerular filtration rate
GMP   Groningen Machine Perfusion   
GS  graft survival
h    hour(s)      
Hb  hemoglobine 
Hct  hematocrit
HES    hydroxyethyl starch    
HLA  human leucocyte antigen
HMP    hypothermic machine perfusion   
HOC   hypertonic-citrate-solution (Marshall’s solution) 
HR  heart rate 
HR  hazard ratio     
HTK    Histidine-Tryptophan-Ketoglutarate   
ICAM-1   intercellular adhesion molecule-1   
IF   interstitial fibrosis     
IGL-1  Institut Georges Lopez-1    
IHD   isovolemic hemodilution    
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IPK  isolated perfused kidney
IL-6    interleukin-6     
IL-18   interleukin-18
iNOS    inducible nitric oxide synthase   
IRI   ischemia/reperfusion injury     
IU   international units     
IV   intravenous     
kDa  kilo Dalton
LDH    lactate-dehydrogenase    
LORCA   laser-assisted optical rotation cell analyzer  
MAP   mean arterial pressure    
MCP-1   monocyte chemotactic peptide-1   
MDA   malondialdehyde     
min    minute(s)     
mmHg   millimeters mercury    
MPS   machine perfusion solution    
MW   molecular weight     
NAG   N-acetyl-ß-D-glucosaminidase    
NHB    non heart-beating    
NHBD   non heart-beating donor    
NMP    normothermic machine perfusion   
NO   nitric oxide     
NOS     nitric oxide synthase    
OR  odds ratio
PBS   phosphate-buffered-sucrose solution  
PE    phenylephrine     
PEG    polyethylene glycol    
PFC    perfluorocarbon     
PNF    primary non function    
PRA  panel-reactive antibody
PS  patient survival
RBC    red blood cell     
RCT  randomized controlled trial
RVR  renal vascular resistance
ROS    reactive oxygen species     
s  second(s)
SCD  standard criteria donation
SMCs  smooth muscle cells    
TA  transplant arteriosclerosis
TBARS    thiobarbituric acid-reactive substances  
TNFα   tumor necrosis factor-alfa    
UW-CSS   University of Wisconsin cold storage solution  
UW-MPS  University of Wisconsin machine perfusion solution 
vWF   von Willebrand factor    
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WIT   warm ischemic time 
yr  year(s)  
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